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ABSTRACT 
Progesterone has been shown to be neuroprotective in a number of central 
nervous system injury models, including cerebral ischaemia. There is still a 
lack of understanding behind SURJHVWHURQH¶V QHXURSRWHFWLYH SURSHUWLHV, 
and the purpose of this project is to clarify some of these issues. 
Osmotic mini-pump infusion was hypothesised to more effective in 
delivering progesterone to the target organ of the brain, when compared to 
a bolus intraperitoneal injection. Progesterone pharmacokinetic profiles 
were compared between different dosing regimes. Intraperitoneal 
progesterone injection had a short half-life in both plasma and brain, while 
osmotic mini-pumps delivered higher concentrations of progesterone in 
plasma and particularly in brain, over a longer period, which supports the 
hypothesis.   
It was hypothesised that progesterone will reduce NO production and cell 
death in in vitro. Progesterone reduced nitric oxide production after 
challenging microglia with LPS, which supports our hypothesis and the 
nuclear progesterone receptor was found not to have a major role in nitric 
oxide attenuation. Neither of the microglial cell lines, BV-2 and HAPI cells 
produced elevations in NO formation in ischaemic conditions. The in vitro 
oxygen and glucose deprived model of ischaemia, reduced viability in both 
microglial and neuronal cells. Also, high pharmacological concentrations of 
progesterone exacerbated ischaemic injury, which does not support the 
hypothesis of progesterone in reducing cell death.  
Progesterone administration, via osmotic mini-pump infusion, was 
hypothesised to have a better outcome compared to vehicle treatment. 
After the onset of experimental stroke, progesterone delivery via osmotic 
mini-pump with loading dose was found to be beneficial in terms of 
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neurological deficit score in adult male mice, which supports the 
hypothesis. Also, we hypothesise that co-morbidity can affect the efficacy 
of progesterone treatment in outcomes. Aged animals have an increased 
sensitivity to experimentally induce stroke and did not display, in the 
outcomes measured, any benefit from progesterone treatment. NOD/ShiLtJ 
mice had severe symptoms, resulting in high mortality after surgery and 
are not recommended as a model of diabetes for experimental stroke. 
Hypertensive BPH/2 mice are a potential hypertensive model and had 
better functional outcomes after treatment with intraperitoneally 
administered progesterone, compared to non-treated hypertensive animals 
in our small preliminary study. This supports our hypothesis that co-
morbidity can affect the efficacy of progesterone treatment in outcomes.    
The gold-standard for assessing intervention effects across studies within 
and between subgroups is to use meta-analysis based on individual animal 
data. We hypothesise meta-analysis would reveal progesterone to reduce 
lesion volume, but also discover other effects in different subgroups of 
animals. Progesterone significantly reduced lesion volume, it also appeared 
to increase the incidence of death following experimental stroke. 
Furthermore, this negative effect appears to be particularly apparent in 
young ovariectomised female animals. These findings support the 
hypothesis that progesterone reduces lesion volume and progesterone 
having other effects in different subgroups.  
This investigation has clarified some issues and expanded our 
understanding on the neuroprotective properties of progesterone. 
However, these findings indicate further investigation is still required 
before progesterone can be considered for use in clinical trials as a 
neuroprotectant in stroke. 
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1.1 INTRODUCTION 
1.1.1 Definition of stroke 
Stroke is defined as an acute loss of focal brain function cause by either 
rupture of a blood vessel of the brain (haemorrhagic stroke), or caused by 
inadequate blood supply to a part of the brain due to a blockage of a blood 
vessel (ischaemic stroke) (Hankey, 2007).   
 
1.1.2 Types of stroke  
 
1.1.2.1 Ischaemic stroke 
Approximately 80% of strokes are ischaemic and are caused by a sudden 
interruption of blood flow within a cerebral artery due to a blood clot 
(thrombosis) or a detached intravascular mass (embolism) (Donnan et al., 
2008). The brain requires a constant supply of oxygen and glucose via the 
blood and is highly sensitive to blood flow changes. Any interruption of the 
blood supply to an area of the brain for more than a few minutes will stop 
the affected area from functioning properly (Mehta et al., 2007). If oxygen 
and glucose supply is not restored, permanent damage may result within 
5-6 minutes (Hutchins and Barger, 1998).   
 
The Ischaemic stroke subtype is a significant predictor for long term 
VXUYLYDODFFRUGLQJ WR WKH µ7ULDORI25* LQ$FXWH6WURNH7UHDWPHQW¶ 
(TOAST) criteria (Madden et al., 1995). In a small study, it was found that 
the incidence rate of large artery atherosclerosis is more than twice as high 
in men as compared to women in the European population (age adjusted) 
and small artery occlusion patients are three times more like to be alive as 
compared to patients with cardio embolism after two years of onset 
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(Kolominsky-Rabas et al., 2001). Ischaemic stroke subtypes includes: 
cardio embolism, small artery occlusion, large artery atherosclerosis, 
stroke of other determined cause and stroke of undetermined cause (due 
to two or more causes identified, negative evaluation and incomplete 
evaluation) (Donnan et al., 2008).    
 
Transient Ischaemic attack (TIA) of the brain can be described as an acute 
loss of focal brain or monocular function, which lasts less than 24 hours. 
The clinical syndrome is thought to occur due to inadequate blood supply 
to a part of the brain or eye due to low blood flow, thrombosis or embolism 
associated with diseases of blood vessels, the heart or blood. In this 
respect it is similar to an ischaemic stroke, however symptoms are 
resolved within a 24 hour period (Hankey, 2007). TIA is also a risk factor, 
which increases the chances for eventually developing a stroke (Ferro et 
al., 1996).  
1.1.3 Haemorrhagic stroke 
The majority of strokes are caused by ischaemia as mentioned previously, 
while the remainder are caused by haemorrhage. Haemorrhagic stroke is 
FKDUDFWHULVHGE\D³EXUVW´DUWHU\UHVXOWLQJLQEORRGEOHHGLQJRXWLQWREUDLQ
tissue (intracerebral haemorrhage) or over the brain surface area 
(subarachnoid haemorrhage). A rupture to the arterial wall will result in 
EORRG³VSXUWLQJ´RXWDWKLJKSUHVVXUHDQGFDQWHDUEUDLQWLVVXHIRUPLQJD
mass of blood (haematoma). Alternatively, a haematoma can slowly form 
as a result of blood seeping out over a prolonged period. Haematoma puts 
pressure on the normal surrounding brain and prevents the surrounding 
area from receiving blood from other surrounding blood vessels. As a 
result, the tissue surrounding the haematoma may die (Hankey, 2007).    
           
4 
 
1.1.4 Epidemiology 
1.1.4.1 Statistics 
In the UK the third leading cause of death after heart disease and cancers 
is stroke (Stroke Association, 2003), and causes a greater range and 
impact of disability compared to any other condition (Adamson J., 2004). 
In England, a minimum of 450,000 people are severely disabled from the 
condition (2005). Approximately every 5 minutes in the UK someone has a 
stroke, which adds up to an estimate of 150,000 people a year. A quarter 
of strokes each year in the UK happen to people under the age of 65 and 
approximately 10,000 happen to those under 30. In total, 1,000 occur in 
children and babies (2008). The risk of a recurrent stroke is between 30-
43% by 5 years, following the first incidence (2008). Globally, stroke care 
consumes in the region of 2-4% of the total health care costs and in 
industrialised countries stroke care can account for more than 4% of direct 
health care costs (Donnan et al., 2008).  
 
1.1.4.2 Prevalence 
The prevalence of stroke in the population is dependent on age and 
gender. Male stroke prevalence is 41% higher than females, with very 
large variation between age bands and populations (Appelros et al., 2009). 
Stroke prevalence is also dependent on incidence and survival. The 
incidence of stroke can vary between the populations in countries.  A study 
of the incidence of stroke in Europe found higher rates on average in 
eastern countries, while lower rates were observed in more southern 
European countries (Heuschmann et al., 2009). Different ethnic groups 
also have different incidences of strokes and its subtypes (Schneider et al., 
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2004). Such differences are partly due to genetic susceptibility and 
variations in diet and life style.     
Mortality rates vary depending on factors such as incidence, aetiological 
subtypes, case-fatality and severity of stroke, as well as age and sex. 
Stroke mortality rises substantially with age and can vary within countries 
and even within large cities. In general, stroke mortality is falling with the 
exception of Easton Europe and may be due to the decline in the incidence 
of stroke and improved survival rates. As mentioned previously, the 
incidence of stroke is in decline, which may be because of environmental 
factors and so can be modified by improved diet, reduced smoking and 
better control of blood pressure. Even if the incidence of stroke is 
declining, it is still going to be substantial in the foreseeable future. If the 
decline is not at least 2% per annum every year then the absolute number 
of strokes will increase in view of the ageing population in western 
societies (Hankey, 2007).    
 
1.1.5 Risk factors 
Risk factors for ischaemic stroke include: high blood pressure, increasing 
age, male gender, smoking, low social status, diabetes, atrial fibrillation,  
ischaemic heart disease, TIA, carotoid stenosis, peripheral vascular 
disease, hyperlipidemia, hormonal treatment (e.g. oral contraceptive pill), 
post menopausal state, pregnancy, alcohol use, poor diet, obesity and 
genetic risk factors. Some of these risk factors are linked, including: 
obesity and blood pressure, while others can be reduced by lifestyle 
changes, such as diet and exercise.  
Age is the single most important risk factor for stroke and the incidence of 
stroke increases with age (Feigin et al., 2003; Herman et al., 1982; 
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Niessen et al., 1993). For each successive 10 years after the age of 55, the 
stroke rate more than doubles in both men and women (Brown et al., 
1996; Wolf et al., 1992). Stroke incidence rates are 1.25 times greater in 
men, but because women tend to live longer than men, more women than 
men die of stroke each year (Sacco et al., 1997).  Stroke severity at onset 
and patient age are the most important factors for predicting prognosis 
(Ingall, 2004). In an epidemiology study, aged patients of over 80 years 
old, was found to have a higher proportion of conscious impairment at 
admission, a longer acute ward stay, a higher incidence of total anterior 
circulation infarct and a lower frequency of lacunar infarct (Lee et al., 
2007).  
High-risk patients with vascular risk factors, including hypertension and 
dyslipidaemia, are prone to stroke. Effective control of these risk factors 
remains the best therapy for reducing stroke burden (Toyoda, 2009). 
Hypertension is an established stroke risk factor and studies, such as the 
µ3HULQRSULO SURWHFWLRQ DJDLQVW UHFXUUHQW VWURNH VWXG\¶ PROGRESS) helped 
to clarify this. Anti-hypertensive pharmacotherapy reduced the risk of 
recurrent stroke or TIA, including 11% of patients with intracerebral 
haemorrhage (PROGRESS Collaborative Group, 2001). A meta-analysis of 
seven randomised control trials, including PROGRESS also showed reduced 
risk of stroke by anti-hypertensive pharmacotherapy (Rashid et al., 2003). 
The µ6WURNH SUHYHQWLRQ E\ DJJUHVVLYH UHGXFWLRQ LQ FKROHVWHURO OHYHOV¶
(SPARCLE) study was the first to show the impact of lipid lowering therapy 
by statins in reducing the risk of recurrent stroke (Amarenco et al., 2006).  
Diabetes mellitus is one of the most rapidly growing diseases in the world, 
affecting over 230 million people worldwide and with an estimated global 
prevalence of 5.1%. It is a major cause of excess cardiovascular morbidity 
and mortality in the Western world (Reimann et al., 2009). Diabetes can 
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be categorised into type 1 and type 2. Type 1 diabetes mellitus involves 
the autoimmune destruction of insulin-producing pancreatic beta-cells via 
auto-aggressive T-cells and pancreatic infiltration by macrophages. It 
accounts for approximately 10% of all diabetes cases (Achenbach et al., 
2005; Foulis et al., 1991). The other 90% is Type 2 and is the most 
common endocrine disorder worldwide. Pathogenesis of type 2 involves 
abnormalities in glucose and lipid metabolism, inadequate insulin secretion 
from pancreatic beta-cells and resistance to insulin activity (insulin 
resistance) (Goldstein, 2007). Significant loss of beta-cell mass (>50%) 
over time is casually related to hyperglycemia (Butler et al., 2003).            
Abnormally increased levels of homocysteine (Hyperhomocysteine), is an 
emerging risk factor for ischaemic stroke. However, the role of 
homocysteine is controversial. A study investigated if there was a 
correlation of homocysteine with stroke severity and clinical outcome, but 
did not find a link between elevated plasma homocysteine and the severity 
or outcome of stroke. However, they did find an association with ischaemic 
and haemorrhagic stroke. At higher levels, there was also an association 
with small artery stroke (Perini et al., 2005). Additional findings from the 
HOPE 2 trial, found lowering of homocysteine with folic acid and vitamins 
B6 and B12 reduced the risk of overall stroke. It did not however reduce 
the severity of stroke (Saposnik et al., 2009).  
 
1.1.6 Atherosclerosis  
Atherosclerosis is associated with acute ischaemic stroke and can lead to 
early mortality (Roquer et al., 2007). The development of artherosclerosis 
involves the hardening and thickening of the arterial wall, due to build up 
of fatty materials, such as cholesterol. Common arterial sites of 
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atherosclerosis are areas of haemodynamic sheers stress, turbulent blood 
flow, stagnation of blood, and sites of endothelial trauma. The main areas 
affected are mainly large and medium sized arteries at places of arterial 
branching, tortousity and confluence.  
Lesions of artherosclerosis are characterised by focal areas of lipid 
accumulation and intimal smooth muscle cell (SMC) proliferation within the 
arterial wall. The pathogenesis of artherosclerosis is not fully clear, but is 
thought to involve altered functional or structural integrity of the 
endothelial barrier, thereby allowing a net influx of lipids from circulating 
plasma (Alexander et al., 1991). Low density lipoprotein (LDL) is oxidised 
by free radicals, such as reactive oxygen species (ROS), and is deposited 
within the arterial wall where it is absorbed by macrophages, which then 
become foam cells. The inflammatory response is evoked with T-cells and 
the production of cytokines, with platelet activating factor (PAF) as the 
crucial mediator of this inflammatory response and is synthesised by many 
cells involved in the development of artherosclerosis, including platelets, 
monocytes, foam cell-macrophages and endothelial cells. Both PAF and 
PAF-like lipids are associated with elevated oxidised LDL (Demopoulos et 
al., 2003). SMC proliferate with fibrosis occurring forming fibrolipid 
plaques. These plaques, also known as atheromatous plaques, invade the 
media and gradually spread along and around the arterial wall, resulting in 
QDUURZLQJRIWKHDUWHULDOOXPHQ3ODTXHVFDQEHFRPHµDFWLYH¶RU µXQVWDEOH¶
from time to time and can become complicated plaques by erosion or 
fissuring of thin parts of the fibrous caps, haemorrhaging into the plaque, 
or rupture of the plaque. Subsequently, platelet adhesion, activation and 
aggregation result in thrombus formation.  Alternatively, plaques may 
become calcified or necrotic. Heavily calcified or fibrotic plaques make the 
whole artery rigid, elongated, and tortuous and at times ectatic. Dilation or 
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distension from ectasia and aneurysmal bulging, particularly of the basilar 
artery can compress nearby structures, such as the lower cranial nerves 
and brainstem (thromboembolism may also result), although arterial 
rupture is uncommon (Hankey, 2007).  Unable to process accumulating 
oxidised LDL, foam cell-macrophages grow and eventually rupture 
depositing more oxidised cholesterol into the artery wall. This activates 
more macrophages and results in a continuous cycle.    
 
1.1.7 Artherothrombosis 
The acute rupture of atherosclerotic plaque is usually the trigger that leads 
to ischaemic disease. Mechanical and immunological forces partly 
contribute to the vulnerability of plaque rupture. The rupturing of 
artherosclerotic plaque exposes collagen either within the plaque or in the 
sub-endothelium, which allows platelets to adhere to the arterial wall or 
leading to the activation of the platelets. Once activated, platelets secrete 
products such as adenosine diphosphate (ADP), serotonin and 
thromboxane A2 that, themselves, promote further platelet activation, 
vasoconstriction and neointimal proliferation and, therefore, contribute 
further disease progression. Activated platelets produce other 
inflammatory modulators such as platelet derived growth factor, platelet 
factor 4, CD40 ligand, thrombospondin, transforming growth factor and 
nitric oxide (NO). Also, CCL5; µregulated on activation, normal T cell 
expresVHG FHOO H[SUHVVHG DQG VHFUHWHG¶ 5$17(6 promotes the directed 
migration of leukocytes into damaged or inflamed tissue. Platelets are a 
likely source of RANTES, as they are known to release large amounts of 
WKH FKHPRNLQH IURP Į-granules once activated (Yilmaz et al., 2006). 
RANTES is also produced by other cells, including T-lymphocytes, 
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endothelial, smooth muscle and glial cells (Terao et al., 2008). Final steps 
in the aggregation of platelets involve the activation of the platelet 
glycoprotein IIb/IIIa (GPIIb/IIIa) receptor, which binds to fibrogen and in 
turn to other platelets. This leads to the formation of a platelet rich mural 
thrombus, with or without peripheral embolisation, leading to the 
manifestation of stroke (Chaturvedi and Yadav, 2006). Embolic blockade of 
the blood vessel is the most common cause of ischaemic stroke. 
 
1.1.8 Pathophysiology of ischaemic stroke 
The pathophysiology of ischaemic stroke involves a complex process 
involving excitotoxic, inflammatory, and microvascular mechanisms leading 
to tissue necrosis and apoptosis. Some areas of brain tissue are 
salvageable if reperfusion is initiated early before the processes become 
irreversible. After occlusion of a cerebral artery that supplies an area of the 
brain, the centre of this poorly perfused area forms a central core of 
necrotic tissue and is considered to be irreversibly damaged. Under normal 
physiological conditions, the normal cerebral blood flow is maintained 
approximately 50-60 ml/100g/min, but blood flow in the core drops to <7 
ml/100g/min (Baron, 1999). This area is surrounded by a moderately 
ischaemic zone called the penumbra. It is characterised as an area of 
dysfunction, due to metabolic and ionic disturbances, but the structural 
integrity is preserved and so is potentially salvageable. The cerebral blood 
flow in this region is 7-17 ml/100g/min (Baron, 1999). If the area is not 
reperfused early enough, then the lack of oxygen and ATP availability will 
result in cellular apoptosis, such that the core region is likely to expand 
into the penumbra. With declining blood flow, functional synaptic activity is 
affected first and as ischaemia progresses, metabolic activity is then 
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suppressed. This is needed to maintain the structural integrity of cells 
(Jordan et al., 2007).  
Figure 1.1: Cascade of biochemical events leading to apoptosis or necrosis following 
cerebral ischaemia 
 
Vascular occlusion in a blood vessel initiates a complex signalling cascade that leads to 
neuronal cell death. The reduction of blood flow causes ionic pump failure and anoxic 
depolarisation leading to enhanced glutamate release and a sudden increase of intracellular 
calcium. This rise in calcium triggers mitochondrial collapse, free radical production, cytotoxic 
oedema and increased NO generation. Also, reperfusion produces injury by augmenting blood 
brain barrier break down, inflammation and free radical production leading to apoptosis. The 
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red borders represent important events in the cascade. Blue borders indicate reperfusion 
(Sutherland et al., 2012). $$  DUDFKLGRQLF DFLG $03$  Į-amino-3-hydroxyl-5-methyl-4-
isoxazolepropionic acid, BBB= blood brain barrier, iNOS= inducible nitric oxide synthase, 
NADPH= nicotinamide adenine dinucleotide phosphate-oxidase), NMDA= N-methyl-D-
aspartate, nNOS= neuronal nitric oxide synthase, NO= nitric oxide, PLA2= phospholipase A2, 
VSCC= voltage-sensitive Ca2+ channels. 
    
A decrease in blood flow after vessel occlusion, promotes a complex 
biochemical cascade in the ischaemic tissue, leading to activation of 
multiple pathways dependent on the intensity and duration of ischaemia. 
The events include glutamate mediated cytotoxicity, involving N-Methyl-D-
aspartic acid (NMDA) and 2-amino-3-(hydroxyl-5-methyl-isoxazol-4-
yl)propanoic acid  (AMPA)/kainate receptors, calcium overload, oxidative 
stress, stress signalling, neurovascular pathophysiology and inflammation, 
cell death and gene expression (Mehta et al., 2007). This biochemical 
cascade interferes with glucose metabolism and causes cell sodium pump 
failure, leading to neuronal depolarisation (Hutchins and Barger, 1998). As 
a result, the influx of calcium leads to the activation of calcium dependent 
enzymes such as calpain, endonucleases, ATPases, phospholipases and the 
generation of free radicals, such as ROS, eventually resulting to excitotoxic 
cell death (see figure 1.1 for detailed time course of events). Apoptosis in 
the penumbra can go through three stages: activation, commitment and 
execution. Activation involves rising calcium concentrations and ROS 
formation, promoting apoptotic gene expression. The commitment stage is 
the point of no return and is thought to involve mitochondria, regulated by 
changes in permeability of their outer membrane. In the final stage, 
degradation enzyme complexes including caspases, calpins and 
endonucleases play an active role. It is thought that preventing the first 
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two stages, might avoid neuronal damage. Acting on the last stage might 
only delay but not impede cell death. All of these different complex 
processes are thought to be potential targets for neuroprotection (Jordan 
et al., 2007). 
Inflammatory events, which are initiated a few hours following focal 
ischaemia is characterised by peripheral leukocyte influx into the cerebral 
parenchyma and activation of endogenous microglia (Zheng and Yenari, 
2004), underlie the transition from ischaemic to inflammatory injury. The 
interruption of cerebral blood flow leads to energy depletion and necrotic 
cell death, which can trigger immune responses that ultimately lead to 
inflammatory cell activation and infiltration. Reperfusion of the occluded 
vessel (by compensation of the collateral circulation or spontaneous or 
therapeutic recanalisation of the occluded vessel causes) leads to 
generation of ROS either by reperfusion of oxygenated blood or production 
within brain and immune cells.  The generation of ROS then stimulates 
ischaemic cells, including ischaemic neurons to secrete inflammatory 
cytokines and chemokines, which upregulates adhesion molecules 
(selectins, integrins and immunoglobulins) in the cerebral vasculature and 
peripheral leukocyte recruitment, respectively. Activation of inflammatory 
cells can release a variety of cytotoxic agents, including more cytokines, 
matrix metalloproteinases (MMPs), NO and more ROS. These substances 
may induce more cell damage as well as disruption of the blood brain 
barrier (BBB) and extracellular matrix (Danton and Dietrich, 2003). BBB 
disruption can further potentiate injury and secondary ischaemic injury by 
allowing serum elements and blood to enter the brain (Rosenberg et al., 
2001). This secondary damage development is a consequence of brain 
oedema, post-ischaemic microvascular stasis and 
vasomotor/haemodynamic deficits leading to hypoperfusion and post-
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ischaemic inflammation, involving activation of microglia and brain 
infiltration of peripheral inflammatory cells. Migration of periphery 
circulating inflammatory leukocytes can amplify the inflammatory signal 
cascade, which enhances damage (Dirnagl et al., 1999).  
Focal cerebral ischaemia and post-ischaemic reperfusion causes cerebral 
capillary dysfunction, results in progressive alteration to the permeability 
of the BBB, leading to oedema formation and haemorrhagic conversion. 
When the capillaries that form the BBB can no longer retain the 
intravascular constituents, such as Na+, water, serum proteins and blood, 
these substances enter the extracellular space of the brain, causing 
swelling. Oedema can be divided into different subtypes that can progress 
through cytotoxic oedema, ionic oedema, vasogenic oedema to eventual 
haemorrhagic conversion (Simard et al., 2007). Cytotoxic oedema is a pre-
morbid process involving oncotic swelling of cells due to the movement of 
osmotically active molecules (principally Na+, Cl- and water) from the 
extracellular to the intracellular space. Depending on the severity of 
ischaemia, cytotoxic oedema may take place within minutes, or hours after 
stroke. Oncotic death of neurons is the ultimate consequence of cytotoxic 
oedema (Kimelberg, 1995). Ionic oedema results from cytotoxic oedema of 
endothelial cells, due to expression of cation channels both the luminal and 
abluminal side, allowing Na+ ions from the intracellular compartment to 
traverse the capillary wall and replenish NA+ in the extracellular space 
(Young et al., 1987). Vascular oedema results from the degradation of the 
junctions between endothelial cells, transforming capillaries into 
µIHQHVWUDWHG¶ FDSLOODULHV WKDW DOORZ H[WUDFHOOXODU RXWZDUG ILOWUDWLRQ RI
proteinatious fluid. Oncotic death of endothelial cells results in complete 
loss of capillary integrity and in extravassation of blood i.e. heamorrhagic 
conversion (Simard et al., 2007).      
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1.1.9 Symptoms and diagnosis 
The clinical diagnosis of stroke is crucially dependent on an accurate 
history taken from the patient, witness or carer.  The decision on whether 
signs and symptoms indicate a vascular event in the brain depends on 
many factors and includes: neurological symptoms, which are focal in 
stroke and negative such as loss of function, rather than positive.  The 
onset of focal neurological symptoms is usually sudden and symptoms are 
often maximal at onset rather than progressive.  Clinical diagnosis tends to 
be accurate around 80-85% of the time (Hankey, 2007).  
Focal neurological symptoms arise from identifiable areas of the brain, 
such as unilateral weakness of the brain (cortical spinal tract), clumsiness 
(cerebellum), unilateral sensory loss (spinothalamic tract), speech disorder 
(dominant hemisphere) and double vision (ocular pathways).   
 
1.1.9.1 Focal neurological and ocular symptoms: 
Speech or language disturbances 
Difficulty in:  
x Understanding or expressing spoken language (dysphasia) 
x Reading (dyslexia) or writing (dysgraphia)  
x Calculating (dyscalculia)  
x Slurred speech (dysarthria)*  
Sensory symptoms 
x Altered feeling on one side of the body, partly or whole 
(hemisensory disturbance) 
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x Loss of vision in one eye, partly or whole (transient monocular 
blindness or amaurosis fugax) 
x Loss of vision in left or right half or quarter of visual field 
(hemianopia, quadrantanopia) 
x Bilateral blindness    
x Double vision (diplopia)* 
Vestibular symptoms (balance) 
x Spinning sensation (vertigo)* 
Motor symptoms 
x Weakness or clumsiness on one side of the body, partly or whole 
(hemiparesis) 
x Bilateral weakness (paraparesis, quadriparesis)* 
x Difficulty swallowing (dysphagia)* 
x Imbalance (ataxia)* 
Behavioural or Cognitive symptoms 
x Difficulty in daily routines- dressing, brushing teeth etc 
x Geographical disorientation 
x Difficulty in copying diagrams such as clock, flower or intersecting 
cubes (visual-spatial-perceptual dysfunction) 
x Forgetfulness (amnesia)* 
*Does not necessarily indicate focal cerebral ischemia as an isolated 
symptom may be due to many other potential causes.  
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1.1.10 Diagnosis 
1.1.10.1 Brain imaging with CT and MRI 
If the clinical diagnosis is stroke, then computerised tomography (CT) 
brain imaging is required in order to confirm recent cerebral infarction, 
subarachnoid or intracerebral haemorrhage, and to exclude non-vascular 
intracranial pathology, for instance a brain tumour, as the cause of focal 
neurological symptoms and signs. Early CT brain imaging within the first 
few hours of stroke allows intracerebral haemorrhage to be identified 
straight away and in all cases. Subarachnoid haemorrhage (SAH) can be 
identified in about 95-97% of cases and cerebral infarction in around two 
thirds. The lower identified cases of cerebral infarction may be due to poor 
CT resolution, CT scans being too early, too small for an infarct to be 
imaged or because of artefact obscuring the image (particular relevent in 
the posterior fossa). Even within five hours, however of symptom onset, 
the CT scan will show abnormalities in cerebral infarction in half of cases 
(Von Kummer, 1997). If CT scanning is delayed for over two weeks after 
the onset of stroke, then CT imaging is not reliable in distinguishing 
ischaemic from haemorrhagic stroke. This is because CT appearances of 
haemorrhage will change over time to resemble the appearance of an 
infarct on a CT scan. Magnetic resonance imaging (MRI) however, can 
show intracerebral haemorrhage months and even years after the event 
(Hankey, 2007).  
 
1.1.10.2 Carotid ultrasound (Doppler ultrasound) 
Carotid ultrasound is a non-invasive diagnostic tool, using ultra high 
frequency sound waves to create images of the carotid arteries. The 
technique is frequently performed to detect stenosis of the carotid artery 
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and can also be used to measure blood-flow. It provides reliable 
information on localisation and extent of stenosis, as well as flow 
dynamics, plaque structure and vessel wall characteristics. There are 
limitations with the technique, including: high operator variability, inter-
hospital variability, susceptibility to artefacts from calcified plaques and 
difficulty in distinguishing a subtotal occlusion from a total occlusion (U-
King-Im et al., 2009). Also, doppler ultrasound can overestimate the 
severity of stenosis (Qureshi et al., 2001).    
 
1.1.10.3 Electrocardiogram  
Electrocardiogram (ECG) is a useful tool in monitoring the vital functions in 
patients with acute stroke and abnormal ECGs are frequently recorded in 
patients. The key findings looked for are atrial fibrillation (AF), myocardial 
infarction (MI) and arterial embolism (AE). ECG is paramount in identifying 
cardiac embolic stroke. Abnormalities in ECGs are frequent in acute stroke 
and often reflect cardiac morbidity. Also, some ECG abnormalities and 
increasing heart rate predict poor recovery. Common abnormalities in 
ECGs include: QT prolongation, ischaemic changes, arrhythmias, 
tachcardia and U-waves (Goldstein, 1979). Patients with ischaemic stroke, 
atrial fibrillation, atrio-ventricular block, ST elevation and depression, or 
inverted T-waves have a predicted mortality at 3 months in multivalent 
testing (Christensen et al., 2005). ECGs have been commonly used in 
physiological monitoring during carotid endarterectomy (Findlay et al., 
2004). 
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1.1.10.4 Echocardiography 
A proportion of infarctions are thrombotic and the rest, as a result of 
emboli, are either artery to artery within the cerebral circulation or from 
the heart or aorta. Diagnosis of a cardiac source for emboli is based to 
some degree on clinical presentation and results of CT or MRI. However, 
diagnosis is ultimately based on ECG and echocardiography findings. 
Echocardiography is the technique of choice when a cardiac source of 
embolism is suspected (Channon K.M., 1999). The technique can either be 
transthoracic (non-invasive) or transoesophageal (invasive) (Chambers, 
1997). Transthoracic echocardiography is useful to confirm a diagnosis 
when valvular heart disease is suspected. It is also valuable in 
documenting underlying structural heart disease. However, imaging of the 
aorta is limited to the proximal root and the arch in most patients. 
Transoesophageal imaging can image the ascending and the entire 
descending aorta, as well as see a clot in the left atria, also image quality 
is improved. The use of transoesophageal echocardiography may be 
required when embolic events occur in anticoagulated patients with native 
or prosthetic valvular heart disease, particularly if endocarditis is suspected 
or when transthoracic images are inconclusive (Channon K.M., 1999).     
 
1.1.11 Acute ischeamic stroke treatments  
1.1.11.1 Thrombolysis 
Currently tissue plasminogen activator (t-PA) is the only thrombolytic 
agent licensed for use in clinical practice. However, it is thought to be most 
effective within the first 3 hours of ischaemic stroke onset (Jordan et al., 
2007). Although, the µ(XURSHDQFRRSHUDWLYHDFXWHVWURNHVWXG\¶ (ECASS 3) 
trial for t-PA, demonstrated t-PA treatment 3-4.5 hours after stroke onset 
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can still be effective and safe (Hug et al., 2008).  T-PA acts by attaching to 
and activating fibrin bound plasminogen, thereby mediating lysis of the 
thrombus and recanalisation of the artery (Hankey, 2007).   
 
1.1.11.2 Aspirin 
Aspirin is given acutely to reduce early recurrence by 15% and protects 
one in six patients from cardiovascular death (Albers et al., 2001). The 
drug prevents the aggregation of platelets by irreversibly inhibiting cyclo-
oxygenase (COX) and thereby impairing thromboxine A2 (TxA2) synthesis 
in activated platelets. It also acts to limit an important positive feedback 
mechanism of the propagation of platelet activation during thrombosis. 
However, aspirin resistance is a well recognised and another antiplatelet 
clopidogrel, may be used for patients intolerant of aspirin. Clopidogrel 
blocks another feedback mechanism by irreversibly antagonising the major 
platelet ADP receptor P2Y. It is a pro-drug and has a marginally greater 
efficacy than aspirin but with an increased chance of bleeding. (Hamilton, 
2009)        
 
1.1.11.3 Stroke units 
Stroke units allow specialised care and rehabilitation for stroke patients. In 
comparison to general wards, stroke patients receiving treatment in stroke 
units, have lower mortality and dependency (Fuentes and Diez-Tejedor, 
2009; Langhorne et al., 1993). This is partly due to better medical 
management to prevent fatal complications (such as, pulmonary emboli, 
aspiration, pneumonia) and because geographical concentration of patients 
under multidisciplinary management, led by a trained consultant, focuses 
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on the needs of stroke patients (Stone, 1999). Stroke units are efficient, 
cost-effective and benefits are consistent over time. When compared with 
other specific stroke therapies such as aspirin, stroke units have a higher 
target population and greater benefit in terms of reducing mortality and 
dependency (Fuentes and Diez-Tejedor, 2009).   
 
1.1.11.4 Hemicraniectomy  
Space-RFFXS\LQJ KHPLVSKHULF LQIDUFWLRQV RU ³0DOLJQDQW´ middle cerebral 
artery (MCA) territory infarctions are the most devastating form of 
ischaemic stroke. They result in poor prognosis and the case fatality rates 
reach 80% with conventional medical therapy (Hacke et al., 1996). It is 
characterised by progressive swelling of the infarct, brain tissue shifts, 
compartmentalise elevation of intra-cranial pressure and extension of 
ischaemia to adjoining vascular areas. Decompressive hemicraniectomy 
and duroplasty is intended to normalise intra-cranial pressure, restore 
compromised blood flow in the penumbra and adjacent vascular area, as 
well as restore the midline position of the brain stem and diencephalon 
(Mayer, 2007). There have recently been a number of hemicraniectomy 
WULDOV IRU ³PDOLJQDQW´ 0&$ WHUULWRU\ LQIDUFWLRQV LQFOXGLQJ µ6HTXHQWLDO-
design, multicenter, randomized, controlled trial of early decompressive 
craniectom\ LQ PDOLJQDQW PLGGOH FHUHEUDO DUWHU\ LQIDUFWLRQ¶ DECIMAL) 
(Vahedi et al., 2007b), µDecompressive surgery for the treatment of 
PDOLJQDQW LQIDUFWLRQ RI WKH PLGGOH FHUHEUDO DUWHU\¶ (DESTINY) (Juttler et 
al., 2007) and µHemicraniectomy after middle cerebral artery infarction 
with life-WKUHDWHQLQJ (GHPD WULDO¶ (HAMLET) (Vahedi et al., 2007a). A 
meta-analysis of the data from the three trials, showed a substantial 
reduction in the risk of poor outcome and case fatality after surgery in 
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patients, who were randomised within 48hr from onset of stroke 
(Hofmeijer et al., 2009). Although hemicraniectomy improves functional 
outcomes, it is less effective in older patients (Curry et al., 2005).            
 
1.1.12 Preventative ischaemic stroke treatments 
1.1.12.1 Antiplatelet therapy 
Antiplatelet therapies are usually recommended for patients with 
noncardioembolic stroke (accounts for the majority of cases of ischaemic 
stroke) and for long-term stroke prevention after carotid endarterectomy 
(Lutsep, 2009). Aspirin is one of the most widely evaluated antiplatelet 
medications (Albers et al., 2004) and has been used alone, or in 
conjunction with other antiplatelet agents such as, dipyridamole or 
clopidogrel in the prevention of secondary ischaemic stroke (Toyoda, 
2009). Dipyridamole acts though a number of mechanisms to reduce 
platelet aggregation and may exert anti-inflammatory and antithrombotic 
actions. It inhibits the adenosine transporter, which is necessary to clear 
adenosine from plasma. The resulting elevations in local plasma adenosine 
levels stimulate adenylate cyclase. In turn, this leads to higher intracellular 
concentrations of cyclic adenosine monophosphate, a potent inhibitor of 
platelet aggregation. Prostacyclin levels are also increased by 
dipyridamole, stimulating NO release from the endothelium. Acting in 
synergy with NO, dipyridamole increases platelet cyclic guanosine 
monophosphate levels, which is another inhibitor of platelet aggregation 
(Lutsep, 2009). The use of both, aspirin and dipyridamole has a superior 
effect on antiplatelet aggregation compared to either alone (Muller et al., 
1990). Both µEuropean stroke preventative study¶ (ESPS-2) and 
µEuropean/Australasian stroke prevention in reversible ischaemia trials¶ 
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(ESPRIT), showed aspirin plus extended-release dipyrimadamole (ER-DP) 
was more efficacious than aspirin alone in preventing secondary stroke 
(Diener et al., 1996; The ESPRIT Study Group, 2006). However, Aspirin 
and clopidogrel was found to be an ineffective treatment because of 
increased bleeding, based on results from the µManagement of 
atherothrombosis with Clopidogrel in High-ULVN¶ (MATCH) and µClopidogrel 
for high atherothrombotic risk and ischaemic stabilization, management, 
DQGDYRLGDQFH¶ (CHARISMA) trials (Ruland, 2008).    
 
1.1.12.2 Cholesterol lowering  
Statin therapy has been shown to reduce the occurrence of stroke by 
reducing LDL cholesterol (Nassief and Marsh, 2008). The mechanism of 
action by statin involves inhibiting the enzyme 3-hydroxy-3-methyl-
glutaryl-CoA (HMG-CoA) reductase, which controls the first committed step 
of sterol synthesis. Niacin is affective at raising high density lipoprotein 
(HDL), which is associated with anti-artherosclerotic, anti-inflamatory 
properties and reducing cardiovascular events such as stroke. HDL also is 
involved in several mechanisms that protect against artherosclerosis 
(Sanossian et al., 2007). The use of Niacin is considered to be safe in 
conjunction with statins (Keener and Sanossian, 2008).     
 
1.1.12.3 Carotid endarterectomy and stenting   
Carotid endarterectomy (CEA) is a surgical procedure used as an effective 
means to prevent stroke by correcting severe stenosis in the carotid 
DUWHU\ %RWK WKH µ1RUWK $PHULFDQ 6\PSWRPDWLF &DURWLG (QGDUWHUHFRWRP\
7ULDO¶ 1$6&(7 (North American Symptomatic Carotid Endarterectomy 
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Trial Collaborators, 1991) DQGWKHµ(XURSHDQ&DURWLG6XUJHU\7ULDO¶(&67
(Farrell et al., 1998) shown a reduction in the recurrence of stroke after 
surgical treatment. Appropriate patients for CEA are those with TIA or non-
disabling stroke due to 70-90% carotid stenosis; the maximum allowable 
operative stroke and death rate should be no more than 6%. Uncertain 
candidates for the procedure are those with 50-69% symptomatic stenosis 
and those asymptomatic with stenosis with 60% (Findlay et al., 2004). 
Carotid artery stenting (CAS) is beginning to emerge as an alternative 
technique to treat carotid stenosis. However, clinical trials including µStent-
protected angioplasty versus carotid endarterectomy¶ (SPACE) (Eckstein et 
al., 2008), SPACE-2 (Reiff et al., 2009), µ(QGDUWHUHFWRP\ YHUVXV
DQJLRSODVW\LQSDWLHQWVZLWKV\PSWRPDWLFVHYHUHFDURWLG6WHQRVLV¶EVA-3S) 
(Mas et al., 2008), Carotid and vertebral artery transluminal angioplasty 
study (CAVATAS) (Brown et al., 2001) and µInternational carotid stenting 
VWXG\¶(ICSS) (2004) did not show better efficacy compared to CEA.  Both 
of these techniques are best viewed as complementary rather than 
competing therapies and currently, it seems premature to incorporate CAS 
in routine practice to replace CEA (Findlay et al., 2004; Narins and Illig, 
2006).             
   
1.1.13 Sex differences in physiology outcome and treatment for 
stroke 
There is evidence, that differences in sex and sex steroids can influence 
outcome in stroke (Mehta et al., 2007). Laboratory findings have found 
male and female cells differ in response to death or survival signals after 
cerebral ischaemic injury (Vagnerova et al., 2008). Sex hormones can alter 
procoagulant protein levels, platelet function and also the vessel wall in a 
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way that may translate into sex based differences in thrombosis. The 
differences in platelet and coagulation functions may partly explain why 
women are more likely to be aspirin resistant. Also, alterations in the 
vessel wall biology between the two sexes could contribute to thrombosis 
patterns, as well as antithrombotic therapy. In the case of women, 
bleeding complications are higher, in part due to their smaller size and 
older age compared to males when given antithrombotic therapy 
(antiplatelets are generally given in fixed, not weight adjusted doses). Sex 
based differences in vessel or blood functions also contribute to increased 
bleeding rates in women (Bailey et al., 2009a).    
 
1.1.14 Female sex steroids for neuroprotection 
The occurrence of stroke in pre-menopausal women is significantly reduced 
and females have a better outcome relative to males of the same age 
(Barrett-Connor and Bush, 1991; Kannel and Thom, 1994). However the 
incidence of stroke rapidly increases as the levels of circulating sex 
hormones (oestrogen and progesterone) decrease around the menopause 
(Wenger et al., 1993) (see figure 1.2). This trend has led to the idea that 
female steroid hormones might be protective against stroke.  
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Figure 1.2: Female/Male stroke incidence rate ratios for different 
age bands with 95% CIs 
 
(Appelros et al., 2009) 
 
As a result, hormone replacement therapy (HRT) has been widely used in 
clinical trials, aimed at reducing the occurrence of stroke. Although, the 
protective role of HRT has been well documented in cardiovascular disease 
(Grodstein and Stampfer, 1995; Grodstein et al., 1996), its protection in 
stroke is less clear. A number of studies found a reduction in the 
occurrence of stroke after HRT (Falkeborn et al., 1993; Finucane et al., 
1993; Henderson et al., 1991), while others found no significant benefit 
(Bushnell et al., 2001; Pedersen et al., 1997; Petitti et al., 1998; Viscoli et 
al., 2001). In a more recent large clinical trial, HRT was tested in the 
:RPHQ¶V +HDOWK ,QLWLDWLYH :+, VWXG\, in order to assess the incidence 
and outcome of stroke and on other vascular events, as well as cancer. 
However, it was halted prematurely over concerns on increased hazards to 
health (Wassertheil-Smoller et al., 2003). A systematic review of 
completed trials involving HRT, found it was associated with elevated risk 
of stroke, especially of ischaemic type and of increased severity (Bath and 
Gray, 2005). The principle findings on stroke from the WHI clinical trials of 
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hormone therapy indicate that oestrogen, alone or with progestogen, 
increases the risk of stroke (Henderson and Lobo, 2012). Although, there 
was a large amount of variation between HRT trials in terms of selection 
criteria of participants, outcome measures, definition of an HRT user and 
the examination of primary and secondary incidents of stroke (Paganini-
Hill, 2001). Therefore, it is difficult to conclude, definitively, the effects of 
HRT on stroke incidence.  
Despite this set back, female sex hormones for the use of neuroprotection 
is still of interest and preclinical studies have shown, that oestrogen is still 
a candidate treatment for ischaemic stroke (Alkayed et al., 1998; Simpkins 
et al., 1997). Although, many of these studies, as reviewed by Stein 
(2001) (Stein, 2001), have focussed on protecting against ischaemic injury 
and hence, commenced treatment prior to injury. These studies tended to 
be in models of overiectomised (Rusa et al., 1999), or reproductively 
ageing females (Toung et al., 2004). Preventative treatments would be 
beneficial, but therapies aimed at reducing damage post-stroke are 
essential. Any treatments concerned with reducing stroke risk should also 
be applied to males, who have a similar risk to post-menopausal women. 
Oestrogen may not be an advisable in males, due to undesirable side 
effects from chronic exposure. In pre-menopausal women, oestrogen 
administration increases the risk of uterine cancer (Grady et al., 1995) 
and, to counteract this, progesterone must be prescribed in combination. 
Hence, oestrogen only treatment would seem only applicable to a subset, 
albeit a significant proportion of the population (i.e. post-menopause 
women). However, the outcome of the oestrogen-only arm of the WHI trial 
was not encouraging (Powledge, 2004). The alternative sex hormone, 
progesterone, has been shown to have neuroprotective properties in 
experimental models of traumatic brain injury (TBI) (Roof et al., 1996; 
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Shear et al., 2002), spinal cord injury (Gonzales Deniselle et al., 2002), 
and stroke (Gibson and Murphy, 2004). As a treatment option, it is far 
more desirable for use in clinical practice. The steroid has advantages 
compared to oestrogen in terms of reduced side effects in males and a 
better safety profile, e.g. there is lower incidence of breast cancer 
associated with exogenous progesterone (Sharpe and Boivin, 2000).  
 
1.2.1 Progesterone 
Progesterone is a naturally occurring C21 sex steroid hormone, also known 
as P4 (pregn-4-ene-3, 20-dione) and is involved in the female menstrual 
cycle, pregnancy (supports gestation) and embryo genesis in many species 
including humans. Although progesterone can by produced in the lab it 
should not be confused with progestins, which are synthetically produced 
progestogens. The production of progesterone in mammals is mainly in the 
ovaries, particularly after ovulation in the corpus luteum and during 
pregnancy in the placenta. Female levels of progesterone in the menstrual 
cycle are relatively low at pre-ovulation phase (<2ng/ml) and then rises 
after ovulation (>5ng/ml). If pregnancy occurs, progesterone levels are 
initially maintained at luteal levels (4-20 ng/ml) but, with the onset of 
luteal-placenta phase, there is a shift to increase progesterone in order to 
support pregnancy, e.g. to reach 100-200 ng/ml at term. The 
concentration of progesterone drops to low levels after delivery in the 
placenta and during lactation. Progesterone levels are relatively low in 
children, postmenopausal women and in adult males, the progesterone 
concentration is similar to those found in women during the follicular phase 
of the menstrual cycle (0.2-0.8 ng/ml) (Erickson, 1995). The brain has the 
capability of producing progesterone and has its own mechanisms for 
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regulating progesterone synthesis (Corpechot et al., 1997). The brain can 
produce progesterone by de novo neurogenesis from cholesterol, via the 
precursor of pregnenolone. The side chain of cholesterol is cleaved by 
cytochrome P450scc, a rate-limiting mitochondrial enzyme to form 
SUHJQDQRORQH ZKLFK LV WKHQ IXUWKHU FRQYHUWHG WR SURJHVWHURQH E\ ǃ-
hydroxysteroid dehydrogenase (Schumacher et al., 2000).    
      
1.2.2 Progesterone as a candidate for neuroprotection 
Few effective treatments currently exist for acute ischaemic stroke. 
Although t-PA is effective, its use is limited by its narrow treatment 
window. A main focus of stroke research is the development of novel 
neuroprotective strategies to reduce on-going neuronal damage. 
Progesterone has advantages compared to oestrogen in terms of reduced 
side effects in males and a better safety profile, e.g. there is lower 
incidence of breast cancer associated with exogenous progesterone 
(Sharpe and Boivin, 2000). Also, no severe adverse effects have been 
associated with high progesterone doses in transient use (Gaver et al., 
1985; Little et al., 1974). Progesterone has already been shown to be safe 
and effective for many other clinical applications, e.g. hormone 
replacement therapy and a variety of preparations are available for 
different modes of administration (Goletiani et al., 2007). Synthetic 
progestins, which are similar to progesterone but not chemically identical, 
can cause undesirable side effects (Simon et al., 1993). This could be a 
possible explanation as to why HRT studies failed since progestins were 
used rather than natural progesterone.   
The majority of research on progesterone has been focussed on the 
treatment of TBI (Stein and Sayeed, 2010). Stroke has overlapping 
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pathophysiological mechanisms with TBI and so there is growing interest in 
the use of progesterone for stroke treatment. Several experimental studies 
have shown progesterone to be a potential neuroprotectant following 
cerebral ischaemia (Alkayed et al., 2000; Gibson et al., 2005b; Gibson and 
Murphy, 2004; Jiang et al., 1996; Kumon et al., 2000; Murphy et al., 
2002). These studies have found, post-injury administration of 
progesterone reduces lesion volume and improves functional outcomes in 
both sexes, and in both transient and permanent models of stroke. Also, 
studies have used µknock-out¶ animals to better understand the 
mechanisms involved in post-injury neuroprotection by progesterone. 
Gibson et al found that, mice lacking the nitric oxide synthase-2 gene (also 
known as inducible nitric oxide) were unable to benefit from progesterone 
treatment, in reducing lesion volume (Gibson et al., 2005b).      
The protective actions of progesterone appear to be numerous and have 
been investigated, both by in vitro and in vivo approaches. In TBI, damage 
caused by injury-induced lipid peroxidation was reduced by progesterone, 
which scavenge free radicals via a membrane-stabilising type of 
antioxidant action (Roof et al., 1996). This is also quite relevant in 
ischaemic stroke, as both reactive oxygen species and oxygen free radicals 
are produced during the ischaemic cascade.  
Progesterone can limit excitotoxic cell death by enhancing inhibitory 
synaptic neurotransmitters, thereby resulting in reduced neuronal 
excitability. Also, it is capable of reducing excitatory amino acid release 
(Smith, 1991), as well as subsequent excitatory neurotransmission 
(Goodman et al., 1996) and enhancing GABAergic neurotransmission, as it 
inhibits pre-synaptic glutamate release (Majewska, 1992). Progesterone 
and its metabolites have vasodilationary properties and thereby increasing 
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blood supply to the affected ischaemic area (Molinari et al., 2001; 
Perusquia et al., 1996).  
At the site of damage after cerebral ischaemia, inflammatory responses are 
generated and contribute to cell death (Leker and Shohami, 2002). 
Progesterone inhibits the production of pro-inflammatory cytokines and so 
reduce inflammation (Goodman et al., 1996). It has been observed that 
progesterone suppress ischaemic induced expression of interleukin (IL)-1h, 
nitric oxide synthatase (NOS)-2 and transforming growth factor (TGF)h2 
DQG SURJHVWHURQH¶V QHXURSURWHFWLRQ LV SDUWO\ UHODWHG WR WKH UHGXFWLRQ RI
oedema, most likely related to IL-1b suppression (Gibson et al., 2005b). 
Progesterone has shown to substantially reduce the expression of tumour 
necrosis factor (TNF)-Į DWWHQXDWH FHUHEUDO RHGHPD DQG increase 
expression of claudin 5, which plays an important role to maintain the 
structure of the blood brain barrier (Jiang et al., 2009). In neuronal 
cultures, progesterone activates mitogen-activated protein kinase 
(MAPK)/Extracellular signal-regulated kinase (ERK) and protein kinase B 
(Akt) signalling pathways, which are associated with neuroprotection. 
Neuroprotection from progesterone can also be attributed by its ability to 
up-regulate brain derived neurotrophic factor (BDNF), increase levels and 
activity of choline acetyltransferase and reduce mitochondrial dysfunction 
(Brinton et al., 2008). Neuroprotection has also been shown to involve the 
regulation of the expression of trophic factors though classical stimulation 
of progesterone receptors (Gonzalez SL, 2004).      
Although, studies have shown post-administration of progesterone after 
cerebral ischaemia is neuroprotective, further research is still required to 
clarify our understanding. Often, researchers have used progesterone 
doses that have previously shown to confer neuroprotection in other 
studies. However, progesterone pharmacokinetics has been neglected, as 
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there has been no detailed pharmacokinetic study, which has measured 
progesterone levels in both brain and plasma over time. A pharmacokinetic 
study is essential in order discover the levels of progesterone achieved and 
to evaluate whether other dosing methods, such as infusion, can maintain 
high levels of progesterone. Continuous drug administration has the 
advantage of avoiding the associated oscillating drug concentrations 
produced by intermittent bolus administration. As mentioned previously, 
there are numerous PHFKDQLVPVZKLFKPD\EHLQYROYHGLQSURJHVWHURQH¶V
neuroprotective actions but much still needs to be done. It is still unclear 
how progesterone affects different cell types in cerebral ischaemia. 
Therefore, more needs to be done to investigate isolated cell types, such 
as neurones and microglia and how progesterone affects their functions, 
for instance NO production of microglia. Underlying risk factors such as, 
diabetes, age and hypertension can have a major influence in terms of 
stroke outcome. It is also possible that co-morbidities could influence the 
effectiveness of a neuroprotectant. However, there is a lack of studies 
involving co-morbidities and progesterone in experimental stroke studies. 
The majority have been in young, healthy and usually male animals and do 
not represent the demographic of stroke patients. Therefore, more studies 
are required to explore the effectiveness of progesterone as a 
neuroprotectant in these co-morbid animals, particularly the major risk 
factors in stroke of age, diabetes and hypertension.     
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1.2.3 Translational perspective on progestogens for ischaemic 
stroke 
Progesterone has a long history of clinical use for the treatment of 
reproductive disorders e.g. infertility, inadequate luteal phase cycles and 
post-menopausal hormone replacement. However, non-reproductive 
related clinical applications for progesterone have been considered recently 
e.g. SKDVH  FOLQLFDO WULDOV RI µSURJHVWHURQH YHUVXV SODFHER WKHUDS\ IRU
ZRPHQ ZLWK HSLOHSV\¶ (Herzog et al., 2012) DQG µ6\1$36H $ VWXG\ RI
SURJHVWHURQHLQVHYHUHWUDXPDWLFEUDLQLQMXU\¶(Nelson et al., 2012). These 
trials can give valuable insights in the translation of experimental stroke 
studies to the clinic. Both trials mentioned previously, have already passed 
to phase-3 and have already undergone preliminary safety testing in 
patients, which is encouraging for other non-reproductively related clinical 
applications for progesterone.  
The progesterone and TBI SyNAPSe trial is of particular relevance because 
of the use of progesterone as a neuroprotectant. Stroke and TBI have 
overlapping pathophysiological mechanisms, making progesterone a 
feasible treatment option in stroke. Patients in the SyNAPSe trial received 
an intravenous infusion regimen of progesterone (Nelson et al., 2012). A 
similar infusion method could be emulated to investigate progesterone 
infusion in experimental stroke work.  
Also, progesterone treatment, in the progesterone for women with epilepsy 
trial was found to be ineffective. However, post-hoc analysis identified 
women with higher levels of  perimenstrual seizure exacerbation were 
responsive to progesterone treatment (Herzog et al., 2012). This indicates 
progesterone treatment may have varying effectiveness in different 
subsets of patients. Therefore, different models may be required to 
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determine the effectiveness of progesterone in different subgroups if this is 
the case in experimental ischaemic stroke.   
 
1.2.4 Progesterone in the brain 
The uptake of progesterone (like other steroids) is via passive diffusion 
through the cell membrane. Progesterone acts by binding to intranuclear 
progesterone receptor (PR), leading to receptor conformational change, 
binding of PR to specific progestin response elements (PRE) in the DNA, 
resulting in the activation of gene expression, followed by protein 
synthesis. Many other co-regulatory factors are involved in these complex 
processes. This cascade of processes takes time, and protein synthesis can 
be observed after a few hours from the binding of PR, especially of two 
proteins, PRA and PRB. In humans both proteins are encoded by a single 
gene under control of distinct promoters. Each of these give rise to a 
distinct mRNA species that encodes for PRA or PRB (Giangrande and 
McDonnell, 1999). Progesterone is metabolised in several cells and in 
particular, the brain; progesterone metabolites unable to bind to PR but 
can bind to other receptors.  
Progesterone can target many regions within the central nervous system 
(CNS) including hypothalamus, hippocampus and cortex. The receptors are 
broadly expressed throughout the brain and there is no apparent 
restriction to the any specific types of cells. However, PR expression may 
vary depending on brain regional areas, cell type or hormonal status 
(Brinton et al., 2008). Progesterone receptors are not only influenced by 
progesterone, but also indirectly by the sex hormone oestrogen via 
oestrogen receptors, which up-regulates the expression of progesterone 
receptors (Kastner et al., 1990). Post-mortem concentrations of 
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SURJHVWHURQHĮ-pregnane-3, 20-GLRQHĮ-DHP) and allopregnanolone in 
fertile and postmenopausal women vary regionally for all three steroids. 
Highest progesterone levels were found in the amygdala and cerebellum, 
ZKLOHKLJKHVW OHYHOVIRUERWKĮ-DHP and allopregnanolone were observed 
in the substantia nigra and basal hypothalamus. The concentrations of 
these steroids, were found to be significantly higher in fertile women in the 
luteal phase as compared to postmenopausal women (Bixo et al., 1997).        
Another route of signalling from progesterone is via a second mechanistic 
pathway that operates though non-genomic interactions. These actions in 
this route in general, require a rapid time frame that occur in seconds to 
minutes compared to genomic action, which are detected in hours to days 
(Gellersen et al., 2009). Other progesterone receptors unrelated to nuclear 
receptors have been described recently and include a number of 
membrane bound receptors. Both progesterone receptor membrane 
component (PGRMC)1 and the related PGRMC2 belong to the membrane 
associated receptor family, which are widespread in eukaryotes (Cahill, 
2007). Other membrane progesterone receptors, which are unrelated, 
have been discovered. At least three sub-types of the seven 
transmembrane progesterone adinopectin Q receptor have been described 
 ?ɲ ?ɴ ?ɶ ? (Thomas, 2008). These membrane progesterone receptors display 
high affinity, limited capacity, displaceable and specific progesterone 
binding. They are also coupled to G-proteins and inhibitory G proteins that 
down-regulate adenylyl cyclase activity (Thijssen, 2009). The 
WUDQVPHPEUDQHGRPDLQ7035ǃLVDQRWKHUUHFHSWRUZKLFKLVDWDUJHWIRU
progesterone (Brinton et al., 2008). Also, the progesterone membrane 
binding site 25-Dx may also be involved in neuroprotection (Labombarda 
et al., 2003).             
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1.2.5 Polymorphisms in progesterone receptors and enzymes 
Any polymorphisms in the PR or in enzymes, which catalyses progesterone 
may result in altered response. There is evidence of polymorphisms in the 
gene encoding for PR, and studies have already attempted to show 
associations between particular polymorphisms and human diseases (Diaz-
Cueto et al., 2008). Presently, there is no consistent or conclusive picture, 
which has emerged on clinically important associations (Thijssen, 2009). 
The progesterone receptor gene polymorphism (PROGINS) variant occurs 
at frequencies of up to 0.15 in Caucasians of different origins (Romano et 
al., 2007). Studies indicate that, women carrying the PROGINS allele are at 
an increased risk of developing pathologies, which progesterone exposure 
is normally associated with protection, like ovarian cancer (Romano et al., 
2006). However, PROGINS carriers have a reduced risk of breast cancer 
(Dunning et al., 1999). 
The liver as a major source of metabolising enzymes, such as the 
hydroxylation of progesterone in the human liver by cytochrome P450 3A4 
(CYP3A4) (Rendic, 2002). There are also catalysing enzymes in the brain 
such as CYP2D isoforms that catalyses 21-hydroxylation of 
allopregnanolonHSURJHVWHURQHDQGĮ-progesterone. It is suggested that 
CYP2D may be involved in the regulation of endogenous neurosteroids.  
Polymorphism of CYP2D6 may have some influence on the nervous system 
though endogenous compounds, such as neuroactive steroids (Toshiro 
Niwa, 2004).  
 
1.2.6 Allopregnanolone 
Progesterone is converted into several metabolites such as 
DOORSUHJQDQRORQHĮ-pregnan-Į-ol-20-one), which has been found to be 
37 
 
a more potent neuroprotectant compared to progesterone (Sayeed et al., 
2006; Sayeed et al., 2009). The metabolite allopregnanolone, but not 
progesterone, has been found to strongly inhibit the mitochondrial 
permeability pore, which appears to be an intrinsic pathway of apoptosis-
induced neuron loss (Sayeed et al., 2009). Progesterone can indirectly 
affect CNS function independent of PR though allopregnanolone, which acts 
as a positive modulator for GABAA receptors. In a paper studying the 
anticonvulsant activity of progesterone and allopregnanolone in PRKO 
mice, it was found that PR was not required for the antiseizure effects of 
progesterone, which mainly occurs through its conversion to 
allopregnanolone (Reddy et al., 2004). This indicates that pharmacological 
actions of allopregnanolone may act though a different route.   
Both progesterone and allopregnanolone are potent neuroprotective agents 
but both have different pharmacological properties. The progesterone 
metabolite allopregnanolone does not bind to PR, and also does not bind to 
the putative progesterone membrane receptor or the glucocorticoid 
receptor. Allopregnanolone increases GABAergic transmission, unlike 
progesterone, and may exert differential effects on GABAA receptor 
plasticity in neurons. This is likely to account for some of the physiological 
actions of this compound (Biggio et al., 2006). Allopregnanolone 
fluctuations in the brain can also change the subunit composition of GABAA 
receptors in thalamic relay neurons (Pisu et al., 2008). The divergent 
physiological actions of the two neurosteroids may be attributable to the 
conversion of progesterone to allopregnanolone, which primarily takes 
place in the brain and not in serum (Schumacher et al., 2007). 
Interestingly in a rat model of TBI, it was found that progesterone 
maintained procoagulants thrombin, fibrinogen and coagulation factor XIII, 
while allopregnanolone increased anticoagulant protein expression of tPA. 
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This means, it is more appropriate to use allopregnanolone in thrombotic 
stroke (VanLandingham et al., 2008). With this in mind, together with the 
knowledge that progesterone is converted to allopregnanolone in the brain, 
it is not known to what extent this reaction occurs before progesterone can 
act at various sites in the damaged brain before being converted.        
 
1.2.7 Considerations for SURJHVWHURQH¶V PHFKDQLVP IRU
neuroprotection 
As mentioned previously, progesterone can act on a variety of receptors 
including PR, which initiates a genomic signalling pathway and other 
receptors that act on non-genomic routes. Because both signalling 
pathways have different physiological response times after signalling, it 
would influence the window of opportunity for neuroprotection. If the main 
therapeutic response from progesterone is due to PR, then gender could be 
a major factor in determining the neuroprotective response. The PR is 
influenced by oestrogen, as mentioned previously and so varying 
concentrations of oestrogen present may affect the response from PR 
signalling. Pre-menopausal women have a greater concentration of 
oestrogen in their systems compared to post-menopausal females and 
males. There are also considerations for the transcription and metabolism 
of progesterone between genders and hormonal status. However, 
progesterone as mentioned can act via non-genomic signalling pathways. 
These non-genomic signalling pathways would result in a much faster 
physiological response. As mentioned previously, progesterone metabolites 
do not bind to the PR receptor and there is good indication that 
progesterone metabolites, such as allopregnanolone have a greater 
protective effect and may be the main contributor to protection (Sayeed et 
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al., 2006; Sayeed et al., 2009). These are some of the considerations that 
need to be evaluated in order to ascertain, whether progesterone will be 
neuroprotectinve in different subgroups, at what concentrations and at 
what therapeutic window.   
1.3 Research with animal models 
Treatments are usually initially tested on animals for a number of reasons. 
Regulatory authorities concerned with public safety require extensive 
animal testing to screen new treatments for toxicity and to establish 
safety. Animal studies provide a degree of environmental and genetic 
manipulation, which is rarely feasible in humans (Lemon R, 2005). If 
preliminary testing of treatment on animals show they are not clinically 
useful, then it may not be necessary to test them on humans (Hackam, 
2007).       
There are a variety of animal species, which have been used in the 
research of stroke. These range from rodents, such as mice and rats to 
primates like marmosets. They are a valuable tool in understanding the 
pathology of disease and the affects of different treatments on a living 
system. Cell culture or in vitro approaches will only give you information 
on the cells or tissues that are being tested. It does not however, give 
insight on systemic effects. This would include: pathophysiology in a 
systemic system, affects on different organs, tissues and cell types.  A 
compound, which has certain effects on one type of cell, may have greatly 
different effects in another from different tissues in an organism. The use 
of animal models allows pharmacokinetics and dose response relationships 
to be observed for drug treatments. Also, animal models allow insightful 
observations on physiology and behaviour, during and after interventions. 
It is possible to observe the effects of pathological damage, both on the 
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structure of the brain and the resulting behaviour. As well as, gaining 
insights into the pathophysiology and causes of disease, animal studies 
often reveal novel targets for directed treatments.    
Considerations must be made in order to select an appropriate model. 
These include: the breeding of animal models (if required), gestation 
period and time for maturity to reach desired age, behaviour of animal, the 
genetics of animals and strains available, the suitability of the model for 
experimentation, drug treatments and surgery. There are also financial 
considerations, not only on the actual animals themselves, but also on 
facilities available to keep them.      
 
1.3.1 Choice of ischaemic model 
The choice of an ischaemic model can be either global or focal. Global 
cerebral ischaemia occurs when blood flow to the brain is stopped or 
reduced, while focal cerebral ischaemia is the result of a blood clot, which 
has occluded a cerebral vessel and so reduces blood flow to a specific 
region of the brain. Ischaemic strokes tend to be focal and so the focal 
ischaemic model would better represent ischaemic stroke. There are a 
variety of focal ischaemic models available, each with their pros and cons 
(table 1.1).  
Middle cerebral artery occlusion (MCAO) is the preferred method of 
inducing focal lesions that represent stroke. This is an acceptable model, 
as the majority of human strokes result from occlusion in the region of the 
middle cerebral artery (Yoo et al., 1998). Both transient and (Gibson and 
Murphy, 2004; Murphy et al., 2002) permanent (Ishrat et al., 2009; Jiang 
et al., 2009) focal cerebral ischaemia can be induced with the MCAO 
intraluminal filament method. The majority of human cases of stroke tend 
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to be permanent occlusion of cerebral arteries. However, the stroke 
therapeutic academic round table (STAIR) group suggests, that compounds 
need to show efficacy in both transient and permanent focal ischaemia 
models. The STAIR criteria are a set of standards for the development of 
pre-clinical neuroprotective drugs in order improve experimental design 
and reduce experimental bias. Also, the STAIR criteria suggests that, 
compounds which have only been shown to be only effective in pre-clinical 
transient ischaemic models, should only be tested in strokes where there is 
reperfusion, if they progress to human clinical trials (Stroke Therapy 
Academic Industry Roundtable (STAIR), 1999).   
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Table 1.1: Advantages and disadvantages of different focal ischaemic models  
Model Advantages Disadvantages 
MCAO by 
permanent 
electrocoagulation 
Good reproducibility in outcome measures 
achievable 
Requires craniectomy 
Successful occlusion confirmed visually by section of th
occlusion site  
Technically challenging 
Some control of infarct size and location possibly 
by occluding different segments of the middle 
cerebral artery 
Model not suitable for transient ischaemia or thrombolysis 
studies 
Infarct matures quickly and is maximal within 24-
48 hrs 
 
Low mortality  
MCAO by an 
intraluminal 
filament 
Good reproducibility in outcome measures 
achievable 
Successful occlusion by confirmed visually  
Suitable for transient or permanent ischaemia Reproducibility dependent on identifying optimal filament 
dimensions and construction for the rodent strain and size 
Technically straightforward  surgery (no 
craniectomy) 
Increased haemorrhagic risk with certain filament types 
 Significant mortality may be encountered with large 
strokes (>24 hrs) and before infarct has fully evolved   
 Model not suitable for transient ischaemia or thrombolysis 
studies 
MCAO by 
endothelium-1 
(topical or 
intraparenchymal) 
Good reproducibility in outcome measures 
achievable 
Dependent on endothelium-1 vasoconstrictor potency to 
be consistent from batch to batch 
Successful occlusion confirmed visually (topical 
model) 
Topical administration requires craniectomy 
Modifications to intraparenchymal model may 
allow ischaemia induction in conscious rat  
Model not suitable for thrombolysis studies 
MCAO by 
clip/mechanial 
device 
Successful occlusion confirmed visually  Requires craniectomy 
Suitable for transient or permanent ischaemia Technically challenging 
 Likely to require more than one occlusion site, 
hypotension or common carotid artery occlusion to 
achieve reproducibility 
MCAO by 
autologous blood 
clot 
Most closely mimics human ischaemic stroke  Less reproducible than other models 
Model suitable for thrombolysis studies Less control over ischaemic location and duration  
 More variable in outcome measures 
 Secondary microclot formation possible with clot 
breakdown 
MCAO by by 
intravascular 
thrombin injection 
Reproducibility in cortical ischaemia and infarct 
volume achievable 
Requires craniectomy 
Position and persistence of clot of clot confirmed 
visually 
Secondary microclot formation possible with clot 
breakdown 
Model suitable for thrombolysis studies Limited sensorimotor deficit due to small size and location 
of infarct  
Low mortality compared to autologous clot 
models  
 
Photochemical 
ischaemia 
Reproducibility in cortical ischaemia and infarct 
volume achievable 
Photocoagulation insult causes severe damage to affected 
blood vessels and substantial vasogenic oedema 
uncharacteristic of human stroke 
Blood vessel thrombosis can be achieved through 
intact skull 
Limited sensorimotor deficit due to small size and location 
of infarct  
More recent modifications of the model are 
suitable for thrombolysis studies 
  
(Macrae, 2011) 
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1.3.2 Choosing the species  
Mice are particularly useful for experimental stroke, in terms of expense, 
facilities available and time it takes to reach appropriate maturation and 
age for experiments. Ischaemic mouse models have been increasingly used 
to investigate pathogenesis and treatments in stroke. This is partially due 
to advantages compared to rats, in newly available transgenic mice strains 
and specific molecular probes. Both transient and permanent MCAO models 
can give reproducible brain injury. Also reperfusion in the transient model 
is relatively easy. The type of ischaemic injury observed in a mouse model 
is similar to both rats and humans. Therefore, information gained from this 
model should be relevant (Mao et al., 2000).  
 
1.3.3 Physiologically relevant models 
Sex differences can affect the effectiveness on treatments and so it is 
essential to test treatments for both sexes separately. The problem of 
using female models is the confounder of endogenous sex steroids. 
Overiectomy allows the study of the effects of oestrogen or progesterone 
without the confounder of endogenous sex steroids contributed by the 
ovary. Overiectomised rodents have been used in stroke models and 
overiectomy, results in a dramatic reduction not only in circulating 
oestrogen, but also progesterone. However, this procedure may result in 
an impairment of cognitive performance (Luine et al., 1998). The problem 
with overiectomy is that, it better mimics surgically menopausal women 
and not necessarily the model of menopause (Singh et al., 2008). Natural 
menopause is characterised by lengthy continuum of biologic changes 
where ovarian hormone biosynthesis provides low circulating levels of sex 
hormones and androgens. Comparatively, surgically induced menopause 
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results in a severe and sudden reduction, so physiological changes occur 
quickly (Bachmann, 2001).       
 
1.3.4 Limitations of using experimental stroke models 
Although the mouse model is a relevant one, there are limitations to keep 
in mind when comparing a mouse model to human patients. 
Considerations are required for the brain structure between species, drug 
dosing and recovery. 
There are a number of dissimilarities between the brains of rodents to non-
human primate models and humans. As a result, there may be differences 
in response to an identical ischaemic insult. Mice brains are considerable 
smaller compared to a humans and structurally, the mouse brain surface is 
relatively smooth (agyric), while the human brain is more complex with 
many folds and fissures (gyric) (Mehra et al., 2012). Also, the human brain 
has a relatively larger frontal lobe compared to other brain areas. With this 
in mind, a model with a more similar structure to humans may be a more 
comparable model, such as a primate one. Primates could be used as an 
intermediate step for the development of a non-invasive mechanism in 
delivering drugs to patients. However, the use of primates can be 
problematic in terms of expense, facilities and time it would take to reach 
an appropriate age for experimental conditions, such as post-menopause. 
Also, concerns in terms of ethics are always associated with primate 
models, making approval more difficult (Stroke Therapy Academic Industry 
Roundtable (STAIR), 1999).  
In terms of drug dosing and recovery, it is difficult to scale up dosing 
regimens from rodents to humans, as well as dose and duration of drug 
delivery. Recovery from stroke can be far slower for humans when 
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compared to rodents, up to several months in fact. An optimal animal 
model for testing stroke recovery with drug treatments would encompass 
some, but not complete recovery as it would approximate human stroke 
(Stroke Therapy Academic Industry Roundtable (STAIR), 1999). 
 
1.4 Clinical trials for neuroprotection  
Presently the testing of neuroprotective drugs in clinical trials has resulted 
in disappointment, as none so far has resulted in an effective treatment in 
acute ischemic stroke (Green, 2002). An example would be trials that 
tested disufenton sodium (NXY-059) a free radical scavenger. The results 
for the combined µ6WURke-DFXWHLVFKDHPLF1;<WUHDWPHQW¶ (SAINT) 1 and 2 
trials for NXY-059 have resulted in no significant effect (Shuaib et al., 
2007b), despite the positive pre-clinical studies, that have lead to such 
clinical trials. One explanation, is because of pre-clinical studies, which 
have inconsistent findings and more undue weight given to positive studies 
rather than neutral ones. A meta-analysis of available individual animal 
data from pre-clinical studies for NXY-059, did find it was neuroprotective. 
However, its efficacy may of been overstated because of bias (Bath et al., 
2009).  
Often in pre-clinical studies, animals are young, healthy, rarely have co-
morbidities, and are not exposed to the range of competing (and 
interacting) interventions that humans receive. These make poor 
predictors of clinical outcome (Hackam, 2007). Problems of pre-clinical 
studies include publication bias. If there are neutral or negative studies, 
which are not published or are not considered, as with positive published 
findings, then positive studies will be over emphasised and treatments may 
progress to clinical trials unjustifiably. Animal studies with small sample 
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sizes are more likely to report higher estimates of effect than studies with 
larger numbers; this distortion usually regresses when all available studies 
are analysed in aggregate. It is not very common for animal studies to 
report a sample size calculation, which is a fundamental step in helping to 
ensure an appropriate powered precise estimate of effect (Sena et al., 
2007).          
The use of meta-analysis for the assessment of pre-clinical studies before 
the progression to clinical trials, would be an advantage, by combining 
results from similar studies quantitatively, to reduce biases between 
studies (Stewart and Parmar, 1993). In order that meta-analysis of studies 
is valid, statistical tools are needed in order that included studies are not 
biased. Tools to identify publication bias include funnel plots (plots of effect 
HVWLPDWHV DJDLQVW VDPSOH VL]H DQG (JJHU¶V 7HVW WHVt for funnel plot 
asymmetry, the more asymmetric the more likely of bias) (Egger et al., 
1997). Sources of biases include English language bias in which, 
preferential publication of negative findings of journals in other languages 
besides English and therefore, making locating and including of negative 
findings more difficult. Citation bias can also be problematic when negative 
studies are quoted less often, and so are more likely to be missed in 
searches for relevant trials. Sometimes positive trials are reported more 
than once in searches for trials (multiplication bias). Biases such as the 
ones mentioned are more likely to affect smaller studies to a greater 
degree, compared to much larger trials (Egger et al., 1997).   
Some have argued, that the reason why clinical studies have failed after 
favourable preclinical studies with animals is because the animal models 
are inadequate for testing neuroprotective compounds (Wiebers et al., 
1990). However, the biochemical mechanisms involved in cell death and 
functional outcome changes are very similar between the brains in humans 
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and animal models, such as the rat. It is more likely the design of studies 
maybe flawed. Randomisation, concealed allocation and blinded outcome 
assessment standards that are considered the norm when planning and 
reporting human clinical trials can be inconsistent in animal studies. In an 
attempt to improve the quality of studies, recommendations for standards 
regarding clinical neuroprotective and restorative drug development 
(STAIR criteria) was developed. The STAIR criteria quality uses a 8 point 
rating scale, a point is given for: presence of randomisation (pseudo 
randomised 0.5), monitoring of physiological parameters, assessment of 
dose response relationship, assessment of optimum time window, masked 
outcome measurement, assessment of outcome 1-3 days, assessment of 
outcomes 1-30, combined lesion volume and functional outcome (Stroke 
Therapy Academic Industry Roundtable (STAIR), 1999). In addition to the 
STAIR criteria, blinded surgery has also been suggested (Bath et al., 
2009).       
At present there have only been two clinical studies that have investigated 
progesterone as a potential neuroprotectant. These have been in TBI and 
have shown improved outcome and good safety tolerance in the 
progesterone-group (Wright et al., 2007; Xiao et al., 2008). However, no 
clinical trials have yet examined the acute administration of progesterone 
following cerebral ischaemia so far.   
 
1.5 AIMS 
There is still a lack of understanding in SURJHVWHURQH¶V neuropotective 
properties and the purpose of this project is to clarify some of these issues. 
The pharmacokinetics profiles in plasma and brain, following different 
administration methods, have not been previously investigated. Therefore, 
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progesterone pharmacokinetic profiles in plasma and brain, following 
administration via intraperitoneal (i.p.) injection, versus infusion via 
osmotic mini-pump with a pre-loading dose of progesterone, would be 
compared. The pharmacokinetic model will then used to estimate 
progesterone concentrations in published studies that have shown 
neuroprotection. Delivering progesterone, via osmotic mini-pumps has not 
been employed previously and information on release characteristics could 
pave the way for its use in neuroprotection studies. We hypothesise that 
osmotic mini-pump infusion could be more effective in delivering 
progesterone to the target organ of the brain, when compared to a bolus 
intraperitoneal injection. Following this, further experiments will determine 
whether progesterone administration, via osmotic mini-pump, is effective 
at conferring neuroprotection after the onset of experimental stroke. It is 
hypothesised that animals receiving progesterone, via mini-pump delivery, 
will have a better outcome compared to vehicle treatment. Co-morbidities 
could influence the effectiveness of a neuroprotectant. However, there is a 
lack of studies involving co-morbidities and progesterone in experimental 
stroke studies. Therefore, the effectiveness of progesterone, as a 
neuroprotectant, in these co-morbid animals will be explored in the major 
stroke risk factor groups of aged, diabetic and hypertensive animals. We 
hypothesise that co-morbidity can affect the efficacy of progesterone 
treatment in outcomes. As well as investigating in vivo aspects, 
progesterone actions will be explored in vitro by studying the effects of 
progesterone on NO production and microglia viability, as well as the 
viability of SHSY5Y neuroblastoma cells, subjected to simple models of 
OGD that is associated with ischaemia. It is hypothesised that 
progesterone will reduce NO production and cell death. Furthermore, the 
gold-standard for assessing effects across studies within and between 
subgroups is to use a meta-analysis based on individual animal data (IAD). 
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A systematic review and meta-analysis, based on IAD of pre-clinical 
studies of progesterone in experimental stroke models will be conducted, 
in order to better understand the overall neruoprotective effectiveness of 
progesterone. We hypothesise meta-analysis would reveal progesterone to 
reduce lesion volume, but also discover other effects in different subgroups 
of animals.   
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CHAPTER 2 
Progesterone pharmacokinetics in the mouse: 
implications for potential stroke therapy 
 
Publications contributing to this chapter: 
Wong, R., Ray, D., and Kendall, D.A. (2012). Progesterone 
pharmacokinetics in the mouse: implications for potential stroke therapy. J 
Pharm Pharmacol 64, 1614-1620. 
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2.1 INTRODUCTION 
There is growing evidence to suggest that differences in gender (Appelros 
et al., 2009), possibly due to endogenous sex steroids, can influence the 
incidence and outcomes of stroke. The occurrence of stroke in pre-
menopausal women is significantly lower than in men and females have 
better clinical outcomes relative to males of the same age (Barrett-Connor 
and Bush, 1991; Kannel and Thom, 1994). However, the incidence of 
stroke in women rapidly increases as the levels of circulating sex hormones 
(oestrogen and progesterone) decrease during the menopause (Wenger et 
al., 1993). These trends have led to the proposal that female steroid 
hormones might be protective against stroke, and although the majority of  
studies to date have focused on oestrogen (Gibson et al., 2006), attention 
has also been directed towards progesterone (Alkayed et al., 2000; Chen 
and Chopp, 1999; Gibson et al., 2005b; Gibson and Murphy, 2004; Ishrat 
et al., 2009; Jiang et al., 1996; Kumon et al., 2000; Murphy et al., 2002; 
Sayeed et al., 2009; Sayeed et al., 2007) 3URJHVWHURQH¶V SURWHFWLYH
properties have also been demonstrated in other models of CNS injury, 
including traumatic brain injury and spinal cord injury (De Nicola et al., 
2009). Pre-clinical studies have shown progesterone to be neuroprotective 
following cerebral ischaemia (Alkayed et al., 2000; Chen and Chopp, 1999; 
Gibson et al., 2005b; Gibson et al., 2007; Gibson and Murphy, 2004; 
Ishrat et al., 2009; Jiang et al., 1996; Kumon et al., 2000; Murphy et al., 
2002; Sayeed et al., 2009; Sayeed et al., 2007). The steroid has 
advantages compared to oestrogen in terms of reduced side effects in 
males and a better safety profile, e.g. there is lower incidence of breast 
cancer associated with exogenous progesterone (Sharpe and Boivin, 
2000). Also, no severe adverse effects have been associated with high 
progesterone doses over a short course of treatment (Gaver et al., 1985; 
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Little et al., 1974). Progesterone has already been shown to be safe and 
effective for many other clinical applications, e.g. hormone replacement 
therapy in conjunction with oestrogen, and a variety of preparations are 
available for different modes of administration (Goletiani et al., 2007). In 
two clinical trials, progesterone, following traumatic brain injury, has been 
shown to be beneficial and safe (Wright et al., 2007; Xiao et al., 2008). 
The neuroprotective potential of progesterone has been demonstrated in 
numerous experimental stroke studies and although dose-response 
relationships (Chen and Chopp, 1999; Kumon et al., 2000; Murphy et al., 
2002; Murphy et al., 2000) and optimal time windows for administration 
(Jiang et al., 1996; Murphy et al., 2002; Murphy et al., 2000) have been 
reported, only one study has investigated progesterone concentrations in 
both brain and plasma following administration (Coomber and Gibson, 
2010). In that study, the progesterone concentration was measured 7 days 
after progesterone pellet implantation. It is important to determine the 
pharmacokinetic profile in normal healthy animals first, to determine if 
there are any toxic effects to a range of doses, without the complication of 
disease present. Once this is determined, drugs can then be tested in 
disease models. In terms of neuroprotection, the time immediately after 
the onset of stroke is the most crucial in terms of efficacy for 
neuroprotectants (Ginsberg, 2008). Therefore, it is crucial to establish 
SURJHVWHURQH¶V SKDUPDFRNLQHWLF SURILOH LPPHGLDWHO\ IROORZLQJ FHUHEUDO
ischaemia and for the following period of 1-2 days. The ideal solution 
would be to achieve therapeutic concentrations in the brain quickly and for 
these to be sustained over the critical period of time. Continuous drug 
administration has the advantage of avoiding the associated oscillating 
drug concentrations produced by intermittent bolus administration.               
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The aim of these experiments described in this chapter was to compare 
progesterone pharmacokinetic profiles in plasma and brain following 
administration via intraperitoneal (i.p.) injection, versus infusion via 
osmotic mini-pump with a pre-loading dose of progesterone. The 
pharmacokinetic model was then used to estimate progesterone 
concentrations in published studies that have shown neuroprotection. 
Delivering progesterone via osmotic mini-pumps has not been employed 
previously and information about the release characteristics could pave the 
way for its use in neuroprotection studies.  
 
2.2 MATERIALS AND METHODS 
2.2.1. Ether extraction protocol   
Brains were homogenised with ultrapure water to make a 20% w/v 
homogenate and underwent ether extraction based on a protocol 
mentioned previously. 5 ml of ice-cold diethyl ether was added to brain 
homogenates in glass test tubes, vortexed and left for 15 minutes. Test 
tubes were then placed in an acetone and dry ice bath for 30 seconds or 
until the water/debris layer at the bottom was frozen. The ether layer was 
then decanted into a new test tube and the procedure was repeated 3 
times. The new test tube containing the extracted sample was then placed 
into the acetone and dry ice bath to freeze any residual water and the 
ether layer was decanted into a scintillation vial. This was placed in a fume 
cupboard and allowed to evaporate to dryness.  
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2.2.2 Animals 
Experiments were carried out in accordance with the UK Home Office 
Animals (Scientific Procedures) Act, 1986 (Project License 40/3207) and 
were approved by the University of Nottingham ethical review process. 
Male C57 Bl/6 mice (10-12 weeks) were used, weighing between 20.5 and 
30.5g at the time of injection. Mice were assigned a code by a non-
experimenter and assigned randomly to different time point groups. In 
total, 74 animals were used in this study, 3 at time point 0 for both i.p. 
injection alone and infusion, 58 animals for i.p. only (see table 2.1 for 
individual numbers at each time point) and 13 for infusion only (see figure 
2.2 for individual numbers at each time point). 
  
2.2.3 Progesterone administration 
Mice were injected intraperitoneally with 8 mg/Kg of progesterone (USP) 
(Sigma, St Louise, MO, U.S.A) using a solution of 16mg/ml progesterone 
dissolved in 100% dimethyl sulfoxide (DMSO; Sigma). Control animals only 
received 100% DMSO. Mice were injected under isoflurane anaesthesia 
(induction 4%: maintenance 1.5% in a NO2/O2 70/30% mixture) and were 
allowed to recover from the anaesthesia. Animals receiving i.p. injection 
without mini-pump implantation also received anaesthesia for control. 
Mini-pumps with an infusion rate of 1.0 µl/h and a reservoir with up to 3 
days delivery capacity (Alzet 1003D; Alzet, Cupertino, CA, USA) were 
loaded with progesterone solution (50mg/ml dissolved at 37oC in 100% 
DMSO). These were submerged in 0.9% sterile saline solution at 37oC 
overnight in order to prime the pumps to start progesterone delivery 
immediately after implantation. Mini-pumps were implanted 
subcutaneously behind the neck under isoflurane anaesthesia (induction 
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4%: maintenance 1.5% in a NO2/O2 70/30% mixture). Mice were given a 
progesterone loading dose (8mg/Kg i.p. progesterone dissolved in 100% 
DMSO) immediately after implantation before being allowed to recover 
from anaesthesia.   
 
2.2.4 Determination of progesterone in plasma and brain 
At appropriate time points i.e. 4h, 6h and 24h, following the onset of 
dosing mice were given an i.p. overdose of pentobarbital and killed by 
exsanguination via cardiac puncture. Blood samples were collected from 
the cardiac puncture and whole brains were removed. The brains collected 
at 4 and 24 h were dissected into 6 regions: vulnerable cortex, non-
vulnerable cortex, hippocampus and striatum, midbrain, cerebellum and 
brainstem for progesterone assay. The vulnerable cortex is the area of the 
cortex closest to the middle cerebral artery (MCA), which is occluded in the 
majority of studies (for example see Gibson & Murphy (Gibson and 
Murphy, 2004)) to surgically induce stroke, and therefore, suffers the 
greatest degree of ischaemic damage (dissection of this region was carried 
out 2.5 mm anterior and posterior from MCA). Non-vulnerable cortex 
comprises the anterior and posterior regions of the cortex furthest away 
from the middle cerebral artery (beyond 2.5 mm anterior and posterior 
from MCA) and, would therefore be least affected in future studies utilising 
experimental stroke via occlusion of the MCA.     
Blood was centrifuged at 16,000g, at room temperature for 15 minutes and 
plasma collected. Plasma and brains were stored at -80oC for later 
analysis. Brains were homogenised with ultrapure water to make a 20% 
w/v homogenate and underwent ether extraction based on the protocol 
described previously (section 2.2.1). Ether extracts were stored at -80oC 
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and then reconstituted with 5% ethanol in ultrapure water prior to 
progesterone assay using a commercial kit (Progesterone Enzyme 
Immunoassay Kit; Cayman Chemicals, Michigan, USA). Progesterone 
standards were also ether extracted and recovery was calculated to be 
98.9%. Samples were analysed in duplicate according to the 
PDQXIDFWXUHU¶VLQVWUXFWLRQVDQGDEVRUEDQFHZDVUHDGXVLQJDSODWHUHDGHU
(Dynex Technologies MRX II) at 405nm.  
    
2.2.5 Data analysis 
Data are expressed as means ± standard error of the means (SEM). 
Differences between plasma and brain progesterone concentration time 
points were analysed with a linear mixed effects model (PASW Statistics 
18.0.2, IBM, Chicago, IL, USA). Area under the curve (AUC) was measured 
using the linear trapezoidal rule, which was used to calculate total body 
clearance and apparent volume of distribution (Vengpedersen, 1989). 
GraphPad Prism version 5.0 for Windows (GraphPad Software, San Diego, 
CA, USA) was used to analyse differences in brain regional progesterone 
concentrations at different time points, using two-way analysis of variance 
(ANOVA). If a significant difference was observed, post-hoc Bonferroni 
multiple comparison was performed. The criterion for statistical significance 
was P < 0.05 for all analyses. Pharmacokinetic parameters for components 
were calculated by methods and equations given by Gibaldi and Pierrier 
(Gibaldi, 1982) and Martin (Martin, 1986), using Excel and GraphPad Prism 
Version 5.0 for windows.   
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2.3 RESULTS 
Inspection of the progesterone absorption, distribution, elimination profile 
after a single bolus injection revealed two phases and so a two-
compartment analytical model was applied. The two-compartment model 
assumes that, following drug administration into the central compartment, 
the drug distributes between that compartment and the peripheral 
compartment. This distribution i.e. equilibration is not instantaneous 
between the compartments and in a concentration time-profile a biphasic 
response can be seen. Mean values of plasma and brain progesterone 
concentration are shown in Table 2.1. These values were used to construct 
a time-course, which shows total progesterone concentration over time 
and comprises a fast and slow component after one bolus i.p. injection 
dose of 8mg/kg of progesterone in both plasma and brain (see figure 2.1 
for brain profile).  
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Figure 2.1: Elimination of progesterone from the brain after one 
bolus intraperitoneal dose of 8mg/kg.  
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The total component comprises both fast and slow components. Fast 
component half-life was 0.2 hr with 96% eliminated for this component 
and the slow component being 2.3 hr. There were no samples taken prior 
to the first 15 minute sampling point; therefore, the extrapolation from the 
time zero to the first time point is a theoretical estimate (shown in solid 
lines). This figure shows only the first 2 hrs of elimination and the sampling 
intervals at this time were 0, 0.25, 0.5, 1 and 2 hrs.     
 
In plasma the fast component half-life of progesterone was 0.2 hr with 
96% eliminated and 23.1 hr for the slow component. In brain, the fast 
component half-life for progesterone was 0.2 hr with 96% eliminated and 
the slow component half-life was 2.3 hr. Half-life calculations were based 
on sampling time points of 15 minutes onwards. Therefore, half-life 
calculations may not represent the true half-life of progesterone because 
earlier measurements prior 15 minutes were not available for half-life 
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calculations. The maximum concentration time (T max) after one bolus 
injection was estimated to be in the region of up to 15 minutes for both 
plasma and brain. The maximum recorded concentration (C max) was 
achieved at this time point for both brain and plasma (plasma; 110.3 
ng/ml, brain; 268.3 ng/g). Similarly, the AUC was 297.6 ng/hr/ml in 
plasma, and 172.8 ng/hr/g in brain (for a time out to 24 hrs). The 
difference between plasma and brain progesterone concentrations at 
sampling time points was statistically significant (P<0.001) (Table 2.1). 
 
Table 2.1: Progesterone concentrations in plasma and brain, 
following a single bolus i.p. dose of 8mg/kg.  
Time (hrs) n 
Mean Plasma 
(ng/ml) 
Mean Brain 
(ng/g) 
Mean of 
Brain/Plasma Ratios 
     
0 3 0.89 ± 0.41 0.72 ± 0.56 1.58 ± 1.29 
0.25 7 110.28 ± 40.69  268.27 ± 136.49 1.74 ± 0.38 
0.5 9 65.58 ± 23.62 66.38 ± 15.59 1.48 ± 0.29 
1 7 34.32 ± 18.71 10.35 ± 3.64 0.61 ± 0.14 
2 7 13.94 ± 3.93 13.91 ± 5.41 0.87 ± 0.22 
4 7 11.81 ± 1.37 2.48 ± 0.34 0.21 ± 0.02 
8 7 16.80 ± 1.85 4.65 ± 0.89 0.29 ± 0.05 
16 7 5.07 ± 1.27 1.23 ± 0.20 0.61 ± 0.35 
24 7 7.63 ± 1.73 1.73 ± 0.72 0.35 ± 0.15 
 
Data are expressed as means ± SEM. Mean brain plasma ratios are the 
overall means of brain ng/g divided by plasma ng/ml. Differences between 
plasma and brain were significant (P<0.001).  
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Progesterone concentrations achieved by a loading i.p. dose and mini-
pump infusion were much higher compared to the bolus dose alone at the 
same time points. T max was 4 hr in plasma and 24 hr in brain. C max for 
plasma was 69.3 ng/ml and 87.5 ng/ml for brain. The AUC for plasma was 
968.0 ng/hr/ml up to 24 hrs and 1167.0 ng/hr/ml up to 48 hrs while brain 
reached 1641.8 ng/hr/g up to 24hrs and 3358.6 ng/hr/g up to 48hrs. Brain 
progesterone concentrations stayed at a relatively high steady state 
concentration, peaking at 24 hrs (figure 2.2). In comparison, progesterone 
plasma concentrations did not stay at steady state concentrations but was 
in decline after peaking at 15 minutes (figure 2.3). The AUC shows that far 
higher progesterone concentrations were reached and maintained in both 
plasma and brain using osmotic mini-pump delivery with loading dose 
compared to a bolus dose alone.   
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Figure 2.2: Brain progesterone concentrations in mini-pump-
implanted male C57 Bl/6 mice injected with 8mg/kg of 
progesterone after implantation.     
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Data are expressed as means ± SEM. There were no samples taken prior 
to 4 hrs; therefore the extrapolation from time zero to the first time point 
is a theoretical estimate from time 0 concentration (shown in solid lines). 
n=3-5 (times 0 hrs n=3, 4 hrs n= 4, 24 hrs n= 5 and 48 hrs n=4) 
independent samples analysed in duplicate.  
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Figure 2.3: Plasma progesterone concentrations in mini-pump-
implanted male C57 Bl/6 mice injected with 8mg/kg of 
progesterone after implantation.     
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Data are expressed as means ± SEM. There were no samples taken prior 
to 4 hrs; therefore the extrapolation from time zero to the first time point 
is a theoretical estimate from time 0 concentration (shown in solid lines). 
n=3-5 (times 0 hrs n=3, 4 hrs n= 4, 24 hrs n= 5 and 48 hrs n=4) 
independent samples analysed in duplicate.  
 
The difference between plasma and brain progesterone concentrations was 
found to be significant in mini-pump-implanted animals (P<0.001). 
Progesterone regional concentrations were found to be elevated at 24hrs, 
compared to 4hrs [F(1,36)= 2.92, P=0.0258] (figure 2.4), but the 
distribution of progesterone between brain regions was found to be 
unchanged [F(5,42)= 2.17, P=0.0756] (figure 2.5). This indicates regional 
distribution of progesterone to be in a steady state, unchanged by 
progesterone concentration in the whole brain.   
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Figure 2.4: Progesterone concentration in difference brain regions 
after mini-pump implantation 
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Progesterone regional concentrations were found to be elevated at 24hrs, 
compared to 4hrs [F(1,36)= 2.92, P=0.0258]. Regional concentrations of 
progesterone (ng/g) were measured at 4 hrs (n=4 per region) and 24 hrs 
(n=5 per region) after loading dose of 8mg/kg and mini-pump 
implantation. Brains were dissected into 6 regions: vulnerable cortex, non-
vulnerable cortex, hippocampus and striatum, midbrain, cerebellum and 
brainstem for progesterone assay. The vulnerable cortex is the area of the 
cortex closest to the MCA. Non-vulnerable cortex comprises the anterior 
and posterior regions of the cortex furthest away from the MCA and, would 
therefore be least affected in future studies utilising experimental stroke 
via occlusion of the MCA. Data are expressed as means ± SEM. 
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Figure 2.5: Distribution of progesterone in whole brain after mini-
pump implantation 
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The distribution of progesterone between brain regions was found to be 
unchanged [F(5,42)= 2.17, P=0.0756]. Regional progesterone distribution 
were measured at 4 hrs (n=4 per region) and 24 hrs (n=5 per region) 
after loading dose of 8mg/kg and mini-pump implantation. Brains were 
dissected into 6 regions: vulnerable cortex, non-vulnerable cortex, 
hippocampus and striatum, midbrain, cerebellum and brainstem for 
progesterone assay. The vulnerable cortex is the area of the cortex closest 
to the MCA. Non-vulnerable cortex comprises the anterior and posterior 
regions of the cortex furthest away from the MCA and, would therefore be 
least affected in future studies utilising experimental stroke via occlusion of 
the MCA. Data are expressed as means ± SEM. 
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2.4 DISCUSSION 
Before attempts can be made to optimise the dosing of animals in 
preclinical experiments, the pharmacokinetics of progesterone need to be 
established. The study by Jiang et al  conducted a experimental stroke 
study, using a dosing regimen based on other studies (Roof et al., 1996; 
Roof et al., 1992), which had shown neuroprotection and they conducted 
their own preliminary pharmacokinetic experiment (Jiang et al., 1996). In 
that preliminary pharmacokinetic study (n=2), they found plasma 
progesterone concentrations to rise to 41.9 and 70.7 ng/ml 4hrs after i.p. 
administration of 4 mg/kg progesterone dissolved in DMSO, from pre-
injection levels of 7.17 and 5.29 ng/ml in male rats. However, the 
progesterone half-life in this and other studies was not calculated, although 
the metabolism and clearance of progesterone is believed to be quite rapid 
in mice, Beckley at al found after a single i.p. injection of 5mg/kg 
progesterone in mice, plasma progesterone dropped from around 125 
ng/ml (0.4 µM) at 0.5 hrs to around 30 ng/ml (0.1 µM) at 2 hrs and below 
20 ng/ml at 8 hrs (<0.1 µM), but did not calculate the progesterone half-
life or investigated other forms of dosing (Beckley and Finn, 2007). The 
use of mini-pumps for the delivery of agents has been used previously in 
pre-clinical stroke studies (Altura and Altura, 1999; Farr et al., 2007; 
Marshall et al., 2000), but progesterone dosing, via mini-pump in pre-
clinical studies of stroke have not been conducted previously. Hence, due 
to the lack of detailed pharmacokinetic information for both i.p. and 
infusion of progesterone, it was necessary to establish a pharmacokinetic 
profile in the mouse model to allow the construction of a dosing regimen to 
maintain a therapeutic level of progesterone.    
Previous studies demonstrating the neuroprotective properties of 
progesterone following experimental stroke in male mice, such as that by 
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Gibson & Murphy (Gibson and Murphy, 2004), have used a dosing regimen 
of 8mg/kg progesterone injected intraperitoneally (dissolved in 100% 
DMSO). This dose and route of administration were also found to be 
neuroprotective in several other studies (Gibson et al., 2005b; Gibson et 
al., 2011; Ishrat et al., 2009; Kumon et al., 2000; Sayeed et al., 2009; 
Sayeed et al., 2007). The present study was focused on clarifying the 
progesterone pharmacokinetic profile in both plasma and brain, comparing 
intraperitoneal administration previously shown to be neuroprotective, to 
an infusion delivery method of progesterone. Infusion methods are 
commonly used to maintain drug concentrations within the therapeutic 
range. Osmotic mini-pumps were used as the method of infusion as they 
release progesterone at a constant rate, therefore avoiding the diminishing 
levels of release over time as is the case with pellet implants. However, 
with mini-pumps there is an unavoidable delay before effective tissue 
concentrations are reached, so an i.p. loading dose of progesterone was 
employed to achieve effective concentrations rapidly. Progesterone was 
only measured up to 48 hrs from the start of treatment due to brain levels 
peaking and reaching steady state by this time.             
Progesterone delivered via a single i.p. injection had a very short half-life 
in both plasma and brain, with brain progesterone levels reaching more 
than twice those in plasma at 15 minutes. It is not surprising that 
progesterone accumulates in the brain, since steroid hormones are very 
lipophilic and so have a tendency to move from plasma into fatty tissues 
(Zhu et al., 2004). Progesterone is readily able to cross the blood-brain 
and blood-nerve barriers, and rapidly accumulates in neural tissue 
(Pardridge and Mietus, 1979; Schumacher et al., 2000). In this study, after 
30 minutes, progesterone levels in the brain fell to concentrations similar 
to plasma and eventually dropped below plasma progesterone levels (Table 
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2.1) which is not surprising given that progesterone undergoes metabolism 
in the brain (Billiar et al., 1975; Frye et al., 1998; Johnson et al., 1976). A 
major pathway responsible for the metabolism of progesterone is via the 
5Į-reductase enzyme, which is widespread in both neurons and glial cells, 
with neurons displaying higher rates of enzyme activity compared to glial 
cells. In particular, white matter structures contain very high levels of the 
enzyme. Progesterone is converted to 5Į-dihydroprogesterone and is 
further metabolised to other compounds (Lephart et al., 2001). One such 
metabolite, allopregnanolone (5Į,3Į-preganolone) may convey greater 
neuroprotection in ischaemic stroke compared to progesterone (Sayeed et 
al., 2006). Progesterone has a high metabolic clearance rate and about 
75% of metabolism takes place in the liver and spleen (Lobo, 2000). This 
may partly explain why the plasma progesterone level is lower in 
comparison to the brain concentrations of animals with mini-pump 
infusions, due to rapid splenic and hepatic elimination. It is unclear why 
plasma progesterone concentrations are higher than brain at later time 
points but there may be some release of progesterone from fatty tissue 
reservoirs which have accumulated the steroid.      
Application of the i.p. progesterone pharmacokinetic model derived in the 
present study to the results of Gibson & Murphy (Gibson and Murphy, 
2004) predict that progesterone concentrations in the brain would peak 
transiently at about 250 ng/g (0.8 µM) around 15 mins after injection with 
almost total clearance within 2 hrs. Despite delivering only transient peaks 
of the steroid in the brain, this dosing method was successful in providing 
neuroprotection to young male mice (Gibson and Murphy, 2004). However, 
the ideal profile would be to maintain progesterone concentration at as 
high as possible concentrations due to the lack of toxicity from the steroid 
(Gaver et al., 1985; Little et al., 1974). Progesterone treatment seems to 
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be most effective 0-2 hrs following cerebral ischaemia (Gibson et al., 
2007), although no studies in pre-clinical stroke have administered 
progesterone after this period. Therefore, an early, high transient peak of 
progesterone may be enough to initiate neuroprotection, although future 
studies will need to determine whether the higher maintained progesterone 
concentrations achieved by infusion produce better neuroprotection after 
experimental stroke. Due to the transient nature of the concentration peak 
following a single i.p. dose, a repeated i.p. dosing schedule was not 
assessed.      
In comparison to physiological levels in mice, plasma progesterone 
concentrations reached 110.28 ng/ml (0.35 µM) 15 minutes after bolus 
injection, which is far higher compared to the healthy male mice that 
received no progesterone at zero time point (0.89 ng/ml or 0.003 µM) 
(Table 2.9). This plasma concentration is somewhat higher than that 
measured around the peak of pregnancy. McCormac & Greenwald found 
the peak progesterone concentration during pregnancy to reach 39 ng/ml 
(0.12 µM)  in plasma (McCormac.Jt and Greenwal.Gs, 1974) and Virgo & 
Bellward found serum progesterone levels in pregnant mice to peak at 81.9 
ng/ml (0.26 µM) (Virgo B.B., 1974). Brain progesterone concentrations in 
the first 30 minutes after dosing were above the highest progesterone 
concentration found in the brain during the mouse oestrous cycle 
(approximately ~45 ng/g or ~0.14) in meta-oestrus 2 (Corpechot et al., 
1997), whilst levels in the brains of mini-pump implanted mice remained 
relatively constant between about 50 and 100 ng/g (0.16 µM and 0.32 µM) 
from 4-48 hrs, approximating to high physiological levels. The oestrous 
cycle has been shown to affect the severity of focal cerebral ischaemia in 
pre-clinical studies. In pro-oestrous spontaneous hypertensive rats, the 
infarct after focal cerebral ischaemia was found to be smaller compared to 
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animals in meta-oestrus (Carswell et al., 2000), meta-oestrous 
spontaneous hypertensive rats also had larger infarcts than respective 
males that underwent ischaemia during meta-oestrus (Carswell et al., 
1999).      
There are few reported studies involving progesterone and experimental 
stroke using infusion delivery; Alkayed et al (Alkayed et al., 2000) is the 
only published study utilising an infusion method with rats and Coomber & 
Gibson (Coomber and Gibson, 2010) with mice. The Coomber & Gibson 
(Coomber and Gibson, 2010) study is the only one to date that has 
measured progesterone in both plasma and brain after treatment with slow 
releasing tablets containing 50 mg of progesterone inserted 
subcutaneously 7 days prior to middle cerebral artery occlusion (MCAO). 
That study failed to show benefit in terms of lesion volume, but the 
progesterone concentration measured in plasma and brain on the day that 
animals received MCAO was found to be 11.6 ng/ml in plasma and 38.2 
ng/g in brain, well below the steady-state levels measured in the present 
study. Therefore, it would be worthwhile employing the present mini-pump 
infusion approach in order to achieve higher maintained brain levels in 
stroke models. However, increasing progesterone dose does not 
necessarily result in greater neuroprotection. Some studies have used 
higher doses of progesterone via i.p. injections but found no significant 
beneficial effect, ranging from 10-32 mg/kg (Chen and Chopp, 1999; 
Murphy et al., 2002; Murphy et al., 2000). Chen et al found 8 mg/kg to be 
neuroprotective but not 4 mg/kg or 32 mg/kg (Chen and Chopp, 1999), 
indicating a dose-response efficacy window. Lower doses of progesterone 
may not be enough to reach pharmacological concentrations, while other 
mechanisms may be involved in terms of higher doses. Cutler et al used 
16mg/kg of progesterone and found acute withdrawal increases apoptosis, 
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inflammation and anxiety behaviours during the acute recovery phase after 
TBI compared to tapered withdrawal, but regardless of progesterone 
treatment regimen all progesterone treated animals showed improvement 
over vehicle treatment (Cutler et al., 2005). They postulated that acute 
withdrawal leads to sudden decrease in GABA-A interactions with the 
progesterone metabolite allopregnanolone, resulting in increased NMDA 
activation, which eventually leads to a excitatory neural environment. 
Under the added stress of trauma, this effect is amplified and results in 
excitotoxicity but with gradual withdrawal, this excitotoxicity, secondary 
injury and inflammation are not exacerbated (Cutler et al., 2006b). 
Because both TBI and stroke share similar pathological mechanisms, it is 
possible that high 32 mg/kg progesterone i.p. dose used in Chen et al may 
amplify this acute withdrawal effect in stroke. The high dose of 32 mg/kg 
in Chen et al did reduce lesion volume but was not significant compared to 
8mg/kg dose. Therefore, tapered withdrawal with high doses of 
progesterone is worth considering. As there are very few published studies 
involving infusion methods and all have been given pre-emptively before 
surgically induced stroke (Alkayed et al., 2000; Coomber and Gibson, 
2010), further investigation is needed to determine whether this infusion 
method is effective when used immediately after stroke.    
There was no difference in the accumulation of progesterone in various 
brain areas (Figure 2.4). Progesterone appears to distribute itself equally in 
areas of predominant white and gray matter. In ischaemic stroke, both 
white and gray matter, are vulnerable to damage and so potential 
neuroprotectants should ideally access and protect both compartments 
(Falcao et al., 2004). Therefore, it is encouraging that progesterone is able 
to accumulate in both compartments since the lack of white matter 
protection may be a contributing factor in the failure of experimental 
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neuroprotective strategies (Cheng et al., 2004; Ho et al., 2005). However, 
caution is needed when extrapolating results from rodent models to 
humans as the amount of white matter in rodents is far smaller in 
comparison (Green, 2003).    
In conclusion, this study demonstrates that osmotic mini-pump delivery (in 
conjuction with a bolus i.p loading dose) is an effective way of delivering 
progesterone to the target areas of the brain. Future studies will employ 
this delivery method to assess potential neuroprotection in experimental 
stroke.  
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CHAPTER 3  
Effects of progesterone and oxygen glucose 
deprivation on microglial and neuroblastoma 
cells 
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3.1 INTRODUCTION 
Ischaemic stroke involves complex excitotoxic, inflammatory, and vascular 
mechanisms that lead to neuronal cell death. Inflammatory cells and 
mediators are important contributing factors in ischaemic brain injury (del 
Zoppo et al., 2000). Stroke triggers an inflammatory reaction that is 
initiated hours after stroke onset and plays a central role in the 
pathogenesis of the condition (Son et al., 2009). This inflammatory 
response is characterised by the accumulation of inflammatory cells, 
including blood-derived leukocytes and activation and accumulation of 
microglia within the brain tissue, which subsequently leads to brain injury 
(Jiang et al., 2009). The disruption of the blood-brain barrier (BBB) after 
stroke allows blood-derived leukocytes to enter the brain, further 
amplifying inflammatory signal cascades (Han and Yenari, 2003).   
Microglia cells are the resident macrophages of the brain and function as 
scavenger cells in the event of infection, trauma, neurodegeneration, 
inflammation and ischaemia (El Khoury et al., 1998; Thomas, 1992). Once 
activated, microglia undergo morphological transformation into 
phagocytes, making them indistinguishable from circulating macrophages 
(Wang et al., 2007). There is considerable evidence to suggest that 
microglial activation precedes and predominates over macrophage 
infiltration after cerebral ischaemia (Jin et al., 2010). Active microglia, are 
particularly detrimental to the injured brain and contribute to infarct 
volume (Schilling et al., 2003; Schilling et al., 2005). Inflammatory cells 
can infiltrate around the ischaemic area and several pro-inflammatroy 
genes or mediators are strongly expressed in the ischaemic brain (Stoll et 
al., 1998). These expressed mediators include; inducible nitric oxide 
synthase (iNOS), cycloxygenase-2 (COX-2) and pro-inflammatory 
cytokines, such as interleukin (iL)-6 and tumour necrosis factor (TNF)-Į
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(Kim et al., 2002). As well as having a detrimental role in cerebral 
ischaemia, micoglia have a potentially positive role in the resolution of 
inflammation and are sources of growth factors for repair, including 
insulin-like growth factor 1 (IGF-1) and glial cell line-derived neurotrophic 
factor (GDNF) (Iadecola and Anrather, 2011).  
Substantial evidence supports the involvement of nitric oxide (NO) in 
ischaemic brain injury (Moro et al., 2004). Immediately after the start of 
ischaemia, vasodilatory effects of NO produced, mainly by endothelial NOS 
(eNOS) protects the brain by limiting the degree of flow reduction caused 
by the arterial occlusion. However, after the development of ischaemia, NO 
produced by neuronal nitric oxide synthase (nNOS), followed by inducible  
iNOS, contributes to the development of brain injury (del Zoppo et al., 
2000). Under basal conditions, NO release from microglial cells is negligible 
but stimulation with lipopolysaccharide (LPS) or  cytokines such as TNF-Į
DQGLQWHUIHURQJDPPD,)1ǄFDXVHVPLFURJOLDOFHOOVWRUHOHDVHVXEVWDQWLDO
amounts of free radical NO (Kawahara et al., 2009; Weinstein et al., 
2008).  
Progesterone has been shown to act at multiple sites and through various 
pathways to either slow or interrupt the complex processes involved in 
neuronal cell death. Mechanisms of neuroprotection include; preventing 
accumulation of fluid inside neurons and astrocytes, up-regulation of GABA 
(counteracting glutamate-mediated excitotoxicity), antioxidant effects, 
reduction of inflammatory cytokines and decreased apoptosis (Stein et al., 
2008). The iNOS gene is transcriptionally activated, probably in response 
to the surge of proinflammatory cytokines such as interleukin (IL)-ǃDQG
TNF-Į IROORZLQJ FHUHEUDO LVFKDHPLD (Murphy et al., 2000). Progesterone 
has been shown to suppress the inflammatory response and iNOS 
expression following cerebral ischaemia in vivo (Gibson et al., 2005b). 
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Also, it has been observed that progesterone decreases iNOS mRNA 
expression and iNOS promoter activity in macrophages in vitro (Lieb et al., 
2003). The expression and function of iNOS can be reduced by 
progesterone or via its activators, including IL-ǃDQG71)-Į(Coughlan et 
al., 2005).  
There are key aspects in which in vitro models differ from in vivo models. 
Typically, a longer duration of an anoxic or hypoxic insult is required to kill 
neurons in vitro, adenosine triphosphate (ATP) depletion is less severe and 
the release of glutamate is delayed compared to ischaemia in vivo (del 
Zoppo et al., 2007). The absence of blood vessels and blood flow in vitro 
eliminates important structural and functional components of the damage 
process found in vivo, including the infiltration of inflammatory cells 
(Taoufik and Probert, 2008). Also, the composition and responsiveness of 
glial cells in vitro differs from those in intact brain (Yuan, 2009). Despite 
these differences, there are still similarities in the way isolated cells behave 
under substrate stress and the way in which cells behave under the 
catastrophic conditions of stroke in vivo (Arumugam et al., 2007). The use 
of in vitro cell models allows stroke mechanisms to be investigated without 
interference from conflicting processes that are present in vivo. In vitro 
models can provide simple, highly controlled experimental systems, which 
can generate detailed basic information as to how cell types respond to 
oxygen and glucose deprivation (OGD). However, the complexity of the 
architecture of the brain also requires in vivo models of ischaemic stroke 
(Woodruff et al., 2011). Therefore, both in vitro and in vivo approaches 
can complement one another in stroke research.        
The aim of the present chapter is to investigate the effects of progesterone 
on NO production, microglial viability and the viability of SHSY5Y 
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neuroblastoma cells, subjected to simple models of OGD representative of 
cerebral ischaemia. 
 
3.2 MATERIALS AND METHODS 
3.2.1 Maintaining SHSY5Y and BV-2/HAPI cell culture stocks 
BV-2 microglial cells were a generous gift from Prof. Nephi Stella, 
University of Washington, while SHSY5Y and highly aggressively 
proliferating immortalised (HAPI) cells were a generous gift from Prof. 
Andrew Bennett, University of Nottingham. The two microglia cells lines 
(BV-2 and HAPI) cells were utilised, in case of differences in inflammatory 
response e.g. HAPI cells could be considered to model more closely to 
activated cells. Cell stocks were grown in 75-cm2 culture flasks containing 
PO RI '0(0 'XOEHFFR¶V 0RGLILHG (DJOH 0HGLXP FXOWXUH PHGLXP ZLWK
10% foetal bovine serum (FBS) and 2mM L-glutamine. This media was 
used unless otherwise stated for growing cells and in the initial seeding of 
plates for experiments. Cells in culture flasks were left to grow in the 
incubator at 37oC with 5% CO2 and 95% air (v/v) at 90% humidity until 
they were sub-confluent ~3x 106 cells/ml (to prevent ischaemic 
conditioning) and were then sub-cultured to maintain cell stocks or for 
experiments. The cells were sub-cultured by dissociating cells with 1 x 
trypsin-EDTA (ethylenediaminetetraacetic acid) and split to a dilution of 
1:5 for SHSY5Y and 1:10 for BV-2/HAPI to maintain cell stocks.   
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3.2.2 LPS experiments 
BV-2 cells were sub-cultured from cell stocks for use in experiments and 
were seeded onto 24 well plates (1:10 from cell stock). Each well 
contained 1 ml of DMEM growth media (previously described for 
maintaining cell stocks) and the cells were left to grow until confluent at 
37oC with 5% CO2 and 95% air (v/v) at 90% humidity. Media was then 
aspirated and replaced with serum-free media (SFM) containing 0.01% 
DMSO with either or combination of control, 100ng/ml lipoplysaccharide 
(LPS), progesterone (5-50 µM), mifepristone (10 µM), depending on 
experimental variables and placed in an incubator at 37oC with 5% CO2 
and 95% air (v/v), at 90% humidity for 24hrs before neutral red viability 
testing and nitric oxide quantification (NO). Progesterone and Mifepristone 
stock concentrations were 1000x greater than the final required 
concentration, dissolved in 100% DMSO. Stock concentrations were then 
diluted 1:1000 with the required media to attain final concentration at 
0.01% DMSO. LPS stocks and final dilution are accomplished in the same 
manner except LPS stock was dissolved in phosphate-buffered saline 
(PBS).   
 
3.2.3 OGD experiments 
3.2.3.1 Cell Preparation 
When preparing cells for ischaemic experiments, cells stocks were sub-
cultured using DMEM growth media and seeded at 1 x105 cells/ml onto 96-
well culture plates. Each well contained 200µl total volume per well. 
Cultures were then incubated at 37oC with 5% CO2 and 95% air (v/v) at 
90% humidity for 48hrs to be used in experiments relating to ischaemia.  
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3.2.3.2 OGD and controls 
When plates were ready, culture medium was aspirated from wells and 
washed twice with glucose-free deoxygenated SFM (200 µl for each well 
per wash) for cells undergoing ischaemia or SFM for non-ischaemic wells. 
Glucose-free DMEM was deoxygenated by bubbling 5% CO2 and 95% N2 
(v/v) through the medium for 15 minutes. After the wash stage, glucose-
free deoxygenated DMEM containing 0.1% DMSO with a combination of 
vehicle (0.1% DMSO only), progesterone (0.1-100 µM) or mifepristone (10 
µM), depending on experimental design, was added to wells (100 µl total 
volume per well) designated for the anaerobic chamber. Oxygen 
concentration in the chamber was maintained at <1 % throughout the 
incubation period using a ProOx 110 controller and chamber (BioSpherix). 
Plates were then placed in an anaerobic chamber that was flushed with 5% 
CO2 and 95% N2 (v/v). Cell cultures were kept in the chamber for between 
2 and 8 hrs at 37oC and at 90% humidity. For cells not designated for the 
anaerobic chamber; after the wash stage, SFM-containing 0.1% DMSO 
with a combination of control, progesterone (10-100 µM) or mifepristone 
(10  µM), depending on experimental design, was added to the wells (100 
µl total volume per well). These cells were then placed at 37oC with 5% 
CO2 and 95% air (v/v) at 90% humidity during the incubation period and 
WKHVHFHOOVZHUHUHIHUUHGWREHLQ µQRUPR[LFFRQGLWLRQV¶Progesterone and 
Mifepristone stock dilutions and final concentrations were achieved in the 
same manner as described in LPS experiments. 
 
3.2.3.3 Re-oxygenation 
Once the ischaemic period was finished, the deoxygenated media was 
aspirated off and replaced with SFM containing different concentrations of 
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progesterone in 0.1% DMSO (w/v) or 0.1% DMSO vehicle for the re-
oxygenating treatment back to normal conditions at 37oC with 5% CO2 and 
 DLU YY DW  KXPLGLW\ IRU KUV &HOOV GHVLJQDWHG IRU µQRUPDO
FRQGLWLRQV¶ZHUHWUHDWHGLQWKHVDPHPDQQHU 
 
3.2.3.4 Assessment of cell viability 
Viability assays determine the ability of cells to maintain or recover their 
viability. Each type of assay assesses a particular cell function i.e. MTT and 
resazurin assays are based on reduction of colouring reagents by enzymes 
in the mitochondria to determine mitochondrial function; neutral red is 
based on the cells ability to incorporate and bind the dye to lysosomes, 
and trypan blue assesses cell membrane integrity. Therefore, a 
combination of viability assays can indicate which particular cell functions 
may be involved in cell death.   
 
3.2.3.5 Resazurin viability assay 
Resazurin (7-Hydroxy-3H-phenoxazin-3-one 10-oxide) is used as an 
oxidation-reduction indicator in cell viability assays. It is a blue dye, itself 
non-fluorescent until it is reduced in mitochondria by oxidoreductase, to 
the pink coloured, and highly red fluorescent resorufin. In the presence of 
diaphorase as the enzyme, NADH or NADPH is the reductant that converts 
resazurin to resorufin. Therefore, resazurin/diaphorase/NADPH system can 
be used to detect NADH, NADPH, or diaphorase level and any biochemical 
or enzyme activity, which is involved in a biochemical reaction generating 
NADH or NADPH. Resazurin is both non-toxic and stable in culture medium, 
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as well as being simple to measure continuously in a high throughput 
manner (Zhang et al., 2004).  
Media was aspirated and wells were washed with the same volume of PBS 
or media in the well. 100 µ0RIUHVD]XULQLQ+DQN¶VEDODQFHGVDOWVROXWLRQ
(HBSS) (w/v) was added to a volume of 200 µl in each well. Cells were 
then incubated in normal conditions of 37oC with 5% CO2 and 95% air 
(v/v) at 90% humidity for 45 minutes.  Plates were then read using a plate 
reader at 540 nm, immediately after incubation. The viability was 
calculated from % of control in normoxic conditions. 
 
3.2.3.6 MTT viability assay 
The MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 
assay measures the activity of mitochondrial dehydrogenase, that reduces 
MTT tetrazolium bromide dye to purple formazan in living cells. 
Tetrazolium dye reduction is dependent on NAD(P)H-dependent 
oxidoreductase enzymes, mostly in the cytosolic compartment of the cell. 
The reduction of MTT and other tetrazolium dyes increase with cellular 
metabolic activity due to elevated NAD(P)H flux. A solubilisation solution is 
added to dissolve the insoluable formazan product to a coloured solution. 
The absorbance of the coloured solution can then be read and used to 
quantify cells.  
Media was aspirated from 96 well plates and washed twice with PBS. MTT 
was added to DMEM growth medium (see cell culture) to a concentration of 
50 µM then MTT in media (200 µl) was added to each well. Cells were 
incubated at 37oC with 5% CO2 and 95% air (v/v) at 90% humidity for 2 
hrs. Media containing MTT was aspirated and an equal volume of propan-2-
ol was added to each well. This was then mixed by pipetting up and down 
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several times to dissolve the formazan product from MTT metabolism.  
Wells were then read at 620 nm in a plate reader (Dynex Technologies 
MRX II).  The viability was calculated from % of control in normal 
conditions. 
 
3.2.3.7 Trypan blue with automated cell-counter viability assay 
Trypan blue is a vital dye, which selectively colours dead cells blue. The 
chromopore is negatively charged and does not interact with the cell unless 
the membrane is damaged and the membrane potential collapsed. Cells 
that exclude the dye are, therefore, viable (Freshney, 1987). A TC10 
automated cell counter (Bio-Rad, Hemel Hempstead, UK) was also used to 
assess cell viability with trypan blue.  
Media from 96 well plates was aspirated and 20 µl of trypsin-EDTA was 
added to each well and incubated at 37oC for 5 minutes. SFM was then 
added to each well (180 µl) and the well contents were mixed by pipetting 
up and down several times to dislodge adherent cells from the surface and 
from other cells to make a homogenous cell suspension. The cell 
suspension was mixed with equal parts of trypan blue solution (0.4%, Bio-
Rad, Hemel Hempstead, UK) and 10 µl of cell suspension/trypan blue 
solution was pipette onto cell counter slides. Slides were then placed into 
the cell counter to read the cell viability. Viability was measured as % 
control and measured in duplicate.         
 
3.2.3.8 Neutral red viability assay 
The neutral red viability assay is based on the ability of viable cells to 
incorporate and bind the dye, neutral red. This weakly cationic dye 
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penetrates cell membranes by non-ionic passive diffusion and concentrates 
into the liposomes. The dye is then extracted from viable cells using an 
acidified ethanol solution and the absorbance of the solubilised dye is 
quantified using a spectrophotometer. It is, therefore, possible to 
distinguish between viable, damaged or dead cells according to their 
specific lysomal capacity for taking up the dye (Repetto et al., 2008).     
Media was aspirated and wells washed with PBS (1ml per wash) before 
adding 400 µl per well of SFM containing 100 µg/ml of neutral red.  Cells 
were incubated for 1 hr at 37oC with 5% CO2 and 95% air (v/v) at 90% 
humidity.  After incubation, neutral red media was aspirated and wells 
washed 2x with PBS (1 ml per wash) before adding 200 µl of fixative 
solution (50% ethanol, 1% glacial acetic acid in distilled water). This was 
incubated as before for 1 hr and read using a plate reader at 540nm 
(Dynex Technologies MRX II).  Viability was calculated as % difference 
from control in normal conditions.  
 
3.2.3.9 Nitric oxide measurements 
Nitric oxide (NO) was measured using the Greiss reaction, which detects 
the presence of organic nitrite compounds. Culture medium (100 µl) was 
transferred into each well of a 96 well plate, each containing 100 µl of 
Greiss reagent. Greiss reagent consists of 20 mg/ml (w/v) of 
sulphanilamide and 1 mg/ml (w/v) of N-1-napthyethylene dihydrochloride 
dissolved in 1M hydrochloric acid (HCL).  Standards were made using 
NaNO2 dissolved in media (100 µl) with Greiss reagent (100 µl) to 
construct a calibration graph to quantify absolute NO in sample media.  
Plates were read with a plate reader at 540nm (Dynex Technologies MRX 
II). 
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3.3 RESULTS 
3.3.1 Nitric oxide production and viability of BV-2 microglia in OGD 
conditions 
BV-2 microglial cells were exposed to progesterone in normoxic conditions 
for 4 hrs and did not reduce viability (figure 3.1).  
Figure 3.1: BV-2 viability after 4 hrs in normoxic conditions 
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Cell viability is expressed as % of normoxic control (untreated cells). 
Vehicle and progesterone (prog, 30 µM) cultures were incubated in 
normoxic conditions for 4hrs and cell viability was measured using the 
Neutral Red assay. Data are expressed as means of 4 repeats on one 
occasion.  
 
Cells were then exposed to OGD conditions and their effect on the 
production of NO determined. Increased NO production has been 
demonstrated in OGD conditions (Lu et al., 2006; Sun et al., 2005). 
However, in the present study, OGD conditions were not found to enhance 
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NO production above background in any experiments.  The first experiment 
employed 4 hrs of OGD and NO production was measured directly after the 
OGD period.  At this stage it was thought that the length of OGD might not 
be long enough to induce significant levels of NO formation; OGD control 
viability was 73.1% (figure 3.2) and cells may not have had adequate time 
to produce significant amounts of NO at 4 hrs (0.88 ± 0.33 µM).  
 
Figure 3.2: BV-2 viability after 4 hrs in OGD 
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Cell viability is expressed as % of normoxic control (untreated cells). 
Cultures were incubated for 4 hrs with increasing progesterone 
concentrations (0-30 µM) and cell viability was measured using Neutral 
Red assay. All treatment wells contained 0.1% DMSO. Data are expressed 
as means of 4 repeats on one occasion.  
 
Therefore, the time of incubation was extended in further experiments. 
Park et al found re-oxygenation was required to stimulate NO production 
after hypoxia (Park et al., 2002). However, longer OGD periods of 6 hrs 
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and 8 hrs with 24 hrs of re-oxygenation (0.84 ± 0.28 and 0.85 ± 0.28 µM 
respectively) were not effective at producing NO above background (1.54 
± 0.89 µM). At 6 hrs with re-oxygenation, OGD conditions reduced viability 
to 65.15% compared with normoxic control. The addition of progesterone 
further reduced viability compared to untreated cells in OGD (figure 3.3).  
Figure 3.3: BV-2 viability after 6hrs treatment in OGD followed by 
24 hrs re-oxygenation 
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Cell viability is expressed as % of normoxic control.  Cultures were 
incubated with increasing concentrations of progesterone (P0-30 µM) in 
OGD conditions, followed by 24 hrs of reoxygenation in SFM. All treatment 
wells contained 0.1% DMSO. Cell viability was then measured with Neutral 
Red assay. Data are expressed as means of eight repeats in one occasion.  
 
After 8 hrs of OGD, followed by re-oxygenation, viability of OGD control 
was severely reduced, compared to normoxic conditions (4.67% ± 0.64, 
compared to normoxic control) and therefore, was not an appropriate time 
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point to use to evaluate the effects of progesterone on NO production 
(figure 3.4).  
 
Figure 3.4: BV-2 viability after 8 hrs of OGD followed by 24 hrs of 
re-oxygenation 
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Cell viability is expressed as % of cells in normoxic conditions. Cell cultures 
were incubated for 8hrs either in normal glucose and oxygen (normoxic) or 
oxygen and glucose deprived (OGD) conditions, followed by 24 hrs of 
reoxygenation in SFM. All treatment wells contained 0.1% DMSO. Cell 
viability was then measured using Neutral Red assay. Data are expressed 
as means of eight repeats on one occasion.  
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3.3.2 Nitric oxide production and viability of HAPI microglia in OGD 
conditions  
BV-2 Cell viability was reduced by OGD conditions, although this did not 
increase NO production. Therefore, a different microglial cell line of highly 
aggressively proliferating immortalised (HAPI) cells were utilised, in order 
to observe if OGD conditions can increase NO production in this model of 
activated microglia. HAPI microglial cells were exposed to OGD conditions 
to ascertain whether NO was produced. The length of exposure was 6 hrs 
with 24 hrs re-oxygenation, as this was shown, in earlier experiments, to 
produce significant differences in viability at this time with the BV-2 
microglia. However, HAPI cells did not produce NO above background 
concentrations found in normoxic conditions (9.11 µM) when exposed to 
OGD (8.98 µM). Background NO concentrations in HAPI cells (9.11 µM) 
were greater compared to BV-2 (1.54 µM). HAPI cell viability was similar to 
that of BV-2 cells undergoing OGD. HAPI cells exposed to OGD had 
reduced viability compared to normoxic controls and progesterone 
treatment reduced viability to OGD control in the same condition (figure 
3.5).  
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Figure 3.5: HAPI viability after 6hrs treatment in OGD followed by 
24 hrs re- oxygenation  
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Cell viability is expressed as % of normoxic control. Cultures were 
incubated with increasing concentrations of progesterone (0-10µM) in OGD 
conditions, followed by 24hrs of re-oxygenation in SFM. All treatment wells 
contained 0.1% DMSO. Cell viability was then measured with the Neutral 
Red assay. Data are expressed as means of eight repeats on one occasion.  
 
3.3.3 Nitric oxide production and viability of BV-2 microglia in the 
presence of LPS 
Bacterial lipopolysaccharide (LPS) has been used frequently to study the 
release of nitric oxide in microglia, (for example see: (Horvath et al., 
2008; Jiang et al., 2011; Son et al., 2009)). Nitric oxide (NO) production 
was measured using the Greiss assay to determine nitrite and viability was 
measured with the Neutral Red assay in BV-2 microglia. Viability of cells 
was not significantly affected by LPS (figure 3.6), but LPS significantly 
enhanced the production of NO in BV-2 cells, in the presence (P=<0.01) or 
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absence of the progesterone receptor (PR) antagonist mifepristone 
(P=<0.01).  
Figure 3.6: Viability of BV-2 controls 
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BV-2 cells were treated with Lipopolysaccharide (LPS, 100ng/ml), 
progesterone (Prog, 50µM) and progesterone receptor antagonist 
mifepristone (Mife, 10 µM). All treatment wells contained 0.1% DMSO. 
After 24 hr incubation in normoxic conditions, cell viability was measured 
with Neutral Red assay. Viability is expressed as % of normal control 
(untreated cells). Data are expressed as means ± SEM (n=3). No 
significance was found between groups in cell viability using one-way 
ANOVA [F(5,12)= 2.20, P= 0.1219]. 
 
Analysis of controls found a significant difference between groups 
[F(5,12)=10.92, P=0.0004]. Newman-Keuls post-hoc analysis revealed the 
addition of progesterone, mifepristone or a combination of the two, did not 
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affect NO production in the absence of LPS (figure 3.7). These results 
indicate that LPS is required to induce NO production and that this is not 
controlled by endogenous progesterone receptor activity. Later 
experiments will determine the effects of progesterone on viability and NO 
production in the presence of LPS and whether the addition of mifepristone 
will have further affects.     
 
Figure 3.7: Nitric oxide production of BV-2 controls 
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NO production using the Greiss assay after 24 hr incubation for control 
groups. Control groups include normal cell culture media (normal control), 
lipopolysaccharide (LPS, 100ng/ml), progesterone (Prog, 100µM) and 
progesterone antagonist mifepristone (Mife, 10µM). All treatment wells 
contained 0.1% DMSO. One-way ANOVA reveals a significant difference in 
groups [F(5,12)=10.92, P=0.0004] and Newman-Keuls post-hoc analysis 
reveals the LPS group and LPS + Mife group to be significantly different 
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from other controls (P=<0.01*). Data are expressed as means ± SEM 
(n=3). 
 
3.3.4 Nitric oxide production and viability of BV-2 microglia in the 
presence of LPS, progesterone and mifepristone 
There was no effect of progesterone on BV2 viability with [F(6,14)= 0.96, 
P=0.4877] or without miefepristone [F(6,14)= 1.23, P= 0.3507] (figures 
3.8 and 3.9). However, increasing concentrations of progesterone 
significantly decreased LPS-induced production of NO and the presence of 
mifepristone did not alter this [F(1,28)= 1.71, P= 0.2014] (figure 3.10). 
This indicates that the PR receptor is not necessarily needed in the 
attenuation of NO production by progesterone. Also, because cell viability 
was unaffected by progesterone, the effect of the steroid on NO production 
is not simply due to reduced cell viability.     
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Figure 3.8: Viability of BV-2 cells in the presence of LPS and 
increasing concentrations of progesterone 
Progesterone (PM)
% 
Vi
a
bi
lit
y 
o
f N
or
m
a
l C
on
tr
o
l
0 5 10 20 30 40 50
0
50
100
150
 
Cell viability is expressed as % of normal control exposed to normoxic cell 
culture media.  Cultures were exposed to lipopolysaccharide (LPS, 
100ng/ml) and increasing concentrations of progesterone (Prog, 0-50µM). 
All treatment wells contained 0.1% DMSO. After 24 hr incubation in 
normoxic conditions, cell viability was measured with the Neutral Red 
assay. Data are expressed as means ± SEM (n=3). No significant 
differences were found between groups regarding cell viability using one-
way ANOVA [F(6,14)= 0.96, P=0.4877]. 
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Figure 3.9: Viability of BV-2 cells in the presence of LPS plus 
mifeprostone and treated with increasing concentrations of 
progesterone 
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Cell viability is expressed as % of normal control exposed to normoxic cell 
culture media.  Cultures were exposed to lipopolysaccharide (LPS, 
100ng/ml) plus mifepristone (Mife, 10 µM) and increasing concentrations 
of progesterone (Prog, 0-50µM). All treatment wells contained 0.1% 
DMSO. After 24 hr incubation in normoxic conditions, cell viability was 
measured with Neutral Red assay. Data are expressed as means ± SEM 
(n=3). No significant differences were found between groups regarding cell 
viability using one-way ANOVA [F(6,14)= 1.23, P= 0.3507]. 
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Figure 3.10: Nitric oxide production in BV-2 microglial cells 
exposed to LPS with and without mifepristone and treated with 
increasing concentrations of progesterone  
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NO production using the Greiss Reagent assay after 24hr incubation. Cells 
were exposed to LPS, (100ng/ml) with or without mifepristone (10 µM) and 
increasing concentrations of progesterone in normoxic conditions. All 
treatment wells contained 0.1% DMSO. Data are expressed as means ± 
SEM (n=3). Two-way ANOVA revealed increasing concentrations of 
progesterone significantly decreases NO production [F(6,28)=5.812, 
P=0.0005]. However, there was no significant difference in NO production, 
when mifepristone was present [F(1,28)= 1.71, P= 0.2014].  
 
3.3.5 SHSY5Y neuronal cell line viability analysis with trypan blue 
(cell counter) viability assay 
OGD reduced microglial cell viability, although this appears to be unrelated 
to NO production due to earlier experiments showing microglial cell 
viability to be unchanged by LPS. The presence of progesterone was 
observed to enhance rather than to reverse the impact of OGD. 
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Interestingly, progesterone did reduce microglial cell function, as reflected 
by the reduced NO production in response to LPS.  
It therefore appears that any protective effects of progesterone that are 
apparent in vivo are not reflected by changes in microglial viability in vitro, 
and that progesterone might provide direct protection for neurones 
challenged by ischaemia. Thus, progesterone treatment and OGD 
conditions were then applied to human neuronal cell lines. Initially 
experiments were undertaken to optimise viability assays for SHSY5Y 
neuronal cell lines (see method development 3.2.4), before it was decided 
to use trypan blue with automated cell counting to monitor SHSY5Y cell 
viability.       
The viability of SHSY5Y control (untreated) and progesterone (100 µM)-
treated cells was analysed over increasing incubation periods in normoxic 
conditions. Although, in previous experiments involving microglia, the 
maximum concentration of progesterone used was 50 µM, progesterone 
concentrations up to 100 µM were used in these experiments to observe 
greater pronounced differences. There were no differences found between 
control and progesterone treatment [F(1,18)= 0.64, P= 0.4341] (figure 
3.11).  
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Figure 3.11: SHSY5Y viability of vehicle and progesterone in 
normoxic conditions over time using the trypan blue assay 
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Cell viability is expressed as % of normoxic control. Cultures consisted of 
vehicle and progesterone (100 µM)-treated cells, exposed to normoxic 
conditions. All treatment wells contained 0.1% DMSO. Cell viability was 
measured with the trypan blue assay. Data are expressed as means ± SEM 
(n= 3-5 for each group). Analysis with two-way ANOVA shows there was 
no significant difference between control and progesterone treatment in 
normoxic conditions [F(1,18)= 0.64, P= 0.4341]. 
 
After establishing progesterone to have no effect on viability in normoxic 
conditions, cells were then introduced to increasing OGD conditions, to 
determine the incubation period required to significantly reduce viability. At 
6 hrs or more of OGD, cell viability was significantly reduced (figure 3.12).  
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Figure 3.12: SHSY5Y viability in OGD conditions over time using the 
trypan blue assay 
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Cell viability is expressed as % of normoxic control. Cultures were exposed 
to OGD conditions over time. Cell viability was then measured with trypan 
blue assay. Data are expressed as means ± SEM (n= 3-5). All treatment 
wells contained 0.1% DMSO. Analysis with one-way ANOVA showed a 
significant trend [F(4,14)= 12.36, P= 0.0002] and Newman-Keuls post-hoc 
analysis reveals that 6 and 8 hrs of OGD significantly reduced viability from 
normoxic controls (6 hrs P=<0.001*, 8 hrs P=<0.05**). 
 
OGD conditions were then applied to cells with increasing progesterone 
concentrations at 6 and 8 hrs. Progesterone was found not to effect 
viability compared to OGD controls over these incubation periods (6 hrs 
[F(6,37)= 0.87, P= 0.7162], 8hrs [F(6,30)= 0.74, P= 0.6255]) (figures 
3.13-3.14).  
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Figure 3.13: SHSY5Y viability after 6 hrs OGD, in the presence of 
different concentrations of progesterone using the trypan blue 
assay 
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Cell viability is expressed as % of normoxic control. Cultures were exposed 
to OGD and cell viability was measured with trypan blue assay. All 
treatment wells contained 0.1% DMSO. Data are expressed as means ± 
SEM (n=6-7). Analysis with one-way ANOVA reveals no significant 
difference in cell viability between treatment groups [F(6,37)= 0.87, P= 
0.7162].  
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Figure 3.14: SHSY5Y viability after 8 hrs OGD, in the presence of 
different concentrations of progesterone using the trypan blue 
assay.  
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Cell viability is expressed as % of normoxic control. Cultures were exposed 
to OGD and cell viability was measured with trypan blue assay. All 
treatment wells contained 0.1% DMSO. Data are expressed as means ± 
SEM of (n=6-7). Analysis with one-way ANOVA reveals no significant 
difference in cell viability between treatment groups [F(6,30)= 0.74, P= 
0.6255]. 
 
However, progesterone at 100 µM was found to reduce viability further 
with increasing OGD incubation from 4 hrs onwards, indicating that high 
progesterone concentrations at 4 hrs or longer exacerbate rather than 
reverse OGD-induced neuronal toxicity [F(1,23)=29.46, P=<0.001] (figure 
3.15). 
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Figure 3.15: SHSY5Y viability of vehicle and progesterone, with 
increasing exposure to OGD using the trypan blue assay. 
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Cell viability is expressed as % of normoxic control. Cultures consisted of 
control (untreated cells) and progesterone (100 µM)-treated cells, exposed 
to OGD conditions over time. Viability was then measured with the trypan 
blue assay. All treatment wells contained 0.1% DMSO. Data are expressed 
as means ± SEM (n=3-6). Analysis with two-way ANOVA showed a trend 
for progesterone to significantly reduce viability compared to OGD control 
[F(1,23)=29.46, P=<0.001]. Bonferroni post-hoc analysis revealed that 
the trypan blue assay showed significantly reduced viability at 4-6 hrs of 
OGD (2-6 hrs P=<0.01*, 8 hrs P=<0.001). 
 
3.3.6 The effect of mifepristone on SHSY5Y cells in OGD conditions 
using the trypan blue viability assay 
Mifepristone was added to SHSY5Y cells, which were treated with 
increasing concentrations of progesterone to determine if cell viability 
would be affected in OGD conditions. Previously, SHSY5Y cell viability was 
determined to be significantly reduced by 6 hrs of OGD conditions (figure 
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3.12). Therefore, this period of OGD was used to observe the affects of 
mifepristone. The addition of mifepristone with increasing progesterone 
concentrations in OGD conditions had no effect on cell viability [F(6,16)= 
1.53, P= 0.2304] (figure 3.16).  
Figure 3.16: SHSY5Y viability in the presence of mifepristone and 
increasing progesterone concentrations, after 6 hrs exposure to 
OGD using the trypan blue assay 
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Cell viability is expressed as % of normoxic control. Cultures were exposed 
to 6 hrs OGD with mifepristone (10µM) and increasing concentrations of 
progesterone (0-50 µM). Viability was then measured with trypan blue 
assay. All treatment wells contained 0.1% DMSO. Data are expressed as 
means ± SEM (n= 3-6). Analysis with one-way ANOVA revealed no 
significant differences between progesterone concentrations, in the 
presence of mifepristone in OGD conditions [F(6,16)= 1.53, P= 0.2304].   
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A direct comparison between increasing progesterone concentrations in 
OGD conditions with and without mifepristone revealed no significant effect 
of the progesterone receptor antagonist [F(1,32)= 0.01, P= 0.9152] 
(figure 3.17).  
 
Figure 3.17: SHSY5Y viability with and without the presence of 
mifepristone and increasing progesterone concentrations, after 6 
hrs exposure to OGD using the trypan blue assay 
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Cell viability is expressed as % of normoxic control. Cultures were exposed 
to 6 hrs OGD in increasing concentrations of progesterone (0-50 µM) with 
and without mifepristone (10µM) present. Viability was then measured with 
trypan blue assay. All treatment wells contained 0.1% DMSO. Data are 
expressed as means ± SEM (n= 3-6). Analysis with two-way ANOVA 
revealed the presence of mifepristone had no significant effect on viability 
compared to non-mifepristone treated cells with increasing progesterone 
concentrations in OGD conditions [F(1,32)= 0.01, P= 0.9152].   
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As shown previously, progesterone at 100 µM was found to further 
decrease cell viability compared to untreated cells in OGD conditions. A 
FRPSDULVRQ RI SURJHVWHURQH¶V HIIHFWV LQ WKH SUHVence and absence of 
mifepristone found no significant difference in cell viability (P=0.1437) 
(figure 3.18) 
 
Figure 3.18: No effect of mifepristone on attenuated SHSY5Y 
viability in the presence of progesterone (100µM), after 6 hrs 
exposure to OGD using the trypan blue assay. 
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Cell viability is expressed as % of cells in normoxic conditions. Cell cultures 
were incubated with progesterone (100 µM), in the presence and absence 
of mifepristone (Mife 10 µM) for 6hrs in OGD conditions. Cell viability was 
then measured using trypan blue assay. All treatment wells contained 
0.1% DMSO. Data are expressed as means ± SEM (n= 3). There was no 
significant effect of mifepristone (T-test) despite a tendency for the 
antagonist to enhance progesterone-mediated reduction in cell viability 
(P=0.1437). 
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Table 3.1: Overview of main experimental results 
  
Cell 
line 
Conditions Treatments n Main Findings 
OGD 
Microglial 
Cell 
Experiments 
BV-2 4hr normoxic 
Vehicle and Prog 
(30µM) 
1 (4 repeats in one 
experiment) 
No decrease in viability from prog 
(prog higher viability), no difference in 
NO production 
BV-2 4hr OGD Prog (0-30µM) 
1 (4 repeats in one 
experiment) 
No decrease in viability from prog, no 
difference in NO production 
BV-2 
6hrs OGD, 24 
hrs re-
oxygenation 
Prog (0-30µM) 
1 (8 repeats in one 
experiment) 
Viability decreased with increasing 
concentrations of prog, no difference 
in NO production 
BV-2 
8hrs OGD, 24 
hrs re-
oxygenation 
Normoxic vs. OGD 
1 (8 repeats in one 
experiment) 
Cell death too severe after 8hrs OGD 
followed by 24hrs re-oxygenation 
HAPI 
6hrs OGD, 24 
hrs re-
oxygenation 
Prog (0-10µM) 
1 (8 repeats in one 
experiment) 
Viability decreased with increasing 
concentrations of prog, no difference 
in NO production 
Microglial LPS 
Experiments 
BV-2 
Normoxic (24 
hrs) 
LPS, Prog (50µM), 
Mife, LPS + Mife, 
Mife + Prog (50µM) 
3 Viability unchanged by treatments 
BV-2 
Normoxic (24 
hrs) 
LPS, Prog (50µM), 
Mife, LPS + Mife, 
Mife + Prog (50µM) 
3 
LPS and Mife increased NO 
production  
BV-2 
Normoxic (24 
hrs) 
LPS + Prog (0-50µM) 3 
Viability unchanged between 
treatments, LPS and Mife increased 
NO production  
BV-2 
Normoxic (24 
hrs) 
LPS + Mife + Prog (0-
50µM) 
3 
Viability unchanged between 
treatments, LPS and Mife increased 
NO production  
BV-2 
Normoxic (24 
hrs) 
LPS + Prog (0-50µM), 
LPS + Mife + Prog (0-
50µM) 
3 Mife does not change NO production 
OGD 
Neuronal Cell 
Experiments 
SHSY5Y 
Normoxic (2-
8hrs) 
Vehicle vs. Prog 
(100µM) 
3 
Viability unchanged between vehicle 
and progesterone  
SHSY5Y OGD (0-8hrs) Vehicle 3-5 
6 and 8hrs OGD decreased viability 
compared to normoxic control  
SHSY5Y 6hrs OGD Prog (0-50µM) 6-7 
Viability unchanged between 
progesterone concentrations 
SHSY5Y 8hrs OGD Prog (0-50µM) 6-7 
Viability unchanged between 
progesterone concentrations 
SHSY5Y OGD (0-8hrs) 
Vehicle vs. Prog 
(100µM) 
3-6 
Prog reduced viability compared to 
vehicle 
SHSY5Y 6hrs OGD 
Prog (0-50µM) and 
Mife 
3-6 
Viability unchanged between 
progesterone concentrations 
SHSY5Y 6hrs OGD 
Prog (0-50µM) with 
Mife and without 
3-6 
Viability unchanged with or without 
Mife present 
SHSY5Y 6hrs OGD 
Prog (100µM) with 
Mife and without 
3 
Viability unchanged with or without 
Mife present 
Lipopolysaccharide (LPS, 100ng/ml), Progesterone (Prog), Mifepristone 
(Mife, 10µM), Nitric Oxide (NO), Oxygen Glucose Deprivation (OGD)  
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3.4 DISCUSSION 
There is considerable evidence to suggest that microglial activation 
precedes and predominates over macrophage infiltration into the brain 
after cerebral ischaemia (Jin et al., 2010). Active microglia, are particularly 
detrimental for the injured brain and contribute to infarct volume (Schilling 
et al., 2003; Schilling et al., 2005). The iNOS gene is transcriptionally 
activated in active microglia, resulting in the production of NO and 
substantial evidence supports the involvement of NO in ischaemic brain 
injury (Moro et al., 2004). Experiments in this investigation shows this, as 
background NO concentrations in HAPI cells, which are activated cells 
(9.11 ± 0.18 µM) are greater compared to non activated BV-2 cells (1.54 
± 0.89 µM). In the development of ischaemia, NO produced by neuronal 
nitric oxide synthase (nNOS), followed by inducible  iNOS, contributes to 
the development of brain injury (del Zoppo et al., 2000). Progesterone has 
been shown to suppress the inflammatory response and iNOS expression 
following cerebral ischaemia in vivo (Gibson et al., 2005b). Also, it has 
been observed that progesterone decreases iNOS mRNA expression and 
iNOS promoter activity in macrophages in vitro (Lieb et al., 2003). This 
investigation supports the role of progesterone in attenuating NO 
production (figure 3.10) 
Although, primary cell lines are, perhaps, a more valid model, being 
directly derived from tissues, the time required for tissue preparation and 
their relatively short life-span can limit their use. Therefore, immortalised 
cell lines were used in this investigation. Despite the associated issues with 
immortalised cell lines of stability, variability, quantity of cells, in vitro 
senescence, along with re-differentiation and subsequent loss of function 
(Allen et al., 2005), in vitro immortalisation enhances tissue survival in 
culture and cells still retain differentiated traits of the original tissue, 
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making them more convenient and practical for use than primary cultured 
cells. Cell lines used in this investigation, have been shown to behave 
similarly to primary cells in relation to NO production. Hovath et al (2008) 
found the microglia cell lines BV-2 and HAPI cells, to respond similarly to 
primary microglial cells, in producing NO due to LPS treatment (Horvath et 
al., 2008), and SHSY5Y cells have been used in other investigations 
involving OGD conditions (Lorenz et al., 2009; Pei and Cheung, 2003). As 
a neuronal model, SHSY5Y cells retain many properties of human neuronal 
cells and can be easily maintained under cell culture conditions (Pei and 
Cheung, 2003).  
The aim of the present chapter was to investigate whether OGD, which is a 
simple in vitro model, of ischaemia, would affect microglial viability and to 
determine whether progesterone could reduce or exacerbate cell death. 
Cells under OGD or re-oxygenation conditions were not exposed to serum 
and were near confluency prior to OGD. Therefore, what was measured 
was cell death and not proliferation. Microglial function was also 
investigated by examining whether microglia could be stimulated to 
produce NO and to observe any effects of progesterone treatment. The 
mode of action of progesterone was investigated using mifepristone which 
is a competitive progesterone receptor antagonist, albeit with partial 
agonist activity. SHSY5Y human neuroblastoma cells were used as a model 
of cerebral neurons and both Pei et al (2003) (Pei and Cheung, 2003) and 
Lorenz et al (2009) (Lorenz et al., 2009) have used SHSY5Y cells to 
investigate ischaemia.  
Different cell viability assays were evaluated, to ascertain if they would be 
sensitive enough to detect cell death from OGD, and to detect any effects 
of progesterone treatment. The Neutral Red assay was used to measure 
cell viability in microglial cells and was found to be sensitive enough to 
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detect difference in both BV-2 and HAPI cells, in terms of reduced viability 
in OGD conditions and differences in effects of progesterone treatment. 
MTT, risazurin and trypan blue viability assays were investigated in 
SHSY5Y cells. It was found that, MTT was inconsistent in detecting cell 
death in OGD conditions and with progesterone treatment, possibly due to 
methodological problems such as the cytotoxicity of MTT formazan which 
makes it difficult to remove cell culture media from culture wells and MTT 
formazan needles to form causing cells to float, allowing formazen to be 
aspirated with culture media, resulting in inconsistent results. The risazurin 
assay was able to detect differences due to progesterone treatment, but 
did not indicate significant cell death in OGD or OGD followed by re-
oxygenation. The Trypan Blue assay was able to detect significant 
reductions in cell viability after 6hrs of OGD and was further used in OGD 
and progesterone experiments involving SHSY5Y cells.             
Initial experiments were to test whether OGD conditions would affect 
microglial viability and whether progesterone would either exacerbate or 
attenuate cell death. Cells were challenged with deoxygenated, non-
glucose-containing SFM and placed in a hypoxic chamber to mimic 
ischaemic conditions. Production of NO from primary microglia and 
microglia cell lines (including BV-2) in hypoxic conditions without any pre-
activation, has been demonstrated in other studies (Lu et al., 2006; Son et 
al., 2009), although Park et al found that a period of re-oxygenation was 
required to produce NO after hypoxia (Park et al., 2002). Reperfusion 
injury in vivo is caused when the blood supply returns to tissues after a 
period of ischaemia, causing inflammation and oxidative damage by the 
influx of oxygen and glucose. Exposing cells to OGD, followed by re-
oxygenation in media with glucose, was an attempt in the current 
experiments to mimic reperfusion injury in vitro. After exposure to OGD 
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followed by re-oxygenation, viability was decreased in BV-2 cells, and 
progesterone increased cell death, compared to non-treated cells in OGD 
conditions. This was unexpected, as in vivo studies have found 
progesterone to be neuroprotective (Gibson et al., 2005b; Gibson and 
Murphy, 2004). However, Murphy et al (2000) did find daily progesterone 
administration of progesterone for a week prior to ischaemia exacerbated 
brain injury in overiectomised rats. The authors speculated that the 
detrimental effects was due to modulation of the GABA system by a sharp 
decline of progesterone after the pre-stroke treatment (Murphy et al., 
2000). This is unlikely to be the case in this investigation, as cells were 
continually treated through OGD and re-oxygenation. Necrosis from 
ischaemia is characterised by cellular metabolism failure and loss of 
membrane integrity (Padosch et al., 2001). Progesterone could possibly 
aggravate this further as steroid hormones, particular progesterone, can 
readily insert into bilayers and perturb plasma membrane functions (Snart 
and Wilson, 1967), resulting in increase cell death.  
OGD did not induce NO production in BV-2 cells and so another cell line 
was investigated. HAPI cells could be considered to model more closely to 
activated cells and more likely to produce NO. These cells were subjected 
to the same condition, in order to determine if the lack of NO stimulation 
was BV-2 specific. HAPI cells were found to be more vulnerable to OGD 
conditions and had reduced viability when exposed to the same length of 
OGD and re-oxygenation compared to BV-2. Progesterone treatment was 
also found to increase cell death when compared to untreated cells in this 
cell line. However, OGD also failed to stimulate NO production in HAPI 
cells. The lack of NO production was contrary to previous reports, that 
microglia do not require pre-activation to produce NO in hypoxic 
conditions. Park et alUHJDUGWKHLUVWXG\DVDµPLOGLVFKDHPLFLQVXOW¶GXHWR
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the presence of glucose in their cultures. In the present study, the removal 
RIJOXFRVHPDNLQJWKH³LVFKDHPLD´PRUHVHYHUHGLGQRWDOWHUWKHODFNRI
effect by hypoxia on NO production and so the reasons for the difference 
with previous studies remain unclear. Microglia may require activation 
conditions, such as LPS or cytokines including TNF-ĮDQG,)1ǄLQRUGHUWR
produce NO. Conventionally, it has been thought that, microglia cells are 
activated by signals originating from dying neurons (Gehrmann et al., 
1995; Gonzalez-Scarano and Baltuch, 1999), and further experiments are 
required, in order to determine the effects of pre-activation with cytokines 
TNF-Į DQG ,)1Ǆ $73 HWF. in ischaemic conditions. Also, co-cultures with 
neurones could clarify the interactions involved between microglia and 
neurones challenged with ischaemia.  
Previous studies have utilised LPS to investigate the inflammatory 
response of microglia without the use of hypoxia (Horvath et al., 2008). 
Therefore, LPS was used to stimulate NO production in order to investigate 
the effects of progesterone. Progesterone reduced NO production after 
challenging microglia with LPS. Also, blocking the PR receptor did not 
inhibit the attenuating effect of progesterone on NO production, indicating 
other mechanisms not involving the PR mediated pathway. In a previous 
study, Drew et al found progesterone to also attenuate LPS-stimulated NO 
production (Drew and Chavis, 2000), although, unlike the present study, 
the authors did not investigate the use of a PR receptor antagonist to 
examine the mechanism of the effect. Oestrogen mediated attenuation of 
microglial NO production has also been demonstrated. Smith et al found 
oestrogen to also reduce NO production by microglia in the presence of LPS 
and oestrogen receptor antagonist fulvestrant, was found to inhibit 
RHVWURJHQ¶V DWWHQXDWLQJ HIIHFW RQ 12 SURGXFWLRQ LQGLFDWLQJ D UHFHSWRU-
mediated mechanism (Smith et al., 2011). In the current investigation, 
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100 ng/ml of LPS was used and no significant loss of viability was found. 
Smith et al used LPS at 200ng/ml, and found it to cause cell death, which 
was also attenuated by oestrogen. It would be interesting to discover, 
whether progesterone would also attenuate cell death due to higher levels 
of LPS. A possible non-PR mediated mechanisms for NO reduction from 
progesterone is iNOS inhibition through binding to the glucocorticoid 
response element in murine macrophages (Miller et al., 1996). However, 
Kohmura et al found progesterone mainly uses a receptor different from 
the glucocorticoid receptor as well as PR (Kohmura et al., 2000), but 
progesterone could possibly use the glucocorticoid receptor when at high 
enough concentrations (Werb et al., 1978).       
In this investigation, the PR antagonist mifepristone did not alter 
SURJHVWHURQH¶V DELOLW\ WR DWWHQXDWH /36-stimulated NO production in 
microglia. The study by Lorenz et al supports our findings, as they found 
that the protection of cortical neurones was not abolished by oestrogen 
and progesterone nuclear receptor antagonists, indicating a non-classical 
steroid mechanism involved in neuroprotection (Lorenz et al., 2009).  
Although, a recent study found PR to be essential for early endogenous 
neuroprotection in PR knockout mice after transient MCAO, interestingly 
they also found rapid activation of cerebral biosynthesis of progesterone 
DQGĮ-dihydroprogesterone (Liu et al., 2012). Neuroprotection has been 
reported involving multiple mechanisms of progesterone-mediated actions, 
suggesting diverse interactions with different pathophysiological 
characteristics of stroke injury (Gibson et al., 2009). This current 
investigation has shown that attenuation of NO production in microglia by 
progesterone may not involve the classical PR. Although, mifepristone has 
a higher affinity for PR than progesterone, higher concentrations of the 
antagonist may be required to block the effects of progesterone.    
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Progesterone acts through a variety of receptors, and neuroprotection has 
been shown to be involved in regulating expression of trophic factors, via 
classical stimulation of PR, including the classical nuclear PRA and PRB 
types (Gonzalez SL, 2004). PR are not only influenced by progesterone, 
but also indirectly by oestrogen via oestrogen receptors, which up- 
regulate the expression of progesterone receptors (Kastner et al., 1990). A 
reductionist in vitro cell line approach, such as the current investigation, 
has the advantage of not having counter regulations as would be present 
in more complex systems, potentially enabling mechanisms to be identified 
more clearly. Other routes of progesterone signalling operate though non-
genomic interactions. These actions, in general operate over a rapid time 
frame that occurs in seconds, to minutes compared to genomic actions, 
which take hours to days (Gellersen et al., 2009). In the current 
investigation, NO production was only measured after 24 hrs of exposure 
and so it can not be confirmed when the attenuating effects of 
progesterone began. Although, this investigation reveals PR is not involved 
in the attenuation of NO production by progesterone, indicating rapid non-
genomic interactions. Measuring NO production over time and observing 
when NO levels begin to diverge from progesterone treated and non-
treated cells could clarify the time scale of progesterone action. In terms of 
progesterone action on SH5YSY viability in OGD conditions, 100 µM of 
progesterone from 4 hrs onwards exacerbates cell death and is unaltered 
at 6 hrs in the presence of miferpistone, indicating PR is not involved in 
SURJHVWHURQH¶VGHOHWHULRXVDFWLRQV&HOOYLDELOLW\ZDVXQFKDQJHGDW hrs of 
OGD with 100 µM of progesterone present, ruling out signalling from a 
non-genomic route being responsible in cell death by progesterone. 
Therefore, another mechanism other than the non-genomic and PR 
signalling routs is causing cell death. It is likely that high concentrations of 
progesterone is exacerbating the loss of membrane integrity, as explained 
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earlier, for increased cell death in microglial cell lines in the presence of 
progesterone in OGD conditions.  
There are also, progesterone receptors unrelated to nuclear receptors, 
which have been described recently, including a number of membrane-
bound receptors. Both progesterone receptor membrane component 1 
(PGRMC1) and the related PGRMC2 belong to the membrane-associated 
receptor family, which are widespread in eukaryotes (Cahill, 2007). Other 
membrane progesterone receptors, which are unrelated, have been 
discovered. At least three sub-types of the seven transmembrane 
prRJHVWHURQH DGLQRSHFWLQ 4 UHFHSWRU KDYH EHHQ GHVFULEHG Į ǃ Ǆ
although their biological significance still needs to be explored (Thomas, 
2008). These membrane progesterone receptors display high affinity, 
limited capacity, displaceable and specific progesterone binding. They are 
also coupled to inhibitory G proteins that reduce adenylyl cyclase activity 
(Thijssen, 2009)7KHWUDQVPHPEUDQHGRPDLQ7035ǃLVDQRWKHUUHFHSWRU
which is a target for progesterone (Brinton et al., 2008). Also, the 
progesterone membrane binding site 25-Dx may also be involved in 
neuroprotection (Labombarda et al., 2003). These non-nuclear receptors 
DUHSRVVLEOHWDUJHWVIRUSURJHVWHURQH¶VDFWLRQVUDWKHUWKDQYLDWKHFODVVLFDO
PR. Therefore, it would be useful to observe the effects of progesterone on 
cyclic adenosine monophosphate (cAMP) formation in microglia and 
neurones, and to test for G protein involvement, for example with 
[356@*73Ǆ6 ELQGLQJ.  0LIHSULVWRQH¶V DQWDJRQLVWLF DFWLRQ KDV RQO\ EHHQ
observed towards the classical progesterone and glucocorticoid receptor 
(Cadepond et al., 1997), but has not been reported to affect these non-
nuclear receptors.            
Glutamate overload is a key neurotoxic effect that is thought to occur, 
following brain injury, including acute ischaemic stroke. The molecular 
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mechanisms of glutamate-induced excitotoxicity have been investigated 
with in vitro neuronal models, and progesterone has been shown to protect 
against excitotoxicity in dissociated cell cultures (Luoma et al., 2011; 
Mannella et al., 2009; Nilsen and Brinton, 2003; Ogata et al., 1993). 
Ischaemia models have been used to reduce viability in neuronal cultures 
and progesterone was shown to provide protection in a concentration-
dependent manner via GABAA receptor activation, thereby reducing 
excitotoxicity in purkinje neurons (Ardeshiri et al., 2006). In this present 
investigation, progesterone was found not to protect microglia and 
neuronal cell lines in terms of cell viability. In relation to GABA system 
modulation in microglia by progesterone, stressed neurons from OGD may 
need to be present to release glutamate and activate microglia (Kaushal 
and Schlichter, 2008). However, pure microglia cultures have been shown 
to release glutamate after stimulation with LPS (Barger et al., 2007), 
although LPS stimulation may not necessarily represent the inflammatory 
response in stroke.  The interaction of co-neuronal and microglial cultures 
would better represent the effects of progesterone on GABA system 
modulation in vivo.  
A possibility for why neuroprotection was not observed, in the presence of 
progesterone in the present study may be due to the cell types employed. 
Coughlan et al found progesterone to protect PC12 neurons deprived of 
trophic support but not cerebellar granule neurons (Coughlan et al., 2009). 
It is possible that cells from different brain regions or cell lines may require 
a combination of sex steroids present in order to benefit from 
neuroprotection. Some neurones have been observed to respond in a 
sexually dimorphic manner, while other neurones in different brain regions 
do not. Other studies found cellular stress responses, leading to cell death 
to be gender-dependent, (Du et al., 2004; Lieb et al., 1995), while others 
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found no such sex differences in other cell line responses to  ischaemic 
insult (Ardeshiri et al., 2006). Cellular responses to ischaemia can vary due 
to gender and so responses to therapy could be affected in a similar 
manner. In previous studies evaluating neuroprotectants, differences in 
outcomes have been observed due to gender (Liu et al., 2009b). In the 
present investigation, SHSY5Y neuroblastoma cells which are genetically 
female were used (Biedler et al., 1973). Although, progesterone 
neuroprotection was not found in this cell line, a male neuronal cell line 
may respond differently, such as SMS-KCN (Reynolds et al., 1986). 
Interestingly, in a systematic review of progesterone in the treatment of 
experimental brain injury, progesterone was found to be more beneficial in 
males compared to females (Gibson et al., 2008b). Lorenz et al found 
combined oestrogen and progesterone, but not the hormones individually, 
prevented neuronal cell injury in cortical neurons. The same study also 
found midbrain neurons and SHSY5Y neruoblastoma cells, as used in the 
present study were not protected, indicating that neuroprotection can be 
cell or region-specific (Lorenz et al., 2009). Although, they found SHSY5Y 
cells not to be protected by progesterone, their cell injury model involved 
glucose-serum deprivation and did not include hypoxia. Oxygen 
deprivation, as employed in the present investigation is, therefore, a more 
relevant model for ischaemic stroke. Ischaemic cell damage is more severe 
and proceeds faster compared to either glucose or hypoxic injury alone. 
The decline of ATP depends not only on hypoxia and attendant cessation of 
oxidative phosphorylation, but also on failure of anaerobic glycolysis as 
found in ischaemic conditions. These mechanisms present extra possible 
targets for progesterone, which would not be present with glucose-serum 
deprivation alone. Also, reperfusion damage can be observed, when the 
availability of oxygen and nutrients during reperfusion allows ischaemic 
cells to restore ATP pools which can cause additional cell damage, due to 
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the energy requirements of apoptosis (Saikumar et al., 1998). An example 
of a possible target for progesterone neuroprotection, is that oxygen free-
radicals have been implicated in the pathogenesis of reperfusion injury 
(McCord, 1985).  
Long incubation periods (6-8 hrs) with high concentrations of progesterone 
at 100 µM exacerbated SHSY5Y, neuroblastoma cell death in ischaemic 
conditions. Brain progesterone concentrations are thought to closely mirror 
circulating serum levels, and the concentrations of progesterone that 
exacerbated ischaemic cell death in the present study could be  considered 
to be pharmacological and above those found even during human 
pregnancy, which is approximately 12.72±63.6 nM (Erickson, 1995). It is 
unlikely, if progesterone were to go into human stroke trials, 
concentrations of progesterone at the higher end of the dosage range 
investigated here could be achieved for prolonged periods in vivo, due to 
metabolism, clearance and bioavailability. It is more likely if an infusion 
method were deployed in a clinical trial for progesterone in stroke, 
progesterone concentrations would reach similar levels to those achieved 
by the clinical trials evaluating progesterone as a neuroprotectant in 
traumatic brain injury (TBI) (Wright et al., 2007; Xiao et al., 2008). In a 
preliminary study prior to these trials, steady-state serum concentrations 
of progesterone reached 337 ± 135 ng/ml, following continuous 
intravenous infusion in patients with acute moderate to severe TBI injury 
(Wright et al., 2005). This method of infusion was utilised in the 
progesterone TBI trials described previously, which found progesterone to 
be beneficial and safe. This concentration of progesterone is approximately 
1µM at which no reduction in viability of SHSY5Y cells during ischaemia 
was observed during the present investigation. Ischaemia followed by re-
oxygenation over a long period of time with progesterone 100 µM reduced 
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SHSY5Y viability in the present study, revealing toxicity of progesterone in 
these conditions. However, as mentioned previously these concentrations 
of progesterone are unlikely to be encountered in vivo for extended 
periods, but this emphasizes why pharmacokinetics and dose response 
studies are important.   
The pharmacokinetics of progesterone after 8 mg/kg via i.p. injection in 
mice, found plasma progesterone concentrations to be 110.28 ng/ml (0.35 
µM). Also, the in vitro effect of progesterone, inhibiting NO production has 
a half maximal effective concentration of approximately 5 µM. These 
concentrations are lower in comparison to the steady-state serum 
concentrations achieved in the preliminary TBI clinical study (337 ± 135 
ng/ml or 1.07 µM) (Wright et al., 2005). However, care must be taken 
when directly comparing progesterone concentrations between species and 
dosing regimens because of different anatomy, biochemistry and 
physiology. The dose of 8 mg/kg of progesterone via i.p. injection, has 
been previously found to be neuroprotective in mice (Gibson et al., 2005b; 
Gibson et al., 2011; Gibson and Murphy, 2004; Liu et al., 2012). In 
relation to the concentrations used to inhibit NO production in vitro, BV-2 
microglia cells are mouse derived. Therefore, the concentration range 
should be relevant to the pharmacokinetic concentrations found in mice 
and where the cells reside i.e. the brain. Brain progesterone concentrations 
after 8 mg/kg after i.p. injection reached a peak of 268.27 ng/g (0.85 µM) 
and mini-pump delivered approximately 70 ng/g (0.22 µM) when at steady 
state over a period of 48 hrs. The use of lower progesterone 
concentrations, and over a longer treatment time, may be a better 
comparison to the expected concentrations found in vivo.  
In summary, progesterone reduced NO production, after challenging 
microglia with LPS and that the nuclear progesterone receptor is not 
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involved. Neither of the microglial cell lines, BV-2 and HAPI cells produced 
elevations in NO formation in ischaemic conditions. The in vitro OGD model 
of ischaemia, reduced viability of both microglial and neuronal cells. Also, 
high pharmacological concentrations of progesterone exacerbated 
ischaemic injury. OGD in vitro modelling is relatively simple to perform and 
has the advantage of allowing key mechanisms to be identified and 
studied, without counter regulations present, that are found in complex 
V\VWHPV 3URJHVWHURQH¶V DELOLW\ WR UHGXFH 12 KDV EHHQ GHPRQVWUDWHG in 
vitro previously in microglia. However, this present investigation has 
LGHQWLILHGWKDW35GRHVQRWKDYHDPDMRUUROHLQSURJHVWHURQH¶VDWWHQXDWLRQ
of NO production in a microglia cell line. Although, the involvement of PR in 
the mechanism of neuroprotection by progesterone has also been identified 
in a  in vivo study of PR knock-out mice (Liu et al., 2012). However, 
further investigation is required on primary cells and in vivo to determine 
the importance of progesterone, PR and NO formation by microglia in 
stroke.    
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CHAPTER 4 
Progesterone treatmet and focal ischaemia on 
mouse models 
 
Publications contributing to this chapter:  
Sustained release of progesterone, enhances functional recovery following 
transient cerebral ischaemia in male mice (Submitted to journal) 
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4.1 INTRODUCTION 
Progesterone delivery via osmotic mini-pump (in conjunction with bolus i.p. 
loading dose) was found to be an effective mechanism for delivering 
progesterone (Wong et al., 2012). We went on to determine whether 
progesterone delivery via osmotic mini-pumps in an experimental stroke 
model, induced via middle cerebral artery occlusion (MCAO), is valid.  
Sustained release of progesterone via mini-pumps could offer a more 
suitable dosing method with the advantages of reducing peaks and troughs 
in drug levels, the stress associated with repeated injections, and 
diminishing levels of release over time as seen with pellet implants. 
Infusion methods are commonly used clinically, to maintain drug 
concentrations, and osmotic mini-pump release of agents mimics this 
approach. Also, tapered progesterone withdrawal has been shown to 
promote long-term recovery after TBI (Cutler et al., 2006b). Stroke 
involves similar pathological mechanism as TBI. Therefore, it is possible 
that tapered progesterone withdrawal could promote long-term recovery in 
stroke.   
Numerous neuroprotective drugs that appear to be effective in animal 
models have failed when reaching clinical trials (O'Collins et al., 2006). A 
possibility may be due to the failure to consider the complexities of human 
disease. The majority of studies, involving animals to test the efficacy of 
potential neuroprotectants, such as progesterone, have involved young, 
healthy and male animals, which do not represent the demographic of 
stroke patients. Co-morbidities are common in patients with stroke and 
have been shown to be negatively correlated with functional outcome 
(Karatepe et al., 2008). Although, the impact of these co-morbidities such 
as age, diabetes and hypertension, have not been fully investigated, they 
are known to have a major influence in terms of stroke outcome. The 
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factor of age in combination with other co-morbidities, such as cardiac co-
morbidities, congestive heart failure, hypertension, hyperlipidemia and 
diabetes, results in a poorer stroke outcome compared to individual co-
morbidities on their own (Turhan et al., 2009).     
Age is the single most important risk factor for stroke and the incidence of 
stroke increases with age (Feigin et al., 2003; Herman et al., 1982; 
Niessen et al., 1993). For each successive 10 years after the age of 55, the 
stroke rate more than doubles in both men and women (Brown et al., 
1996; Wolf et al., 1992). Stroke incidence rates are 1.25 times greater in 
men, but because women tend to live longer than men, more women than 
men die of stroke each year (Sacco et al., 1997).  Stroke severity at onset 
and patient age are the most important factors for predicting prognosis 
(Ingall, 2004). In an epidemiological study involving patients at 80 years 
old and over, were found to have a higher proportion of conscious 
impairment at admission, a longer acute ward stay, a higher incidence of 
total anterior circulation infarct and a lower frequency of lacunar infarct 
compared to patients under 80 years of age (Lee et al., 2007).  
The prevalence and incidence of atherosclerosis increases with age and is a 
major cause of strokes (Costopouzos et al., 2008). In the ageing process 
various changes happen in the brain, which can affect the outcome of 
stroke. Ageing effects neurotransmitter levels, such as dopamine, which 
decline by around 10% per decade from early adulthood (Mukherjee et al., 
2002). Serotonin and brain derived neurotrophic factor levels also fall with 
increasing age and may be implicated in the regulation of synaptic 
plasticity and neurogenesis in the adult brain (Mattson et al., 2004). A 
substance related to neurotransmitter levels, monoamine oxidase, 
increases with age and may liberate free radicals from reactions that 
exceed the inherent antioxidant reserves (Volchegorskii et al., 2004). 
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Other factors that have been implicated in the ageing brain include calcium 
dysregulation (Toescu et al., 2004), mitochondrial dysfunction, and the 
production of reactive oxygen species (Melov, 2004). The ageing brain may 
also suffer from impaired glucose metabolism or a reduced input of glucose 
or oxygen as cerebrovascular efficiency falls, although reduction in glucose 
may partly be attributable to atrophy rather than any change in glucose 
metabolism (Ibáñez et al., 2004).  
Along with age, other risk factors have a significant impact on outcome 
following stroke, including high blood pressure. The global prevalence of 
high blood pressure is 26.4% of the adult population with increasing 
incidence (Kearney et al., 2004). A well recognised risk factor for stroke is 
hypertension and pre-existing hypertension may be present in more than 
half of stroke patients (Arboix et al., 2004; Goldstein et al., 2011). 
Hypertension affects both small and large vessels supplying the brain 
(Rodgers et al., 1996), and there is a strong association between 
hypertension and mortality following stroke (Andersen et al., 2011; 
Heuschmann et al., 2004).  
At the onset of hypertension, there is a long delay from the onset of high 
blood pressure to the complications of artherosclerosis related to the 
phenomenon. In this time frame, a series of changes take place in the 
cardiovascular system, including the cerebral circulation. These changes, 
such as vascular remodelling, inflammation, oxidative stress and baroreflex 
dysfunction etc, may contribute to the pathogenesis of hypertension (Yu et 
al., 2011). Arterial baroflex is an important physiological mechanism 
controlling blood pressure regulation (Persson, 2005). Baroreflex 
sensitivity, a marker for baroreflex function plays an important role in the 
pathogenesis and prognosis of arthrosclerosis, acnonitine-induced 
arrhythmia and LPS-induced shock in animals (Cai et al., 2005; Shen et 
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al., 2004; Shu et al., 2004). Hypertension can reduce baroreflex sensitivity 
by changing vascular dispensability and altered activity in the brainstem 
portion of the reflex (Bristow et al., 1969). A reduction in baroreflex 
sensitivity results in vascular changes, arterial stiffness and contributing to 
a vicious cycle of hypertension complications.  Impairment of the 
Baroreflex has shown to be present in acute ischaemic and haemorrhagic 
stroke (Eveson et al., 2005; Sykora et al., 2008). In addition, oxidative 
stress in cerebral blood vessels is induced by hypertension and participates 
in the structural and functional alterations of cerebral blood vessels, by 
increasing ROS production in cerebral vessels by angiotensin (Ang) II, via 
activation of nicotine adenine dinucleotide phosphate (NADPH) oxidase in 
the vasculature (Sindhu et al., 2005).  Compelling evidence suggests 
oxidative stress plays a critical role in the pathogenesis of hypertension 
and stroke as a long-term complication (Vaziri, 2004; Vaziri and 
Rodriguez-Iturbe, 2006).  
Hypertension has profound effects on the structure of cerebral blood 
vessels including mechanical, neural and humoral factors, which all 
contribute to the changes in the composition and structure of the cerebral 
vascular wall. Examples include; (i) development of atherosclerotic plaques 
in cerebral arteries and promotion of arterioles, leading to arterial 
occlusions and ischaemic injury (Dahlof, 2007; Gkaliagkousi et al., 2009; 
Lammie, 2002), (ii) lipohyalinosis of penetrating arteries and arterioles 
supplying the white matter, resulting in small white matter infarcts or brain 
haemorrhage (Lammie, 2002), (iii) hypertrophy and remodelling of smooth 
muscle cells in the systemic and cerebral arteries, both of which are aimed 
at reducing stress on the vessel wall and protecting downstream micro 
vessels (Baumbach and Heistad, 1988; Laurent et al., 2005), (iv) smooth 
muscle cells when under high chronic intraluminal pressure undergo 
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hypertrophy, hyperplasia or rearrangement and therefore grow inward, 
encroaching into the luminal space of the artery resulting in the narrowing 
of the artery and increasing wall thickness, (v) vascular stiffening is 
present in hypertension, increasing pulse pressure (a good predictor of 
stroke) (Baumbach and Heistad, 1988; Benjo et al., 2007) and, (vi) 
cerebral blood flow is also altered by hypertension, resulting in intracranial 
arterial vasculature dilation, leading to a weakened ability for additional 
vasodilatation in response to ischaemic events and a higher risk of 
subsequent accidents (Yu et al., 2011). 
Inflammation is a vital process that leads to changes in vascular wall 
integrity and is a common pathological mechanisms of damage in a variety 
of vascular diseases, including arthrosclerosis and cerebral aneurysms 
(Chyatte et al., 1999; Henry and Chen, 1993). Studies have shown that 
the biomarkers of inflammation can predict the risk of primary ischaemic 
stroke (Tzoulaki et al., 2007). Inflammatory markers such as C-reactive 
proteins, IL-6, leukocyte elastase, lipoprotein (a), intercellular adhesion 
molecule (ICAM)-1 and E-selectin are consistently higher in people prone 
to develop stroke in comparison to those not at elevated risk. Exacerbated 
inflammation may also lead to worse outcome following stroke, resulting 
from an increase of C-reactive protein (CRP) in response to IL-6 (McColl et 
al., 2009; Wang et al., 2009). Inflammation has been identified as a risk 
factor for stroke (Mehta et al., 2010; Ridker, 2010).  
There are also links between hypertension and changes in the brain.  
Moderate to high 24 hour ambulatory blood pressure has been related to 
increased brain atrophy as has increased variability of systolic blood 
pressure (Goldstein et al., 2002). In Japanese subjects, raised systolic 
blood pressure was related to grey matter volume loss in a cross sectional 
study (Taki et al., 2004), and in the Framingham offspring cohort study, a 
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10 year increase in the risk of having a first stroke was associated with a 
reduction in cognitive function. The authors suggest that this may be 
attributable to cerebrovascular related injuries, accelerated atrophy, white 
matter abnormalities, or asymptomatic infarcts  (Elias et al., 2004). The 
relation of cerebral vasculature to cognitive function is not surprising 
because  the ability of the microvasculature to respond to metabolic 
demand falls with increasing age, and moreover, functional adult 
neurogenesis (Finch, 2003; Kempermann et al., 2004). 
Diabetes Mellitus is also a recognised risk factor for stroke (Tuomilehto et 
al., 1996), although the benefit of glycaemic control on primary and 
secondary prevention for stroke and other micro-vascular events was not 
established untill relatively recently (Wilcox et al., 2007). Sub-group 
analysis from the µ3URVSHFWLYH SLRJOLWD]RQH FOLQLFDO WULDO LQ PLFURYDVFXODU
HYHQWV¶ (PROactive) 04 study found for the first time the positive effect of 
glucose-lowering therapy (pioglitazone) in secondary stroke prevention 
(Wilcox et al., 2007). The population risk of stroke attributable to diabetes 
was found to be 18% in men and 22% in women (proportion of cases 
which potentially could be prevented by eliminating diabetes) (Stegmayr 
and Asplund, 1995). Diabetic patients have higher hospital and long-term 
stroke mortality, greater pronounced residual neurological deficits, more 
severe disability and prolonged hospital stay after acute cerebrolvascular 
occurrence (Mankovsky and Ziegler, 2004). Patients with diabetes have 
higher mortality after stroke onset compared to non-diabetic patients in 
the first three months (Oppenheimer and Hoffbrand, 1985). This trend in 
mortality is also present one year after onset in diabetic patients versus 
non-diabetics (50% vs 25%) (Oliveira et al., 1988). Longer term studies 
found mortality rates to be 1.7 times at one year, and 2 times higher at 5 
years after the onset of stroke despite similar fatality rates at 28 days 
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(Sprafka et al., 1994). Only 20% of people with diabetes survive over 5 
years after first incidence of stroke and half die within the first year 
(Asplund et al., 1980; Olsson et al., 1990).  
There is convincing evidence to suggest that diabetes mellitus is a strong 
independent risk factor of stroke and it is associated with increased 
incidence of recurrent cerebrovascular events. Diabetes is a risk factor 
mainly for ischaemic stroke, while its association with heamorrhagic stroke 
remains controversial. Hyperglycaemia is common in stroke patients. 
However, it is not known whether hyperglycaemia independently influences 
the course and outcome of stroke (Mankovsky and Ziegler, 2004).   
The reasons for worse outcome of stroke in diabetics are not fully 
understood. A possibility is the higher prevalence of atrial fibrillation, 
arterial hypertension, heart failure and prior myocardial infarctions in 
diabetic stroke patients compared to non-diabetic patients (Alter et al., 
1993; Carlberg et al., 1991; Olsson et al., 1990; Stegmayr and Asplund, 
1995). Chronic hyperglycemia, duration, type and complications in 
diabetes, insulin resistance and its associated phenomena may significantly 
contribute to an elevated stroke risk by amplification of the harmful effect 
of existing risk factors or acting independently (Mankovsky and Ziegler, 
2004). Aggressive control of arterial hypertension and dyslipidemia 
decreases the risk of stroke substantially, while the importance of glucose 
control for stroke prevention remains unproven (Mankovsky and Ziegler, 
2004). Recent data supports the suggestion that reduced cerebral blood 
flow and blood brain barrier damage may be behind the aggravating 
effects of hyperglycaemia and diabetes (Kamada et al., 2007; Kawai et al., 
1998). The exacerbation of inflammatory processes may also contribute to 
worse outcome (Ding et al., 2005; Martin et al., 2006; Panes et al., 1996).  
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Diabetes can also directly affect the brain to worsen the outcome of stroke. 
Type-2 diabetes mellitus is associated with atrophy, white matter 
hyperintensities, lacunar infarcts and vascular lesions of the brain (Tiehuis 
et al., 2008; van Harten et al., 2006). Successful stroke recovery hinges 
on the ability of the brain remap sensory and motor functions to surviving, 
functionally homologous brain regions. Diabetes have been shown to 
impair cortical plasticity and functional recovery following ischaemic stroke 
in type-1 diabetic mice (Sweetnam et al., 2012).  
Further investigation is required to explore the neuroprotective 
effectiveness of progesterone in these co-morbid animals, particularly the 
major risk factors in stroke of age, diabetes and hypertension. Stroke 
outcomes found in co-morbid animal models can differ compared to 
healthy adults (table 4.1). 
Table 4.1: Outcomes found in co-morbid models of stroke in 
comparison to healthy adult animals 
Co-morbid 
Model 
Infarct Volume Oedema Functional Deficits  
Aged Older animals develop 
larger infarcts (Alkayed 
et al., 1998; Hurn and 
Macrae, 2000; Li et al., 
1996) 
 
Reduced oedema 
formation (Liu et 
al., 2009a) 
Functional recovery 
suppressed (Popa-
Wagner et al., 2007; 
Tan et al., 2009) 
Hypertensive hypertensive animals 
have larger infarcts 
(Duverger and 
Mackenzie, 1988) 
 
Increased 
oedema 
formation 
(Fenske et al., 
1978) 
 
Variable learning 
deficits and paresis 
(Okamoto et al., 
1975) 
Diabetic Larger infarcts in both 
transient and 
permanent models 
(Duverger and 
Mackenzie, 1988; Liu 
et al., 2007; Morikawa 
et al., 1999) 
Increased 
oedema 
formation 
(Morikawa et al., 
1999) 
Greater functional 
deficit (Ning et al., 
2012) 
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The aims of the investigation reported here, was to evaluate if 
progesterone would be effective in conferring neuroprotection, after the 
onset of experimental stroke, when administered via osmotic mini-pump in 
adult C57 Bl/6 mice. Also, to evaluate whether the effects of induced 
experimental stoke on co-morbid models and the neuroprotective 
effectiveness of progesterone in these models.  
 
4.2 MATERIALS AND METHODS 
4.2.1 Animals 
Experiments were carried out in accordance with the UK Animals (Scientific 
Procedures) Act, 1986 (Project License 40/3207) and were approved by 
the University of Nottingham ethical review process. Mice were assigned a 
code by a non-experimenter and assigned randomly to different treatment 
groups. During all surgical procedures and behavioural tests/analyses the 
experimenter was blinded to treatment. In order to the appropriate risk 
factors for stroke, we aimed to compare outcomes following progesterone 
treatment, in adult, aged, diabetic and hypertensive mice (Table 4.2 for 
type and mice number). All mice were assigned a code by a non-
experimenter and assigned randomly to different treatment groups. During 
all surgical procedures and behavioural tests the experimenter was blinded 
to treatment. Group sizes were determined by power analysis (G*Power 
3.1.7) based on foot-fault results from Gibson et al 2004 (Progesterone 
66.77 ± 5.35 %, Vehicle 77.44 ± 5.55 %) and n=8 per group was 
determined.   
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Table 4.2: Type and overall number of mice in each experimental 
group that underwent surgery 
  Number of animals per MCAO group (minutes of occlusion) 
Mouse Type Sham 5 10 15 30 60 
Adult C57 Bl/6 5 0 0 0 20 4 
Aged C57 Bl/6 0 0 0 4 15 0 
Diabetic NOD/ShiLJ 0 2 0 0 2 0 
Hypertensive BPH/2 0 2 2 9 0 0 
 
4.2.1.1 Adult C57 Bl/6 
A total of 25 male C57 Bl/6 mice (15-25 weeks) were used, weighing 
between 25.9 and 41.2g at the time of surgery, 20 of these were subjected 
to 30 minutes of focal ischaemia and 5 were shams. A small number of 4 
male C57 Bl/6 mice (15 weeks) weighing 27.3 and 30g at the time of 
injection were subjected to 60 minutes of occlusion.  
 
4.2.1.2 Aged C57 Bl/6 
In total, 15 aged male C57 Bl/6 mice (61-65 weeks) were used, weighing 
between 34.10 and 46.5g at the time of injection and undergone 30 
minutes of occlusion. There were 4 animals aged 67 weeks, weighing 42.5 
and 50.7g at the time of injection were subjected to only 15 minutes of 
occlusion.    
 
4.2.1.3 NOD/ShiLtJ  
NOD/ShiLtJ (Non-obese diabetic) mice are a polygenic strain for type 1 
diabetes are characterised as having insulitis, leukocytic infiltration of the 
pancreatic islets. They have a marked decrease in pancreatic insulin 
129 
 
content, which occurs in females about 12 weeks of age and several weeks 
later in males. The onset of diabetes is marked by moderate glycosuria and 
by non-fasting plasma glucose, higher than 250 mg/dl. Diabetic mice are 
hypoinsulinemic and hyperglucagonemic, indicating a selective destruction 
of pancreatic islet beta cells (Makino et al., 1980). Susceptibility to insulin-
dependent diabetes mellitus in NOD/ShiLtJ mice is polygenic and affected 
by environment (including housing conditions), health status, and also diet 
exert a strong effect on penetrance. The major component of diabetes 
susceptibility in NOD mice is the unique MHC haplotype (H2g7 = Kd, Aad, 
Abg7, Enull, Db). NOD/ShiLtJ exhibit multiple aberrant immunophenotypes 
including defective antigen presenting cell immunoregulatory functions, 
defects in the regulation of the T-lymphocyte repertoire, defective natural 
killer (NK) cells cell function, defective cytokine production from 
macrophages, impaired wound healing and lack hemolytic complement, 
C5. These mice also have severely impaired hearing (Serreze et al., 1997).  
In total of 4 male NOD/ShiLtJ mice (21 weeks) were used, weighing 
between 29.8 and 32g at the time of injection for 30 minutes of occlusion. 
The remaining 11 animals (22 weeks of age) were used to monitor 
symptoms and to gather background behaviour data, weighing 29.3 and 
32.9g at the start of monitoring.  
 
4.2.1.4 BPH/2 hypertensive mice 
Hypertensive BPH/2 mice have elevated systolic blood pressures at five 
weeks of age and by 150 days differ from the BPL/1 (low blood pressure) 
by 60 mmHg. The BPH/2 strain has a higher heart rate, larger hearts and 
kidneys, and higher hematocrits than the BPL/1 strain. They also have 
lower renin, aldosterone and angiotensin I levels compared to the BPL/1 
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and BPN/3 (normal blood pressure). The original HBP (high blood pressure) 
and LBP (low blood pressure) selected lines show a number of biochemical 
and physiological differences which have not been re-examined in the 
inbred strains. These include differences in brain catecholamines, 
calmodulin concentrations, heat sensitivity, alcohol preference, and 
longevity. Hypotensive selected lines live two to three hundred days 
longer, on average, than the hypertensive selected lines. Biometrical 
genetic analysis suggested that three to five genes are responsible for the 
difference in blood pressure between the BPH/2 and BPL/1. A genome scan 
of an F2 from a BPH/2 x BPL/1 cross found three chromosome locations 
that cosegregated with blood pressure. Two of these sites were verified by 
candidate gene cosegregation: angiotensinogen on chromosome 8 and 
mouse kallikrein binding protein on chromosome 12. The BPH/2 strain is 
considered a model of chronic hypotension that is rennin independent. This 
hypertensive strain is also associated with hypertrophy in cerebral 
arterioles, but not remodelling (Baumbach et al., 2003).  
A total of 13 male BPH2/2 mice (28-37 weeks) were used, weighing 
between 21.9 and 34.8g at the time of occlusion, 8 of these were 
subjected to occlusion ranging from 5 to 15 minutes and were not treated, 
while 5 animals received progesterone.  
 
4.2.2 Focal cerebral ischaemia  
Anaesthesia was induced by inhalation of 4% isoflurane (in 100% Oxygen) 
and maintained by inhalation of 1.5% isoflurane. Body temperature was 
monitored throughout surgery (via rectal probe) and maintained at 37oC ± 
0.5oC using a heating blanket (Harvard Apparatus, Edenbridge, Kent, UK). 
Laser Doppler flowmetry (Moor Instruments, Sussex, UK) was used to 
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monitor cerebral blood flow.  Focal cerebral ischaemia was induced by 
middle cerebral artery occlusion (MCAO) as previously described (Gibson et 
al., 2005b).  Briefly, a small incision was made in the skin overlying the 
temporalis muscle and a 0.7-mm flexible laser-Doppler probe (model P10) 
was positioned on the superior part of the temporal bone (6mm lateral and 
2mm posterior from bregma), secured by superglue (Loctite). A midline 
incision was made on the ventral surface of the neck and the right common 
carotid arteries were isolated and ligated. The internal carotid artery was 
temporarily occluded using a microvascular clip (Ohwa Tsusho Co., Tokyo, 
Japan). A nylon filament (Drennan, Stridgewarer, UK), exposed to heat to 
give a diameter of 180 µm, was introduced into the internal carotid artery 
via an incision in the common carotid artery.  The filament was advanced 
approximately 10 mm distal to the carotid bifurcation, beyond the origin of 
the middle cerebral artery. Relative cerebral blood flow was monitored for 
the first 5 minutes following MCAO before mice were allowed to return to 
their home cage. After 5 to 30 minutes of MCAO depending on strain and 
treatment group, mice were re-anesthetised and the occluding filament 
was withdrawn back into the common carotid artery to allow reperfusion to 
take place. At this stage, drugs were then administered and osmotic mini-
pumps were implanted (see drug treatment below). Relative cerebral blood 
flow was monitored for an additional 5 minutes before the wound was 
sutured and mice were allowed to recover from the anaesthesia. The 
relative cerebral blood flow had to rise to at least 50% of pre-ischaemic 
values for mice to be included in the study and subject to further analyses. 
Sham-operated mice underwent the same surgical procedure, except that 
the filament was not advanced far enough to occlude the middle cerebral 
artery and they received empty of DMSO mini-pumps.   
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4.2.3 Drug treatment 
Following random allocation, C57 Bl/6 (adult and aged) and NOD/ShiLtJ 
(allocated for MCAO) mice were injected intraperitoneally, at the onset of 
UHSHUIXVLRQ ZLWK D µORDGLQJ GRVH¶ RI HLWKHU SURJHVWHURQe (USP grade, 
8mg/kg in 100% DMSO, Sigma, St Louise, MO, U.S.A) or vehicle (100% 
DMSO).  Mini-pumps, with an infusion rate of 1.0 µl/hr and a reservoir with 
up to 3 days delivery capacity (Alzet 1003D), were loaded with 
progesterone solution (50 mg/ml progesterone dissolved at 37oC in 100% 
DMSO only) or 100% DMSO (placebo). The pumps were submerged in 
0.9% sterile saline solution at 37oC over night in order to prime them so 
that progesterone was delivered immediately after implantation. Mini-
pumps were implanted subcutaneously in the back immediately following 
the onset of reperfusion and administration of the initial loading dose 
(progesterone or vehicle) as stated above. Hypertensive BPH/2 mice only 
received the intraperitoneal injection, at the onset of reperfusion, with the 
µORDGLQJGRVH¶RIHLWKHUSURJHVWHURQH863JUDGHPJNJLQ'062
Sigma, St Louise, MO, U.S.A) or were non-treated.    
 
4.2.4 Assessment of general well-being 
After surgery, mice were weighed every day for 7 days as an indication of 
their general well-being (Gibson and Murphy, 2004). Body weights are 
presented as a change compared with weight on the day of surgery. 
Survival rates of animal groups are also presented as % compared to the 
number of animals undergoing surgery.  
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4.2.5 Neurological deficit score  
Neurological deficit scoring can be used to quantify the different aspects of 
neurological deficits, such as sensory-motor asymmetry caused by focal 
cerebral ischaemia. Animals were scored neurologically for focal deficits 
with the use of a 28-point neurological scoring system based from Clark et 
al (Clark et al., 1998) (table 4.3).  We also used a modified version of this 
whereby animals, that died prematurely, were assigned a score of 29 
points i.e. beyond the maximum neurological deficit possible.  This is done 
in a similar fashion as the modified rankin scale to encompass death in 
analysis. 
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Table 4.3: Neurological score (28 points) 
  
0 1 2 3 4 
(1) Body 
symmetry 
Normal 
Slight 
asymmetry 
Moderate 
asymmetry 
Prominent 
asymmetry 
Extreme 
asymmetry 
(open bench 
top)      
 
     
(2) Gait 
(open bench 
Normal 
Stiff, 
inflexible 
Limping 
Trembling, 
drifting, falling 
Does not walk 
top)      
 
     
(3) Climbing 
(gripping 
Normal 
Climbs 
with strain, 
limb 
Holds onto 
slope, 
Slides down 
slope, 
Slides 
Immediately, 
no effort 
surface, 45° 
angle) 
 
weakness 
present 
does not 
slip or 
climb 
unsuccesful 
effort to prevent 
slope 
to prevent fall 
 
     
(4) Circling 
behavior 
Not 
Present 
Predomina
ntly one-
sided 
Circles to 
one side 
Circles contantly 
to one side 
Pivoting, 
swaying or no 
(open bench 
top)  
turns 
(not 
constantly)  
movement 
 
     
(5) Front 
limb 
symmetry 
Normal 
Light 
asymmetry 
Marked 
asymmetry 
Prominent 
asymmetry 
Slight 
asymmetry, 
no 
(mouse 
suspended 
by 
    
body/limb 
movement 
its tail)      
 
     
(6) 
Compulsory 
circling 
Not 
Present 
Tendency 
to turn to 
one side 
Circles to 
one side 
Pivots to one 
side sluggishly 
Does not 
advance 
(front limbs 
on bench,      
rear 
suspended 
by tail) 
     
 
     
(7) Whisker 
response 
Symetrical 
Response 
Light 
asymmetry 
Prominent 
asymmetry 
Absent response 
Absent 
proprioceptive 
(light touch 
from    
ipsilaterally, 
diminished 
response 
bilaterally 
behind)    
contralaterally 
 
Table shows 28-point neurologically focal deficits scores of 7 categories 
ranging from 0 for no deficit to 4 for extreme deficit.    
 
 
 
 
135 
 
4.2.6 Foot fault 
The foot-fault task assesses motor impairments of limb function and 
placing deficits during locomotion in rodents due to damage to brain 
regions, such as the striatum or motor areas of the cerebral cortex (Rogers 
et al., 1997). As previously described (Gibson and Murphy, 2004) at 24 hr, 
48 hr and 7 days after MCAO or sham surgery, mice were placed on an 
elevated grid surface (30 x 35 x 31 cm) with grid openings of 2.5 cm2. 
During locomotion on the grid, the number of foot faults made by the 
ipsilateral and contralateral limbs was counted. Tests consisted of 3 trials 
of 1 minute each with an interval of 1 minute between trials. The foot 
faults are expressed as the number of errors made by the contralateral 
side limbs in % of the total errors made. Modified foot fault is essentially 
the same as normal foot fault. However, animals which have died or killed 
for welfare are included in analysis and are scored as 100% contralateral 
foot slips.  
 
4.2.7 T-maze  
MCAO can produce secondary, remote impairment of the hippocampus, 
which participates in spatial learning and exploratory behaviour. Mice 
normally alternate at levels significantly above chance, indicating their 
willingness to explore novel environmental stimuli (Lalonde, 2002). Studies 
examining neurological deficits in rodents have reported a lower 
alternation rate in animals with focal ischaemia (Gerlai et al., 2000; 
Ishibashi et al., 2003b; Itoh et al., 1993; Kadam et al., 2009; Matchett et 
al., 2007). Also, animals suffering ischaemic brain injury have a tendency 
to favour the arm ipsilateral to the damaged side (Carloni et al., 2008) and 
take longer to complete t-maze trials (Ishibashi et al., 2003a). The T-maze 
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consists of 3 arms made of grey Perspex, each 41.5 cm long and 6 cm 
wide, surrounded by walls of transparent Perspex (15 cm high). The start 
box (6cm x 7.5 cm) is located at the bottom of the central arm. The start 
box and the entrance of each arm can be closed by vertical sliding doors. 
Mice were subjected to a series of 1 habituation period and 7 trials 
separated by 5 second intervals. The habituation period consists of 1 
minute during which the mouse was left to explore the entire maze and 
allowed to return to the start position. At the start of a trial the door is 
opened and the mice have the option of entering either the left or right 
arm. The mice were then left in the arm of choice for 5 seconds and 
recorded before being allowed to return to the start box. If they did not 
freely return to the start box or remained stationary for 15 seconds, they 
are gently nudged to avoid stress of handling. Alternation rate (% 
alternation) and left/right (% left right ratio) of arm choice was measured. 
The total time was recorded on how long the animals took to complete the 
7 trials. T-maze was conducted on day 7 after surgery. 
 
4.2.8 Brain oedema 
Brain water content, which we interpret as a marker of brain oedema was 
calculated using the wet-dry method as previously described (Gibson et al., 
2005a). Brains were separated into ipsilateral and contralateral 
hemispheres and were gently blotted with tissue paper to remove small 
quantities of absorbent cerebral spinal fluid. All hemispheres were then 
weighed in glass vials with a basic precision scale to within 0.1 mg, giving 
the wet weight. Samples were placed in an oven at 80 °C for 24 h, after 
which they were weighed to obtain the dry weight. The percentage of 
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water of each sample was calculated as follows: percent brain 
water = [(wet weight í dry weight) / wet weight] × 100. 
 
4.2.9 Statistical Analysis 
All data are expressed as means ± standard error of the means (SEM). 
Survival data was analysed by Kaplan-Meier curve and Mantel-Haenszel 
log-rank test to identify differences. All other experiments conducted over 
a period of days (body weight, neurological score, foot fault and t-maze) 
were analysed by repeated measures analysis of variance (Genstat 16.0). 
Tables 4.4-4.5, 4.7-4.8 and 4.10 documents number of animals for each 
group at each time point for young C57 Bl/6 and BPH/2 mice. Brain water 
content data was analysed using two-way ANOVA for differences according 
to hemisphere and treatment. The data from the T-maze and foot fault 
conducted for only one day post-MCAO was analysed using one-way 
ANOVA to identify differences according to treatment. Post hoc analyses 
were carried out using either Bonferroni tests or Newman-Keuls (repeated 
measures). Data analysis was conducted using GraphPad Prism Version 5.0 
for windows (GraphPad Software). The criterion for statistical significance 
was P <0.05. 
 
4.3 RESULTS 
4.3.1 Adult C57 Bl/6  
Initially, MCAO was induced for 60 minutes in 4 animals (2 progesterone 
treated and 2 vehicle treated). However, one animal treated with vehicle 
displayed weight loss of greater than 20% (after 72 hrs post-surgery) and 
one progesterone-treated animal displayed barrel rolling and loss of the 
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ability to self right at 1 hr post-MCAO.  For welfare animals, both of these 
animals were sacrificed and, in an attempt to increase the welfare of 
animals, the occlusion time for subsequent experiments was reduced to 30 
minutes.  
     
4.3.1.1 Assessment of general well being in adult C57 Bl/6 
By 7 days post-surgery, one sham-operated mouse was killed due to 
weight loss being greater than 20% from pre-surgery weight, 6 vehicle-
treated animals were killed for welfare reasons (4 animals for >20% 
weight loss, 2 for barrel rolling) and in the progesterone-treated group 4 
animals were killed for welfare reasons (1 weight loss <20%, 3 barrel 
rolling) and one animal was found dead the day after surgery. Analysis of 
survival data revealed no significant differences in survival rate between 
treatment groups (P=0.3286) (figure 4.1). All animals lost weight for the 
first few days following either MCAO or sham surgery before beginning to 
gain weight.  
Analysis of weight loss found a significant difference between animal 
groups [F(2,22)=3.62, P=0.044]. Newman-Keuls post-hoc analysis found 
both the progesterone (P=<0.05) and vehicle-treated (P=<0.05) groups 
gained weight at significantly slower rate compared to shams. However, 
there were no significant differences in body weight gain between the 
progesterone and vehicle treated groups (figure 4.2). 
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Figure 4.1: Comparison of post-surgery survival according to 
treatment/surgery of adult C57 Bl/6 mice.      
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Mortality data expressed using the Kaplan-Meier curve and analysed using 
the Mantel-Haenszel log-rank test. There was no significant difference 
between groups in % of surviving animals in each group post-surgery 
(P=0.3286).  
Table 4.4: Number of mice in each experimental group used for 
weight loss that underwent surgery for adult C57 Bl/6 
 
  
Number of animals per group 
  
Day Sham Progesterone Vehicle 
0 5 11 9 
1 5 11 9 
2 5 7 7 
3 5 7 7 
4 5 7 6 
5 4 6 4 
6 4 6 3 
7 4 6 3 
Weights for each animal were collected prior to functional outcomes or were killed 
for welfare reasons 
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Figure 4.2: Weight loss of pre-surgery weight of adult C57 Bl/6 
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Analysis of weight loss found a significant difference between animal 
groups [F(2,22)=3.62, P=0.044]. Both the progesterone (P=<0.05) and 
vehicle-treated (P=<0.05) groups gained weight at significantly slower rate 
compared to shams. There was no difference in body weight gain between 
progesterone and vehicle-treated animals groups. Data points are 
expressed as means ± SEM. 
 
Table 4.5: Number of mice in each experimental group used for 
behavioural testing for young C57 Bl/6 
    
Number of animals per group 
  
Day Sham Progesterone Vehicle 
1 5 7 7 
2 5 7 7 
7 4 6 3 
Number of animals that underwent surgery and survived at each time point 
for neurological score, foot-fault and T-maze.   
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4.3.1.2 Neurological score for adult C57 Bl/6 
A significant difference was found between groups [F(2,16)=4.93, 
P=0.021]. Following MCAO, a significant neurological deficit was observed 
in both vehicle-treated (P=<0.05) and progesterone-treated (P=<0.05) 
animals in comparison to sham-operated controls. Progesterone treatment 
significantly reduced the neurological deficit present following MCAO 
compared to vehicle treatment (P=<0.05) (figure 4.3). 
 
Figure 4.3: Neurological deficit score for adult C57 Bl/6 
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A significant difference was found between groups [F(2,16)=4.93, 
P=0.021]. Newman-Keuls post-hoc analysis found both vehicle-treated 
(P=<0.05) and progesterone-treated (P=<0.05) animals to have a greater 
neurological deficit in comparison to shams, and progesterone treatment 
reduced neurological deficit compared to vehicle (P=<0.05). Data 
expressed as means ± SEM. 
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4.3.1.3 Foot-fault for adult C57 Bl/6 
Unilateral foot-faults were expressed by the number of contralateral foot-
faults as a percentage of the total errors made; a value of 50% represents 
an equal number of errors made by both sides. For example, on day 1, 
shams revealed no functional deficit as they made, on average, 51.27 ± 
6.62 (mean ± SEM) errors on the contralateral side, whereas, following 
MCAO, animals showed a greater number of contralateral foot slips.  
Statistical analysis found no difference in the number of contralateral foot-
faults between treatment groups [F(2,16)=1.82, P=0.194] (figure 4.4). 
 
Figure 4.4: Foot fault for adult C57 Bl/6 
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No significant difference was found between groups [F(2,16)=1.82, 
P=0.0194]. Data expressed as means ± SEM. 
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4.3.1.4 T-maze for adult C57 Bl/6 
The T-maze is a test of spatial learning and working memory. There was 
no difference in T-maze performance following either MCAO surgery (in 
comparison to shams) or by drug treatment.  The outcome measures used 
were: alternation rate, left/right alternation % and time taken to complete 
trials (table 4.6). 
 
Table 4.6: T-maze summary for adult C57 Bl/6 
Group % Alternation % L/R Ratio Time taken (mins) 
Sham 58.34 ± 4.81 57.14 ± 5.83 7.78 ± 0.94 
Progesterone 38.89 ± 12.67 54.62 ± 14.03 6.27 ± 0.91 
Control 50.00 ± 9.62 57.14 ± 14.29 5.59 ± 0.21 
There was no significant difference between groups in terms of % 
alternation rate [F(2,10)=0.83, P=0.4656]. Left/Right alternation ratio % 
was found not to be significantly different [F(2,10)=0.01, P=0.9865] as 
well as time taken to complete trials [F(2,10)=1.29, P=0.3184]. Data 
expressed as means ± SEM.   
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4.3.1.5 Modified analyses of outcomes in adult male mice to 
consider death 
Conventionally, as done previously in the results, functional end points for 
pre-clinical studies are based on data from animals which have survived to 
the point of observation, and due to attrition from spontaneous deaths or 
for welfare reasons, animals are lost and no longer contribute to data 
acquisition.  In clinical trials, death is included as an outcome and it could 
be beneficial for pre-clinical studies to also include death as an end point, 
for example, with the modified Rankin Scale; in this respect, death is 
XVXDOO\DVVLJQHGDµZRUVH¶YDOXH 
Animals killed for welfare due to excessive weight loss, were excluded from 
weight loss analysis from that point onwards and so weight loss data is 
lost. Therefore, in order to utilise these animals for analysis, animals which 
have died due to excessive weight loss are given a worse case value of 0% 
weight from pre-surgery at the point they die or killed for welfare (two 
animals from day 4 and one at day 5 in the vehicle treated group, one 
animal from day 4 in the progesterone treated group and one animal in the 
sham group from day 4 post-surgery). In the adjusted analysis, all animals 
lost weight for the first few days following either MCAO or sham surgery 
before beginning to gain weight. Statistical analysis found no difference 
between groups [F(2,22)=2.05, P=0.152] (figure 4.5). 
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Table 4.7: Number of mice in each experimental group used for 
modified weight loss analysis for adult C57 Bl/6 
    Number of animals per group   
Day Sham Progesterone Vehicle 
0 5 11 9 
1 5 11 9 
2 5 7 7 
3 5 7 7 
4 5 7 7 
5 5 7 7 
6 5 7 7 
7 5 7 7 
Weights for each animal were collected prior to functional outcomes and 
animals which were killed for excessive weight loss were counted and 
imputed as 0% weight from pre-surgery 
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Figure 4.5: Modified weight loss of pre-surgery weight for adult 
C57 Bl/6 
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No significant difference was found between groups [F(2,22=2.05, 
P=0.152]. Data points are expressed as means ± SEM (sham n=5, 
Progesterone n=11, Vehicle n=9). 
 
In the modified neurological deficit score analyses, animals that died 
prematurely were assigned a score of 29 points i.e. beyond the maximum 
neurological deficit possible. Animals include; one sham from day 4, four 
animals from day 1 and one from day 4 in the progesterone treatment 
group, two animals from day 2 followed by one from day 3 and two from 
day 4 in the vehicle treated group. No significant difference was found 
between animal groups [F(2,22)= 2.72, P=0.088] (figure 4.6). On day 
seven, sham neurological deficit score is higher compared to previous time 
points. This is due to one animal which was killed for weight loss. In 
comparison of modified to unmodified (figure 4.3) neurological deficit 
scores on day 7, both progesterone and vehicle scores were higher than 
the unmodified analysis due to deaths. Although, neurological scores in 
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terms of treatment were still relative to each other i.e. vehicle neurological 
scores were still higher versus progesterone treatment.    
 
Figure 4.6: Modified neurological deficit score for adult C57 Bl/6 
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No significant difference was found between animal groups [F(2,22)= 272, 
P=0.088]. Data expressed as means ± SEM (sham n=5, Progesterone 
n=7, Vehicle n=7).  
 
Unilateral foot-faults were expressed by the number of contralateral foot-
faults as a percentage of the total errors made; a value of 50% represents 
an equal number of errors made by both sides, as analysed previously with 
foot-faults. However, in this further analysis, animals which have been 
killed for welfare or died spontaneously were scored as having 100% 
contralateral foot faults (one sham from day 4, four animals from day 1 
and one from day 4 in the progesterone treatment group, two animals 
from day 2 followed by one from day 3 and two from day 4 in the vehicle 
treated group). Statistical analysis found no difference between groups 
[F(2,22)= 1.36, P=0.279](figure 4.7). 
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Figure 4.7: Foot fault for adult C57 Bl/6 adjusted for deaths 
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There was no difference in contralateral foot-faults found between groups 
[F(2,66)= 2.89, P=0.063]. Data expressed as means ± SEM (sham n=5, 
Progesterone n=7, Vehicle n=7). 
 
 
4.3.2 Effect of aging on outcome following MCAO and progesterone 
treatment   
In the initial surgeries of aged C57 Bl/6 mice, a total of ten animals (five 
progesterone treated and five vehicle treated) were subjected to 30 
minutes of occlusion.  This length of occlusion was selected, as explained 
previously with the young C57 Bl/6 animals, to increase survival but also 
allow measurable functional deficits. In the progesterone treated group 
only one animal survived to the intended end of study, i.e. day 7 post-
MCAO, one was found dead the following day after surgery, and 3 were 
killed for welfare reasons (barrel rolling).  The vehicle-treated group 
comprised two animals surviving to day 7, one found dead the next day 
after surgery, and two animals killed for welfare (one for barrel rolling after 
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surgery and another on the same day for inability to recover from 
surgery).  
Because of the number of deaths after MCAO in the aged animals, post-
operative care was changed in an attempt to increase survival. All animals 
to this point, including young C57 Bl/6 and initial aged animals recovered 
at 22oC. The temperature at post-operative recovery was then increased to 
28oC for 4 animals (two progesterone treated and two vehicle treated) in 
an attempt to increase survival by keeping animals warm following advice 
from the biomedical sciences unit.  However, all animals were found dead 
the following day.   
Due to the number of deaths following 30 minutes of MCAO  the occlusion 
time was reduced to 15 minutes and the temperature during recovery was 
brought back down to 22oC.  In total four animals underwent 15 minutes of 
occlusion (two progesterone-treated and two vehicle-treated animals) with 
one of the progesterone treated animals having adverse effects from 
anaesthesia and being euthanized. The remaining three animals following 
surgery the next day were killed for welfare due to veterinary advice (two 
progesterone-treated and one vehicle treated). Therefore, reducing the 
occlusion time from 30 to 15 minutes did not improve the survival of aged 
C57 Bl/6 mice. Due to the high number of deaths overall, which revealed 
no significant difference between treatment groups (P=0.5266) (figure 
4.8), the data available was too limited for functional end points. Although, 
enough data was available at day one following surgery for weight loss and 
assessment of brain water content, which we interpret as a marker of brain 
oedema at time of death. There was no difference between treatment 
groups for weight loss the day after surgery or oedema at time of death 
(P=0.8903) (figure 4.9).      
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Figure 4.8: Comparison of post-surgery survival according to 
treatment/surgery of aged C57 Bl/6 mice.      
 
Mortality data expressed using the Kaplan-Meier curve and analysed using 
the Mantel-Haenszel log-rank test. There was no significant difference 
between groups in % of surviving animals in each group post-surgery 
(P=0.5266).  
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Figure 4.9: Weight loss of aged C57/Bl6 24h post-MCAO 
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Body weight was measured the following day post surgery in % of pre-
surgery weight. Analysis with t-test found no difference in body weight 
gain between progesterone and vehicle treated animals groups. Data 
points are expressed as means ± SEM (n=5, P=0.8903). 
 
4.3.2.1 Neurological score for aged animals 
Following MCAO, no differences in neurological deficit was observed 
between treatment groups after 30 minutes of occlusion in aged animals 
(figure 4.10). 
 
 
 
 
152 
 
Figure 4.10: Neurological score for aged C57/Bl6 24h post-MCAO 
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Aged animals underwent 30 minutes of MCAO and were either treated with 
progesterone or vehicle. There was no difference found in neurological 
deficit score between treatment groups. Data expressed as means ± SEM 
(progesterone n=2, vehicle n= 4). 
 
4.3.2.2 Oedema at time of death for aged C57 Bl/6 
Following MCAO, no difference in brain water content at time of death was 
observed between treatment groups after 30 minutes of occlusion in aged 
animals [F(1,18)=2.486, P=0.1323] (figure 4.11). 
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Figure 4.11: Oedema at time of death for aged C57 Bl/6 
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Wet-dry analysis of brain water content found MCAO in aged animals did 
not result in significant increase of ipsilateral brain water content 
regardless of treatment [F(1,18)=2.486, P=0.1323]. Data expressed as 
means ± SEM (progesterone n= 4, vehicle n=7).   
 
4.3.3 Non-obese diabetic mice (NOD/ShiLtJ) 
Information from the supplier of NOD/ShiLtJ mice, informed of marked 
decrease in pancreatic insulin content, which occurs in females about 12 
weeks of age and several weeks later in males. We used male animals at 
21 weeks of age and a small number were subjected to MCAO surgery and 
dosing to evaluate their tolerance to procedures. In total four NOD/ShiLtJ 
mice underwent surgery, two shams and two that underwent MCAO for 30 
minutes (one treated with progesterone and one vehicle treated). The 
following day animals that underwent MCAO had died and one sham was 
killed for welfare reasons. We then used the remaining animals, initially 
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destined for surgery, to monitor urine glucose levels over five days 
(AccuBioTech Co, Newark, DE, USA). Animals were either found to be 
negative for glucose in their urine (non-symptomatic animals) or had 
>55mmol/L of glucose (symptomatic animals). Symptomatic animals had a 
lower body weight compared to non-symptomatic animals [F(1,53)= 
10.87, P=0.0017] (figure 4.12).  
 
Figure 4.12: NOD/ShiLtJ weight over time of monitoring 
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Two-way analysis of variance found symptomatic mice have significantly 
reduced body weights compared to non-symptomatic animals [F(1,53)= 
10.87, P=0.0017]. Data expressed as means ± SEM (non-symptomatic 
n=8, symptomatic n=3).  
 
Also, water consumption in both symptomatic and non-symptomatic 
animals were recorded every 24 hrs, for five days, by measuring water 
consumed from the last recording from the previous 24 hrs. Symptomatic 
animals had extremely elevated water consumption compared to non-
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symptomatic animals, which increased over time of monitoring [F(1,44)= 
1772, P=<0.0001] (figure 4.13).  
 
Figure 4.13: NOD/ShiLtJ water consumption over time of 
monitoring 
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Two-way analysis of variance found symptomatic mice have significantly 
reduced body weights compared to non-symptomatic animals [F(1,44)= 
1772, P=<0.0001] (non-symptomatic n=8, symptomatic n=3). Bonferroni 
post-hoc analysis found symptomatic animal have significantly reduced 
body weights compared to non-symptomatic animals at each time point 
(P=<0.0001*). 
 
Due to symptomatic animals having a high water demand, it is unlikely 
they would have survived when challenged with surgery. This is because 
animals recovering straight after surgery are less inclined to drink and fluid 
replacement would be insufficient for symptomatic animals. Also, non-
symptomatic animals had no signs of diabetic symptoms and so could not 
be used to test for the effects of diabetes on progesterone neuroprotection. 
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Animals were then killed via cervical dislocation and their blood was tested 
for the presence of ketones. Symptomatic mice were found to have 
>27mmol/L of ketones in their blood and non-symptomatic animals were 
negative for ketones (Precision Xtra, Abbot Laboratories, CA, USA).     
 
4.3.4 Hypertensive BPH/2 mice 
4.3.4.1 Hypertensive BPH/2 with increasing occlusion times 
Hypertensive BPH/2 mice received increasing periods of MCAO in order to 
identify the length of occlusion required to cause measurable functional 
deficit without excessive mortality and weight loss. In total eight animals 
underwent transient MCAO (two animals for 5 minutes, two for 10 minutes 
and four for 15 minutes of MCAO). One animal that underwent occlusion 
for 15 minutes of occlusion died on the second day post surgery (table 
4.8). Analysis of survival found no significant difference between different 
occlusion times (P=0.6065) (figure 4.14). All animals lost weight following 
surgery, but no significant difference was found between groups [F(2,5)= 
0.12, P=0.886]  (figure 4.15).  
 
 
 
 
 
 
 
157 
 
Table 4.8: Number of BPH/ 2 mice in each experimental group used 
for increasing occlusion times 
  
Number of animals per 
group 
 
Day 
5 minutes 
MCAO 
10 minutes MCAO 
15 minutes 
MCAO 
0 2 2 4 
1 2 2 4 
2 2 2 4 
3 2 2 3 
4 2 2 3 
5 2 2 3 
6 2 2 3 
7 2 2 3 
 
 
Figure 4.14:  Survival of BPH/ 2 hypertensive mice with increasing 
occlusion time 
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Mortality data expressed using the Kaplan-Meier curve and analysed using 
the Mantel-Haenszel log-rank test. There was no significant difference 
between groups in % of surviving animals in each group post-surgery 
(P=0.6065).  
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Figure 4.15: Weight Loss from pre-surgery weight of BPH/ 2 
hypertensive animals with increasing occlusion time  
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There was no difference in body weight gain between progesterone and 
vehicle treated animals groups [F(2,3)= 0.12, P=0.886]. Data points are 
expressed as means ± SEM. 
 
The length of occlusion was found not to effect neurological deficit 
[F(2,29)=7.5, P=0.360] (figure 4.16). There was no difference in 
contralateral foot slips between groups in the foot fault test at 24 hrs 
[F(2,5)=1.50, P=0.3085] (figure 4.17). The % alternation rate 
[F(2,4)=0.59, P=0.5948], Left/Right alternation ratio % [F(2,4)=1.43, 
P=0.3403] and time taken to complete trials [F(2,4)=4.30, P=0.1008] for 
T-maze were not significantly different between groups (table 4.9). There 
was no difference between treatment groups in oedema formation for 
animals, which survived to the seventh day [F(2,8)=0.77, P=0.4954]  
(figure 4.18). 
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Figure 4.16: Neurological deficit score for BPH/2 with increasing 
occlusion times 
 
The length of occlusion was found not to effect neurological deficit 
[F(2,5)=1.26, P=0.360]. Data expressed as means ± SEM. 
 
Figure 4.17: Foot fault for BPH/2 with increasing occlusion times at 
24 hrs 
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Analysis with one-way ANOVA found no significant difference in 
contralateral foot slips between groups [F(2,5)=1.50, P=0.3085]. Data 
expressed as means ± SEM. 
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Table 4.9: T-maze for BPH/2 with increasing occlusion times 
Group % Alternation % L/R Ratio Time taken (mins) 
5 Minutes 58.33 ± 25.00 35.72 ± 21.43 3.71 ± 0.58 
10 Minutes 58.34 ± 8.34 64.29 ± 7.15 2.95 ± 0.36 
15 Minutes 33.33 ± 19.25 71.43 ± 14.29 5.59 ± 0.76 
Analysis with one-way ANOVA found no significant difference between 
groups in terms of % alternation rate [F(2,4)=0.59, P=0.5948]. Left/Right 
alternation ratio % was also not found to be significantly different 
[F(2,4)=1.43, P=0.3403], as well as time taken to complete trials 
[F(2,4)=4.30, P=0.1008]. Data expressed as means ± SEM.   
 
Figure 4.18: Oedema of animals receiving increased occlusion that 
survived to day 7  
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Wet-dry analysis of brain water content found ipsilateral brain water 
content was not affected by time of occlusion [F(2,8)=0.77, P=0.4954].   
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Although not significant, due to the small number of animals, these 
findings indicate out of all the occlusion times analysed, 15 minutes of 
MCAO may be adequate to cause measurable functional deficit without 
excessive mortality and weight loss. Analysis of survival found no 
significant difference, although there was one death at 15 minutes 
occlusion and so longer occlusion times may result in increased mortality. 
There was no significant difference in weight loss found. However, at 15 
minutes of occlusion, animals did lose the most weight compared to 
shorter occlusions times despite not being significant. Neurological deficit 
scores were higher following 15 minutes occlusion despite not being 
significant. Foot fault analysis found no significant difference between 
occlusion times, despite animals receiving 15 minutes of occlusion had 
increased contralateral foot slips, indicating greater asymmetry. T-maze 
analyses also found no difference between groups. Although, at 15 minutes 
of occlusion, animals did alternate the least, have higher tendency to turn 
left (contralateral to damaged side) and took the most time to complete 
the trials. There was no wet-weight difference found between animals with 
increasing times of occlusion that survived to day 7 after surgery. One 
animal that received 15 minutes of occlusion died spontaneously after 
functional tests on the second day after surgery and was excluded from 
oedema analysis. Oedema measurement for this animal was 77.31% 
contralateral and 80.65% ipsilateral wet weight.   
It is likely that, despite having the most weight loss, neurological deficit 
score, contralateral foot slips, time taken to complete T-maze and least 
alternation rates, there were not enough power from animal numbers for 
these analyse to show a significant effect. However, there were limited 
animal numbers and some were reserved for dosing with progesterone. 
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After an adequate occlusion length was determined, the effect of 
progesterone in MCAO could be determined in hypertensive animals.     
 
4.3.4.2 Progesterone in hypertensive BPH/ 2 animals and MCAO 
Because of limited animal numbers available, the remaining animals were 
assigned to be dosed with progesterone. Animals that previously 
underwent 15 minutes of occlusion, which were non-treated, would act as 
a comparison group. Ideally animals would be injected with vehicle but this 
was not possible due to the number of animals remaining after evaluating 
occlusion times.  A total of five animals receive MCAO for 15 minutes and 
were dosed with progesterone. These were compared with non-treated 
animals that received 15 minutes of MCAO. All progesterone treated 
animals survived to the end of all functional end-points on day seven (table 
4.10).     
 
Table 4.10: Number of BPH/ 2 mice in progesterone treated and 
non-treated experimental group  
  
 
Number of animals per group 
Day Progesterone Non-treated 
0 5 4 
1 5 4 
2 5 4 
3 5 3 
4 5 3 
5 5 3 
6 5 3 
7 5 3 
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Analysis of survival found no significant difference between progesterone 
and non-treated animals (P=0.2636) (figure 4.19).  All animals lost weight 
following surgery, but no significant difference was found between groups 
[F(1,7)= 0.58, P=0.472] (figure 4.20). Neurological deficit analysis found 
progesterone treated mice not to differ significantly in neurological deficit 
in comparison to non-treated animals [F(1,7)=3.62, P=0.099] (figure 
4.21). There was no difference in contralateral foot slips between groups in 
the foot fault test (P=0.0679) (figure 4.22). Analysis of t-maze tasks found 
no difference in treatment groups in % alternation rate [F(1,7)= 0.31, 
P=0.600] (4.23), but did find progesterone treatment to lower Left/Right 
alternation ratio % [F(1,6)=9.35, P=0.022] (figure 4.24) and reduce the 
time taken to complete trials for T-maze [F(1,6)=16.44, P=0.007] (figure 
4.25). There was no difference found in oedema between treatment groups 
[F(1,12)=1.23, P=0.2884] (figure 4.26). 
Figure 4.19: The percentage of BPH/2 animals that survived post 
surgery over time.  
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Mortality data expressed using the Kaplan-Meier curve and analysed using 
the Mantel-Haenszel log-rank test. There was no significant difference 
between groups in % of surviving animals in each group post-surgery 
(P=0.2636). 
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Figure 4.20: Weight loss from pre-surgery weight of BPH/2  
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All animals significantly loss weight after surgery, but there was no 
difference in body weight gain between progesterone and vehicle treated 
animals groups [F(1,7)= 0.58, P=0.472]. Data points are expressed as 
means ± SEM. 
 
Figure 4.21: Neurological score for BPH/2 
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Progesterone treatment reduced neurological deficit compared to controls 
[F(1,7)=3.62, P=0.099]. Data expressed as means ± SEM. 
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Figure 4.22: Foot fault for BPH/2 
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Contralateral foot-faults for day (%) the day following surgery. There was 
no difference found between progesterone and non-treated (P=0.0679).  
Data expressed as means ± SEM.  
 
Figure 4.23: T-maze % alternation for BPH/2 
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T ±maze % alternation on day 5 to 7. There was no difference found 
between progesterone and non-treated groups [F(1,7)= 0.31, P=0.600]. 
Data expressed as means ± SEM.   
166 
 
Figure 4.24: T-maze % left/right ratio for BPH/2 
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Progesterone treated group significantly turns left greater than vehicle 
treated groups [F(1,6)=9.35, P=0.022]. Data expressed as means ± SEM.   
 
Figure 4.25: T-maze for time taken to complete trials for BPH/2  
T
im
e
 
T
a
k
e
n
 
(M
in
s
)
D a
y  
5
D a
y  
6
D a
y  
7
0
2
4
6
8
P ro g e s te ro n e
N o n -tre a te d l
 
Time taken to complete T-maze spontaneous alternation trials on days 5-7. 
Non-treated animals took longer to complete t-maze than progesterone 
treated animals [F(1,6)=16.44, P=0.007]. Data expressed as means ± 
SEM. 
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Figure 4.26: Oedema of BPH/2 that survived to day 7 
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Wet weight measured at the end of day 7 after behavioural tests. There 
was no difference in wet weight between progesterone and non-treated 
groups [F(1,12)=1.23, P=0.2884]. Data expressed as means ± SEM. 
 
4.3.4.3 Modified analyses of outcomes in hypertensive BPH/2 mice 
to consider death 
A modified 29-point neurological deficit score was used to encompass 
animals which have died, including interventions for welfare, as mentioned 
earlier with modified neurological score for young C57 Bl/6 mice. Animals 
that have died are given 29 points to represent worse possible outcome in 
analysis. Following MCAO, progesterone treatment did not significant 
reduce neurological deficit [F(1,7)= 2.23, P=0.179] (figure 4.27). 
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Figure 4.27: Modified neurological deficit Score for BPH/2 
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Progesterone treated animals did not reduce function deficit compared to 
non-treated animals [F(1,7)= 2.23, P=0.179]. Data expressed as means ± 
SEM (sham n=5, Progesterone n=5, Non-treated n=4).  
 
Unilateral foot-faults were expressed by the number of contralateral foot-
faults as a percentage of the total errors made; a value of 50% represents 
an equal number of errors made by both sides, as analysed previously with 
foot-faults. However, in addition, animals which have been killed for 
welfare or died spontaneously were scored as having 100% contralateral 
foot faults (figure 4.28). Progesterone dosed animals had less contralateral 
foot slips compared to non-treated animals (P=0.0313).  
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Figure 4.28: Modified foot fault for BPH/2 
%
 
Co
nt
ra
la
te
ra
l F
oo
t S
lip
s
Pr
og
es
ter
on
e
No
n-
tre
ate
d
0
20
40
60
80
100
 
Percentage contralateral foot faults for day 1 post surgery. Animals which 
have died are imputed as having 100% contralateral foot slips. 
Progesterone was found to reduce contralateral foot slips (P=0.0313). Data 
expressed as means ± SEM. 
 
4.4 DISCUSSION  
The current study shows that sustained delivery of progesterone in adult 
C57 Bl/6 mice, initiated following the onset of transient MCAO, is beneficial 
in terms of promoting functional recovery.  Progesterone treatment 
resulted in an improvement in the neurological deficit, but not a reduction 
in the number of contralateral foot-faults. Following MCAO, there was a 
clear neurological deficit and this deficit was reduced following 
progesterone treatment.  In the present study, our outcomes have focused 
on functional measures, as clinical trials of novel stroke therapies use 
functional measures as their primary end-point. In humans, the size of the 
lesion from stroke does not always correlate well with functional 
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impairment (Pineiro et al., 2000). It is important for pre-clinical studies to 
have functional measures relevant to stroke outcomes in patients, as a 
major goal for the treatment of stroke is for patients to be functionally 
independent and so pre-clinical studies need to reflect the importance of 
functional outcomes. Restoration of behavioural function needs to be 
demonstrated in the pre-clinical evaluation of any putative stroke therapy. 
However, pre-clinical studies vary in terms of species, age, sex and doses 
that PD\EH FRQWULEXWLQJ IDFWRUV WR YDULDWLRQV LQSURJHVWHURQH¶VDSSDUHQW
efficacy as a neuroprotectant. 
Previous studies have also reported the ability of progesterone to improve 
functional deficit, as measured by neurological score following MCAO (Chen 
and Chopp, 1999; Coomber and Gibson, 2010; Gibson et al., 2011; Jiang 
et al., 2009; Kumon et al., 2000; Wang et al., 2010). However, these have 
tended to use a much simpler scale, which simply grades function by 5 
(rats) or 6 (mice) levels, UDQJLQJ IURP µQRUPDO¶ WR µVHYHUHO\ LPSDLUHG¶
(Hayakawa et al., 2008; Longa et al., 1989). In the current study, we 
utilised a 28-point neurological deficit score, first developed by Clark et al 
1998 (Clark et al., 1998), which is specifically designed for assessment 
following focal cerebral ischaemia and is a more sensitive measure. 
Interestingly, when using a modified 29-point version that included death 
as a worse outcome, progesterone was not beneficial compared to vehicle. 
This shows that including animals that died, by giving them a worse score 
than the maximum in analysis can influence outcome.  
Functional deficits, as measured by the foot-fault test found no change in 
the number of contralateral foot-faults between progesterone and vehicle 
treatment. Also, the percentage of contralateral foot-faults, in both vehicle 
and progesterone treatment groups, were not found to be different to 
shams. This could be attributed to the occlusion time, which was 30 
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minutes in this study. Other mouse studies tended to use longer occlusion 
times and would result in greater functional deficits being maintained over 
a longer time period (Coomber and Gibson, 2010; Gibson et al., 2005b; 
Gibson et al., 2011; Gibson and Murphy, 2004). However, we chose 30 
minutes in an attempt to increase survival following MCAO. As with the 
neurological score, death was considered in a modified analysis and 
progesterone was found not to be reduce contralateral foot slips. The 
consideration of death in analysis can affect outcome. However, care must 
be taken when you consider death in analysis, as the value of death can be 
arbitrary (in this case 100% foot slips for death) and a high-death rate can 
influence the outcome quite dramatically. Other behavioural tests, which 
are relevant to measuring functional deficits, include rotarod and water 
maze, have been used in experimental stroke previously (Gibson and 
Murphy, 2004). However, due to time constraints, it was not possible to 
include these behavioural tests in this investigation.      
Stroke commonly affects cognitive processes and T-maze spontaneous 
alternation has been shown to involve cognitive elements of behaviour, 
including spatial learning and working memory (Gerlai et al., 1998). This 
behavioural test allows the detection of potential left or right spatial 
neglect and enables unchallenged locomotion as well as exploratory 
motivation to be observed (Gerlai et al., 1998).  Studies examining 
neurological deficits in mice, rats and gerbils have reported a lower 
alternation rate in animals with focal ischaemia (Gerlai et al., 2000; 
Ishibashi et al., 2003b; Itoh et al., 1993; Kadam et al., 2009; Matchett et 
al., 2007). Animals with ischaemic brain injury have a tendency, to turn 
ipsilaterally towards the damaged side during the T-maze and tests of 
behavioural asymmetry (Carloni et al., 2008; Zhang et al., 2002). 
However, in this current study, there was no difference in the alternation 
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rate, goal arm preference or time to complete the t-maze due to surgical 
or drug intervention. This implies that a 30 min period of transient focal 
cerebral ischaemia did not produce a sufficient neurological deficit to 
impact upon the ability to accomplish the T-maze test.    
Behavioural deficits have multiple causes, and their severity is influenced 
by the size and location of the stroke (Pineiro et al., 2000), extent of 
cortical involvement, plasticity and genetic backgrounds of outbred strains 
(Kadam et al., 2009). Spontaneous recovery is also known to occur in 
rodent brains following local trauma and small degrees of irrecoverable 
tissue damage. The reduced occlusion time employed in this study, as 
compared to others, may have left intact areas of the brain associated with 
exploratory behaviour and working memory. Although the hippocampus is 
not directly affected by transient MCAO (since it is not directly perfused by 
the middle cerebral artery (Hunter et al., 1998), there is evidence to 
suggest that, over time, it can become compromised due to decreased 
collateral blood flow (Tang et al., 2012).  
Some studies have found progesterone to aid survival after ischaemia 
(Gibson and Murphy, 2004), while others have reported no effect (Alkayed 
et al., 2000; Coomber and Gibson, 2010; Gibson et al., 2011). However, 
many studies do not report survival. In the present study, no difference in 
survival was found between treatment groups for either animals that died 
or were euthanized for welfare. Weight loss has been monitored in 
previous studies of progesterone with some showing reduced weight loss 
(Gibson and Murphy, 2004; Jiang et al., 1996; Kumon et al., 2000) and 
others finding no significant difference (Chen and Chopp, 1999; Coomber 
and Gibson, 2010; Gibson et al., 2011). In the present study, progesterone 
and vehicle-treated MCAO groups gained weight at a reduced rate 
compared to shams, with no difference found between progesterone and 
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control groups. However, care must be taken when interpreting weight 
loss, as some animals were not included in the analysis, because they were 
killed following unacceptable weight loss from a welfare perspective (one 
animal in the sham group, four in the vehicle and one in the progesterone 
group). The modified analysis of weight loss, which considered these 
animals, found progesterone not to be beneficial.     
We reported previously, that progesterone delivered via i.p. injection has a 
very short half-life in both plasma and brain (Wong et al., 2012), although 
this dosing method has been successful in providing neuroprotection in 
young male mice (Gibson and Murphy, 2004). There have been only a few 
studies reported involving progesterone and experimental stroke using 
infusion delivery in rats (Alkayed et al., 2000) and mice (Coomber and 
Gibson, 2010). In both studies, animals were treated with progesterone 
prior to MCAO unlike in the present study, the only one to date in which 
progesterone has been delivered via mini-pump infusion after occlusion. 
Our previous pharmacokinetic study of progesterone infusion with mini-
pumps achieved high sustained progesterone concentrations in the brain 
(Wong et al., 2012). The current study demonstrates this method of dosing 
to be beneficial in terms of neurological deficits but not regarding 
indicators of general well-being (survival and weight loss), motor function 
or cognitive performance in the T-maze. Lack of protection in some 
aspects, but not others, may be due to either a dose effect or the length of 
initial occlusion. Increasing the progesterone dose might not necessarily 
result in greater neuroprotection. Some studies have used higher doses of 
progesterone ranging from 10-32 mg/kg via i.p. injections but found no 
greater beneficial effects (Chen and Chopp, 1999; Murphy et al., 2002; 
Murphy et al., 2000). Chen et al found 8 mg/kg but not 4 mg/kg or 32 
mg/kg to be neuroprotective (Chen and Chopp, 1999), indicating a 
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relatively narrow dose-response window. Clearly it will be important to 
determine, in future experiments, whether there is a similar narrow 
therapeutic window when progesterone is delivered by loading dose and 
mini-pump infusion, avoiding the peaks and troughs in tissue 
concentrations produced by repeated injections.  
Continuous progesterone administration has been shown to produce 
enhanced benefit in traumatic brain injury (TBI) as compared to repeated 
injections in a rat model (Cutler et al., 2006a). This may also be the case 
with progesterone in stroke and a continuous dosing method would allow 
tapering off progesterone to be more easily achieved. Also, clinical trials 
investigating the neuroprotective properties of progesterone following TBI 
have shown the hormone to be beneficial and safe (Wright et al., 2007; 
Xiao et al., 2008). In these trials, steady-state serum concentrations of 
progesterone were achieved, following continuous intravenous infusion in 
patients with acute moderate to severe TBI injury (Wright et al., 2005). 
Any future clinical trial evaluating neuroprotection of progesterone in 
stroke would need to use a method of dosing that achieved a steady state 
concentration lasting several days, e.g. infusion or long-acting 
vaginal/rectal administration.  
In humans, age is a predictor of worse outcome following stroke. This 
investigation has also shown this to be true in aged animals. Aged animals 
were very susceptible to MCAO, even when occlusion time was reduced. 
The majority of aged animals were found dead or killed for welfare reasons 
the following day after surgery. Mortality is expected to be higher in older 
animals compared to younger ones. In rats, mortality immediately post-
stroke was found to be low in young animals (6%, 3-4 months) but high in 
old rats (44%, 18-20 months) (Wang et al., 2003). In this investigation, 
the majority of deaths were due to animals being killed for welfare reasons 
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(60%), rather than animals found dead. The majority of animals that were 
found dead (66.67%) could be attributed to increased temperature in the 
recovery phase. Increase of temperature in recovery after MCAO seems 
detrimental to animals, as all mice were found dead the following day in 
these conditions. Temperature can affect outcomes, following stroke. 
Higher temperatures following ischaemic stroke is thought to accentuate 
the ischaemic mechanism  (Zaremba, 2004), which is probably the case 
here. Other studies involving animal models have investigated the effects 
of temperature and found hypothermia in the first 24 hours after stroke 
onset improves stroke outcomes (Barber et al., 2004). A meta-analysis of 
animal studies involving hypothermia and stroke found hypothermia 
improved outcomes by about a third (van der Worp et al., 2007).  
Survival analysis found no significant difference between treatment groups. 
Due to the number of deaths, because of welfare reasons or otherwise, 
data was limited to the first day following surgery for functional outcomes 
and oedema at death. Because there were no available sham animals, it 
was not known if the source of deaths were directly due to the surgery or 
from occlusion. Also, not enough data was available for both treatments 
groups for foot-fault analysis, as animals that were killed for welfare 
reasons under veterinary advice were not approved to undergo further 
behavioural tests. Analysis of weight, neurological deficit score and 
oedema found progesterone not to be beneficial. Although, due to limited 
data from animals in a narrow time frame, this is difficult to determine if 
this is the case, or rather, neuroprotection would manifest later in animals 
that survive.     
Animals in this study are in the region of 15-16 months, which is a phase 
leaving middle to old age. Middle age, in both mice and rats, is considered 
to be 10-15 months and old age is considered to be 18-24 months. In the 
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upper limit of 14-15 months of middle age, most biomarkers relevant to 
ageing may not have changed to their full extent and some have yet to 
manifest (Flurkey K, 2007). A limited number of studies have investigated 
neuroprotection of progesterone in this age range in rodents, but mostly in 
animals treated prior occlusion. Toung et al found female reproductively 
senescent rats, 14-18 months of age, did not benefit from pre-MCAO 
treatment with progesterone (Toung et al., 2004), while Alkayed et al 
using 16 month old female rats found progesterone to be beneficial when 
administered prior MCAO (Alkayed et al., 2000). Studies have not been 
previously performed in aged mice that are as old as the ones investigated 
here. Although, Gibson et al did use 12 months old female reproductively 
senescent mice that were pre-treated with progesterone before occlusion 
and was found to be protective (Gibson et al., 2011). Presently only one 
study has administered progesterone, post-onset to occlusion in old 
animals. This study by Wang et al, found progesterone to improve 
outcomes in 24 month old male rats (Wang et al., 2010). Studies of 
progesterone and experimental stroke involving aged animals are limited, 
particularly for the dosing of animals after the start of occlusion. Age is an 
important factor in the outcome of stroke and further investigation is 
required to determine the efficacy of progesterone in aged animals. Also, 
this study has failed to take into account gender. It would be useful to 
consider, that whilst pre-menopausal females represent the population 
group with the lowest risk of stroke, post-menopausal females represent 
the group at higher risk (Appelros et al., 2009). Therefore, further 
investigation is needed in aged female animals.   
The mortality of NOD/ShiLtJ animals in the preliminary surgeries was high. 
The remaining animals were monitored and tested for the development 
and severity of diabetic symptoms found only a few animals to have high 
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glucose in their urine and considered to be symptomatic of diabetes. High 
ketones in blood, which is an indicator of type 1 diabetes at the end of 
monitoring, helped to confirm this. Monitoring of symptomatic mice found 
reduced weight compared to non-symptomatic mice, which was not 
surprising, as NOD mice are a model of spontaneous type one diabetes and 
is known to be susceptible to weight loss at the onset, similar to patients 
that develop the condition (Kikutani and Makino, 1992). Also, symptomatic 
NOD mice had increased thirst, which is characteristic for the onset of 
symptoms (Zhao et al., 2008). Although, this strain has characteristics of 
type-1 diabetes, they are problematic for the use in experimental stroke. 
The development of diabetes in these animals can be abrupt and age 
dependent, which can vary between animals. Therefore, constant 
monitoring is required and the number of animals that can undergo 
surgery at any one time is limited. Also, the excessive thirst found in this 
investigation for symptomatic mice makes them unlikely to survive post-
surgery due to their demands in water intake. Other studies have managed 
to use other diabetic rodent strains to investigate experimental stroke, 
including type-1 (Toung et al., 2000) and type-2 diabetic strains (Tureyen 
et al., 2011; Vannucci et al., 2001). 
Initial experiments on BPH/2 mice were to determine an adequate length 
of occlusion for functional outcomes. There was no one test of functional 
outcome that showed significance, most likely due to the small number of 
animals available, but occlusion of 15 minutes caused greater functional 
deficit in tests, without excessive mortality and weight loss. Although not 
significant, animals with increasing occlusion times had lower alternation 
rates and took longer to complete the t-maze trials, which concurs with 
previous work in stroke animals (Gerlai et al., 2000; Ishibashi et al., 
2003a, b; Itoh et al., 1993; Kadam et al., 2009; Matchett et al., 2007). 
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However, increased occlusion times resulted in increased tendency to 
favour the left goal arm (contralateral to damaged side), which is contrary 
to what is expected for animals suffering focal ischaemia (Carloni et al., 
2008). One experimental stroke study using Mongolian gerbils had similar 
results and suggested it was due to changes in visual input (Ishibashi et 
al., 2003b), but mice have poorly developed visual system in comparison 
to gerbils (Shankar and Ellard, 2000), indicating the choice of goal arm 
may not be related to the visual system.   
There was no difference between progesterone treated and non-treated 
animals in terms of survival and weight loss, which is not surprising as the 
aim was to cause measureable functional deficit without excessive 
mortality or weight loss. Also, no difference in oedema was found after all 
functional tests were completed, most likely due to animals having fully 
recovered from oedema. Progesterone treatment was found not to be 
beneficial in reducing neurological deficit (both 28 point and modified 29 
point neurological deficit scores). Foot-fault showed progesterone to have 
lower contralateral foot-slips but was not significant due to lack of power. 
However, the modified foot-fault did find progesterone to significantly 
reduce foot slips, due to including animals that died in analysis. T-maze 
found no difference in alternation rate between progesterone treated and 
non-treated animals. Interestingly, progesterone treated animals did have 
a preference to turn left (contralaterally to ischaemic damage). Animals 
with ischaemic brain injury have a tendency to turn ipsilaterally, towards 
the damaged side during the T-maze and tests of behavioural asymmetry 
(Carloni et al., 2008; Zhang et al., 2002). Progesterone has been shown to 
alter cognitive performance (Frye and Walf, 2008). However, mice were 
dosed on the day of occlusion and so progesterone would have been 
metabolised by the time of testing. Therefore, it is unknown why 
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progesterone dosed animals have a preference for the left goal arm rather 
than only approximately 50%, which is expected for normal behaviour. 
Progesterone dosed animals did take quicker to complete T-maze tasks, 
indicating a better functional outcome. There was no difference in oedema, 
most like due to the reasons given previously for the initial experiments of 
BPH/2. Care must be taken with these findings, as our comparison group 
did not receive vehicle, due to the limited number of animals available for 
testing. Progesterone was dissolved in DMSO, which has been shown to 
have neuroprotective properties (Jacob and de la Torre, 2009). Hence, it 
cannot be confirmed on the level neurorpotection is attributed to 
progesterone or DMSO and so further investigation is required to 
determine this.    
Overall, progesterone was found to be beneficial and concurs with the 
findings of Kumon et al, who found progesterone to be neuroprotective in 
spontaneous hypertensive rats (Kumon et al., 2000). However, due to the 
low number of animals, less than ideal vehicle group and lack of shams, 
this needs to be viewed with caution. As a model, BPH/2 mice represent 
another model of hypertension in stroke research. Spontaneously 
hypertensive rats and the related stroke prone hypertensive rats are the 
most widely used hypertensive animals used in stroke research, a choice 
that has been criticised due to the animals limited representation of 
processes involved in hypertension present in humans (Pinto et al., 1998). 
BPH/2 mice represent another possible model of hypertension, one that is 
rennin-independent, while spontaneous hypertensive rats are rennin-
dependent and so offers another mechanism, which can be investigated.        
In conclusion, progesterone given as a loading dose (bolus i.p.) followed by 
maintenance (osmotic mini-pump) delivery is effective in conferring 
neuroprotection in a transient MCAO model in adult male mice. Aged 
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animals have an increased sensitivity to MCAO and did not display, in the 
outcomes measured here, any benefit from progesterone treatment. 
NOD/ShiLtJ mice are not recommended as a model of diabetes for 
experimental stroke research, because of their severe symptoms would 
result in high mortality after surgery. Hypertensive BPH/2 mice are a 
potential hypertensive model and had better functional outcomes after 
treatment with intraperitoneally administered progesterone, compared to 
non-treated hypertensive animals.     
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CHAPTER 5 
Progesterone treatment for experimental 
stroke: an individual animal meta-analysis.    
 
Publications contributing to this chapter: 
Wong, R., Renton, C., Gibson, C.G., Murphy, S.J., Kendall, D.A., and Bath, 
P.M.W. (2012). Progesterone treatment for experimental stroke: an 
individual animal meta-analysis. J Cereb Blood Flow Metab 33, 1362-72 
(Published)  
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5.1 INTRODUCTION 
Studies assessing the safety and efficacy of progesterone in pre-clinical 
models of stroke (Alkayed et al., 2000; Chen and Chopp, 1999; Chheng-
Orn Evans et al., 2004; Gibson et al., 2005b; Gibson and Murphy, 2004; 
Jiang et al., 1996; Kumon et al., 2000; Murphy et al., 2002; Murphy et al., 
2000; Roof et al., 1996) have previously been integrated in a systematic 
review and meta-DQDO\VLV EDVHG RQ SXEOLVKHG VXPPDU\ µJURXS¶ GDWD
(Gibson et al., 2007). However, this systematic review suggested that key 
questions remained to be answered, including demonstrating efficacy as a 
function of sex and age and evaluating the dose and timing of 
progesterone administration. The gold-standard for assessing effects 
across studies within and between subgroups is to use a meta-analysis 
based on individual animal data (IAD), as previously performed for NXY-
059, another putative neuroprotectant (Bath et al., 2009). The present 
study reports the results of a systematic review and meta-analysis based 
on IAD of pre-clinical studies of progesterone in experimental models of 
stroke. 
 
5.2 METHODS 
 
5.2.1 Ethics 
No ethics approval was needed for the present study which follows a 
protocol defined at the beginning of the project based on a previous study 
using IAD from experimental stroke studies of NXY-059 (Bath et al., 2009). 
 
5.2.2 Search strategy 
Completed studies that investigated the effect of progesterone in animal 
models of focal stroke were sought via searches of electronic databases 
ODVWVHDUFK2FWREHULQFOXGLQJµ:HERI.QRZOHGJH¶DQGµ3XE0HG¶
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Search strategies used the following key words: progesterone, stroke, 
ischaemia. Reference lists from existing systematic and non-systematic 
reviews, and identified study publications, were also searched (Gibson et 
al., 2008b; Roof and Hall, 2000). Where duplicate publications were 
identified, information from the primary report was used. Publications 
could be in any language. 
 
5.2.3 Selection of studies 
Completed studies, randomised, and whether published or unpublished, 
were included if experimental focal stroke injury was induced in animal 
models and progesterone was administered. Stroke models could include 
transient or permanent focal cerebral ischemia, and progesterone or its 
metabolite allopregnanolone had to be administered exogenously. Studies 
had to include data on at least one outcome of interest: lesion volume, 
vital status and/or functional outcome. Studies were excluded if they did 
not report induction of focal cerebral ischemia, or administration of 
progesterone, or did not contain original data, or involved just global 
ischaemia.  
 
5.2.4 Validity assessment 
Studies were identified based on the inclusion/exclusion criteria listed 
above. The methodological quality of each study was assessed, using a 
nine point score modified from the original 8-point STAIR system (Stroke 
Therapy Academic Industry Roundtable (STAIR), 1999). A point was given 
for published evidence (supplemented with information from the 
corresponding author) for each of the following criteria: presence of 
randomisation (pseudo randomised 0.5), monitoring of physiological 
parameters, assessment of dose response relationship, assessment of 
optimum time window, masked outcome measurement, assessment of 
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outcome at 1-3 days, assessment of outcomes 1-30 days, combined lesion 
volume and functional outcome; and for blinding of surgery (Bath et al., 
2009). 
 
5.2.5 Data abstraction 
Two reviewers (RW, CG) identified studies. One author resolved 
disagreements by discussion and review (PB). 
 
5.2.6 Data extraction 
Corresponding authors of papers of interest were contacted to ask if they 
would be willing to join the pooling project collaboration and, if so, to share 
,$'ZLWKGDWDILHOGVOLVWHGLQWKHSURMHFW¶VSURWRFRO (Appendix). 
 
Individual data for each animal was sought for: species, gender (male, 
young intact female, old female, ovariectomised young female); age (or 
weight as a surrogate); lesion volume (total, cortical, subcortical); and 
vital status (including information on timing and cause of death ± surgery, 
culling due to poor health, spontaneous). Information on treatment was 
also obtained: time of treatment from occlusion time (hours before/after); 
loading and maintenance dose of progesterone; treatment duration; 
plasma progesterone concentration. 
 
The following study design information was extracted either from the 
publication or via the corresponding author: experimental model ± 
transient, permanent; randomisation - randomised, pseudo-randomised, 
not randomised; blinding of surgeon to treatment; blinding of outcome 
assessors to treatment. Studies were considered randomised if animals 
were numbered before commencement of the study and a randomisation 
code was used to allocate animals to treatment groups; if animals were 
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µSLFNHG DW UDQGRP¶ IURP D FDJH WKHQ WKHVH VWXGLHV ZHUH FRQVLGHUHG
pseudo-randomised since this type of approach is open to bias. 
 
5.2.7 Quantitative data synthesis 
,$'ZHUHWUDQVIHUUHGWRWKHSURMHFW¶VFRRUGLQDWLQJFHQWUHLQ1RWWLQJKDPE\
email attachment, e.g. Excel file. Study datasets were merged into a single 
Microsoft Excel sheet using common field names with one row per animal. 
Where individual data could not be obtained, summary data were obtained 
from the publication and entered into a second Excel sheet. Summary data 
were also created from IAD and added to this second spread-sheet to allow 
summary meta-analysis of all studies. 
 
Lesion volume was recorded as either absolute volume or as a percentage 
of the intact contralateral hemisphere. In order to combine the different 
units, lesion volume was standardised by standard mean difference, i.e. 
the difference in means/standard deviation of score. Data from animals 
that have died before study completion is commonly excluded from meta-
analyses of animal data, but to allow its inclusion, lesion volume was given 
DµZRUVWFDVH¶YDOXH)RUVWXGLHVLQZKLFKOHVLRQYROXPHZDVFROOHFWHG as a 
percentage, a value of 100% was assigned for death; for studies in which 
lesion volume was collected as an absolute value, species-dependent 
maximal values were assigned ± 400 mm3 for rats and 225 mm3 for mice. 
Analyses of lesion volume were performed with death imputed and 
excluded in order to confirm the robustness of conclusions. Taking account 
of the role of progesterone as an endogenous sex steroid, sex was 
trichotomised into male, young female (age<12 months), and old female 
or ovariectomised females. Progesterone dose was standardised to mg/kg. 
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Meta-analysis of individual animal data was carried out using random 
effects mixed modelling with covariate adjustment in SAS (version 9.3). 
Meta-analysis of summary data was carried out using random effects 
analysis in STATA (version 11). Random effects analysis was used in order 
to take account of the expected heterogeneity between studies caused by 
variations in study design, i.e. differences in species, stroke model, dosing, 
study practice. 
 
All analyses were performed unadjusted (no covariates). Additionally, 
analyses using IAD were adjusted for the following covariates, chosen for 
their biological relevance or relationship to treatment: model (transient, 
permanent), age (young <12, aged >12 months), sex (male, young 
ovariectomised female, and aged female), time to treatment, loading 
progesterone dose, total progesterone dose (sum of loading and 
maintenance) and anaesthetic agent (halothane, isoflurane). Interaction 
tests between treatment and covariates were assessed if the covariate was 
significantly associated with the outcome. 
 
Analyses were performed by the backwards elimination procedure. This 
procedure starts with all potential predictor variables in the regression 
model and, successively, variables are dropped one at a time, such that 
the resulting model has the lowest value of the information criteria. 
Variables are dropped on the basis of their contribution to the reduction of 
HUURU VXP VTXDUHV RU µZRUVW¶ LQFOXGHG YDULDEOH 7KLV LV VWRSSHGZKHQ the 
best model is reached according to the Akaike Information Criterion (AIC). 
The AIC is an alternative significance test to estimate quantities of interest 
and judges a model by how closely its fitted values tend to be to the true 
values. AIC serves the purpose of model comparison only and does not 
provide diagnostics about the fit of the model to the data.  
187 
 
 
Data are given as standardised mean differences (SMD, continuous data) 
or odds ratios (OR, binary data) with 95% confidence intervals (95% CI), P 
value for effect, P value for heterogeneity, and P value for interaction; P 
values <0.05 are considered significant. Negative coefficients imply a 
reduction in lesion volume. An odds ratio less than one implies a reduction 
in death. 
 
5.3 RESULTS 
5.3.1 Study flow 
Nineteen completed studies fulfilled the inclusion criteria (figure 5.1, table 
1); since one study included two data sets (Toung et al., 2004), 20 
separate datasets were used in the analyses. Authors were contacted and 
were asked about sharing available individual animal data for analysis. In 
total, IAD were received from 12 published and 2 unpublished studies. 
Shared data included animals excluded in publications, in particular those 
that died before study completion. Altogether, IAD were available for 689 
animals. IAD were not shared for 6 studies in spite of repeated contact 
with authors (Chen and Chopp, 1999; Choi et al., 2004; Ishrat et al., 
2009; Jiang et al., 1996; Kumon et al., 2000; Liu et al., 2012); 
nevertheless, data from these studies were included in analyses based on 
summary data. Five studies were excluded (table 5.3), mostly because 
they did not have data on total lesion volume or vital status, e.g. one 
study only had data on blood volume collected (Alkayed et al., 2000). 
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Figure 5.1: Flow chart showing study search, and included and 
excluded studies. 
 
 
Summary data were used for studies where individual animal data were 
not made available. Studies were excluded if they did not report induction 
of focal cerebral ischaemia, administration of progesterone, or 
measurement of lesion volume, or did not contain original data. n = 
number of studies. 
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5.3.2 Study characteristics 
Study characteristics are reported in tables 5.1 and 5.2. The studies 
compared the effect of exogenously administered progesterone versus no 
progesterone, or vehicle, on lesion volume after acute focal cerebral 
ischaemia. All studies used a monofilament to induce focal cerebral 
ischaemia in the middle cerebral artery territory. Seven studies used mice 
(permanent ischaemia in one, transient ischaemia in 6) and 12 studies 
used rats (permanent ischaemia in one, transient ischaemia in 11). The 
studies included 11 using young male animals, 4 using young 
ovariectomised females, 1 using aged males (age >12 months) and 3 
using aged females. Insufficient data were available on cortical or 
subcortical lesion volume measurements to permit analysis and only total 
or hemispheric lesion volume was analysed. Dosing methods included 
intra-peritoneal injection (12 studies), intra-peritoneal with subcutaneous 
injection (4 studies) and subcutaneous implants of slow release 
pellets/mini-pumps (3 studies). A variety of regimens were used for 
progesterone administration with dosing commencing from 7-10 days 
before MCAO to 2 days afterwards. Lesion volume, assessed from 
histologically stained brain slices, was reported in mm3, % cross sectional 
area, or % of intact contralateral hemisphere. Study quality ranged from 
2-3XEOLFDWLRQELDVZDVDSSDUHQWRQYLVXDOLQVSHFWLRQRID%HJJ¶VIXQQHO
plot based on lesion volume (figure 5.2), and when assessed statistically 
XVLQJ(JJHU¶s test (P=0.001). 
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Table 5.1:  Studies included in the analysis 
          
Study Lab Species Sex Anaesthetic Random 
Surgery 
Blinded 
Outcome 
Blinded 
Temperature 
control 
Model 
Time Prog Loading Dose 
to Occlusion (min) 
Prog Load 
(mg/kg) 
Progesterone 
Maintenance 
(mg/kg/hr) 
Responders with IAD 
            Toung 2004(Toung et al., 
2004) 
Baltimore 
USA 
Rat F Halothane (4-5% Induction, 
1.25-1.5% maintenance 
delivery in O2 enriched air) 
y n n y Focal 
(Transient) 
-30 5 i.p. 5+5 i.p. for 24.5 hr 
Toung 2004(Toung et al., 
2004) (Prog+Est) 
-30 5 i.p. 5+5 i.p. for 24.5 hr 
Parker 2005(Parker S.M, 
2005) 
Portland USA Mice F Halothane (4-5% Induction, 
1.25-1.5% maintenance 
delivery in O2 enriched air) 
y n n y Focal 
(Transient) 
-7 days none 15/30 mg s.c. 21 day 
release implant for 7-8 
days 
Murphy 2002(Murphy et al., 
2002) 
Baltimore 
USA 
Rat F Halothane (4-5% Induction, 
1.25-1.5% maintenance 
delivery in O2 enriched air) 
y n n y Focal 
(Transient) 
-30 5/10/20 i.p. none 
-30 5 i.p. 5+5 i.p. for 24.5 hr 
Murphy 2002[unpub] Baltimore 
USA 
Rat F Halothane (4-5% Induction, 
1.25-1.5% maintenance 
delivery in O2 enriched air) 
y n n y Focal 
(Transient) 
-30 5 i.p. 5+5 i.p. for 24.5 hr 
Murphy 2000(Murphy et al., 
2000) 
Baltimore 
USA 
Rat F Halothane (4-5% Induction, 
1.25-1.5% maintenance 
delivery in O2 enriched air) 
y n n y Focal 
(Transient) 
-30 30/60 i.p. None 
-7 to -10 days 30/60 i.p. 30/60 i.p. daily for 7-10 
days 
Gibson 2004(Gibson and 
Murphy, 2004) 
Nottingham, 
UK 
Mice M Isoflurane 4% (NO2/O2 
70/30% mixture) 
y y y y Focal 
(Transient) 
60 8 i.p. 8 + 8 i.p. for 23 or 47 
hrs 
Gibson 2005(Gibson et al., 
2005b) 
Nottingham, 
UK Mice M 
Isoflurane 4% (NO2/O2 
70/30% mixture) y y y y 
Focal 
(Permanent) 60 8 i.p. 8 + 8 i.p. for 47 hrs 
Sayeed 2006(Sayeed et al., 
2006) Atlanta USA Rat M 
Isoflurane 4% (NO2/O2 
70/30% mixture) y n n y 
Focal 
(Transient) 115 8 i.p. 8 s.c. for 72 hrs 
Intraperitoneal= I.P, Subcutaneous= S.C., F= Female, M= Male, Unpub= Unpublished, Prog= Progesterone, Time Prog Loading Dose to Occlusion (min)= Time to occlusion 
that the progesterone loading dose was given in minutes , Progesterone Maintenance (mg/kg/hr)=  maintenance doses given (mg/kg) over time in hours from start of 
progesterone treatment to lesion volume measurement.  
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Table 5.1:  Continued 
 
           
Study Lab Species Sex Anaesthetic Random 
Surgery 
Blinded 
Outcome 
blinded 
Temperature 
control 
Model 
Time Prog loading dose 
to Occlusion (min) 
Prog Load 
(mg/kg) 
Progesterone 
Maintenance 
(mg/kg/hr) 
Sayeed 2007(Sayeed et al., 
2007) Atlanta USA Rat M 
Isoflurane 4% (NO2/O2 
70/30% mixture) y n y y 
Focal 
(Permanent) 120 8 i.p. 8 + 8 +8 s.c. for 72 hrs 
Sayeed 2009(Ishrat et al., 
2009) Atlanta USA Rat M 
Isoflurane 4% (NO2/O2 
70/30% mixture) y n n y 
Focal 
(Transient) 115 8 i.p. 8 s.c. for 72 hrs 
             
Coomber 2010(Coomber and 
Gibson, 2010) 
Leicester UK Mice F Isoflurane 4% (NO2/O2 
70/30% mixture) 
y y y y Focal 
(Transient) 
-7 days none 50 mg s.c. 21 day 
release implant for 7 
days 
Gibson 2011(Gibson et al., 
2011) 
Leicester UK Mice F Isoflurane 4% (NO2/O2 
70/30% mixture) 
y y y y Focal 
(Transient) 
60 8 i.p. 8 + 8 i.p. for 23 or 47 
hrs 
Wong 2012[Unpub] Nottingham, 
Uk 
Mice M Isoflurane (100% 02) y y y y Focal 
(Transient) 
30,60 8 i.p. 50mg s.c. 3 day release 
implant for 48 hrs 
Non responders/No IAD 
            Jiang 1996(Jiang et al., 1996) Atlanta USA Rat M Halothane (3.5% induction, 1-
2% maintenance delivery 70% 
N2) and 30% 02) 
y n n y Focal 
(Transient) 
-30 4 i.p. 4 + 4 i.p. for 48 hrs 
Chen 1999(Chen and Chopp, 
1999) 
Rochester 
USA 
Rat M Halothane (3.5% induction, 1-
2% maintenance delivery 70% 
N2) and 30% 02) 
n n n y Focal 
(Transient) 
120 4/8/32 i.p. 4 + 4/ 8 + 8/ 32 + 32 
i.p. for 7 days 
Ishrat 2009(Ishrat et al., 
2009) 
Atlanta USA 
Rat M 
Isoflurane 5% Induction, 1.5-2% 
maintenance, 2:1 nitrous oxide 
and O2 mix  n n n y 
Focal 
(Permanent) 60 8 i.p 8 + 8 + 8 s.c for 72 hrs 
 
Rat M Isoflurane 5% Induction, 1.5-
2% maintenance, 2:1 NO2 and 
O2 mix 
n n n y Focal 
(Permanent) 
60 8 i.p. 8 + 8 +8 s.c. for 72 hrs 
Kumon 2000(Kumon et al., 
2000) 
Ehime, Japan Rat M Halothane (3% induction, 1-
2% maintenance delivery 70% 
N20 and 30% O2) 
y y y y Focal 
(Transient) 
120 4 / 8 i.p. none 
Choi 2004(Choi et al., 2004) Pusan Korea Rat M Sodium thiopental (50 mg/kg) n n n y Focal 
(Transient) 
-24 hr 4 i.p. 4 i.p. for 48 hrs 
Liu 2012(Liu et al., 2012) Paris France Mice  M 
Ketamine (50mg/kg) and 
xylazine hydrochloride 
(6mg/kg) y n y y 
Focal 
(Transient) 60 8 i.p. 
8 + 8 i.p. for 23 or 47 
hrs 
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Table 5.2:  Experimental Results 
     
Study 
Exclusions 
from Analysis 
(Prog: 
Control) 
Death 
(Prog: 
Control) 
Lesion Volume Timing (h) 
 Total Lesion 
Animals  
(Prog:Control) 
Total Lesion Volume (SD) ( Prog: 
Control) 
Quality/9 Comments on Progesterone 
Responders with IAD 
       Toung 2004(Toung et al., 
2004) 
5 (4:1) 5 (4:1) 24 20 (10:10) 18.61 (13.45): 24.06 (13.31) 3 Combined hormone reduced infarct volume and 
progesterone does not attenuate estrogen effect. 
Toung 2004 
(Prog+Est)(Toung et al., 
2004) 
2 (1:1) 2 (1:1)  20 (10:10) 7.59 (5.69): 8.92 (9.15)   
        Parker 2005(Parker S.M, 
2005) 
0 0 23.5 24 (16:8) 49.77 (12.9): 53.46 (18.68) 4 Chronic, exogenous progesterone prior to MCAO alters 
ischemic brain injury in ovariectomized female mice 
Murphy 2002(Murphy et 
al., 2002) 
28 (15:13) 2 24 61 (39:22) 17.85 (10.78): 18.9 (14.37) 5 Progesterone both before MCAO and during reperfusion 
decreases ischemic brain injury 
Murphy 2002[Unpub] 0 0 none none none 3 Hormone Measurement 
Murphy 2000(Murphy et 
al., 2000) 
29 (19:10) 11 24 56 (42:14) 13.32 (8.26): 8.42 (8.09) 5 Progesterone does not ameliorate histological injury after 
MCAO in previously ovariectimised adult female rats.  
Chronic progesterone administration can exacerbate 
infarction in subcortical regions 
Gibson 2004(Gibson and 
Murphy, 2004) 
4 4 24, 48 20 (10:10) 13.97 (5.21): 18.64 (5.9) 7 Beneficial effects of progesterone after cerebral ischemia 
Gibson 2005(Gibson et 
al., 2005b) 
6 4 (2:2) 48 24 (12:12) 82.5 (12.58): 90.87 (15.88) 5 Progesterone is neuroprotective in both permanent and 
transient ischemia and effect is related to suppression of 
the inflammatory response 
Sayeed 2006(Sayeed et 
al., 2006) 
9 2 72 13 (6:7) 15.96 (3.6): 24.38 (6.69) 4 Progesterone is effective at reducing infarct pathology 
Sayeed 2007(Sayeed et 
al., 2007) 
3 1 72 15 (7:8) 13.81 (5.68): 27.8 (6.27) 5 Progesterone is neuroprotective 
Sayeed 2009(Ishrat et 
al., 2009) 
0 0 72 16 (8:8) 9.32 (2.29): 20.12 (2.91) 4 Progesterone is neuroprotective 
Coomber 2010(Coomber 
and Gibson, 2010) 
9 4(3:1) 48 13 (6:7) 20.62 (9.22): 23.41 (10.18) 5 No effect 
Gibson 2011(Gibson et 
al., 2011) 
10 8 (5:3) 48 42 (20:22) 21.59 (7.42): 24.67 (5.68) 7 Progesterone is not beneficial in ovariectomised mice but is 
in Aged female mice for lesion volume 
Wong 2012[Unpub] 0 0 none none none 3 Hormone Measurement 
Unpub= Unpublished, Exclusion from Analysis: Total Number (Progesterone: Control), 
Death: Total Number (Progesterone: Control), Total Lesion Volume (SD): Mean Raw 
data (Standard Deviation).  
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Table 5.2:  Continued 
       
Study 
Exclusions 
from Analysis 
(Prog: 
Control) 
Death 
(Prog: 
Control) 
Lesion Volume Timing (h) 
 Total Lesion 
Animals  
(Prog:Control) 
Total Lesion Volume (Prog: Control) Quality/9 Comments on Progesterone 
Non responders/No 
IAD 
        
Jiang 1996(Jiang et al., 
1996) 
- - 48 48 (24:12) 24.43 (10.39): 35.1 (15.59) 5 Progesterone administered before or after MCAO reduces 
ischemic cell damage and improves physiological and 
neurological function 2 days after stroke. 
        
Chen 1999(Chen and 
Chopp, 1999) 
- - 7 days post MCAO 28 (7:7,7,7) 26.57 (11.67): 34.4 (10.5) 5 8mg/kg of progesterone reduce brain lesion and improved 
neurological functional deficit 
        
Ishrat 2009(Ishrat et al., 
2009) 
- - 72 24 (8:8,8) 9.24 (2.96): 20.11 (3.1) 3 Progesterone treated have reduced infarct volume and 
improved ability to stay on rotarod and grip test 
        
Kumon 2000(Kumon et 
al., 2000) 
- - 2 or 7 days after MCAO 48 (32:16) 31.15 (14.13): 41.2 (10.4) 7 Treatment with high dose of 8mg/kg of progesterone 
results in reduction of lesion size, neurological deficits and 
body weight 
        
Choi 2004(Choi et al., 
2004) 
- - 24 11 (5:6) 210 (67.6): 231.4 (154.07) 2 No effect 
        
Liu 2012(Liu et al., 2012) - - 48 64 (32:32) 43.25 (22.75): 52.25 (17.96) 5 Progesterone was neuroprotective in wild-type mice 
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Table 5.3: Excluded studies and reasons for exclusion after meeting 
inclusion criteria  
Study Reason for Exclusion  
Jiang 2009 (Jiang et al., 2009) 
Oedema but no total lesion volume 
data 
Cai 2008 (Cai et al., 2008) 
 
Number of surviving cells but no total 
lesion volume data 
Zhang 2010 (Zhang et al., 
2010) 
 
Number of surviving cells but no total 
lesion volume data 
Morali 2005 (Morali et al., 
2005) 
 
Number of surviving cells but no total 
lesion volume data 
Alkayed 2000 (Alkayed et al., 
2000) 
 
Blood volume but  no total lesion 
volume data 
 
Dang 2011 (Dang et al., 2011) No total lesion volume data 
 
Ischaemic stroke induced in animals and progesterone administered. 
 
 
 
Figure 5.2: %HJJ¶VIXQQHOSORWIRUVWXGLHVRISURJHVWHURQHRQOHVLRQ
volume when combining individual animal and summary data. 
 
The funnel plot relates precision (reciprocal of standard error, SE) to the 
standardised mean difference (SMD). Asymmetry is present indicating 
SXEOLFDWLRQELDV(JJHU¶VWHVW(Egger et al., 1997) P=0.001). 
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5.3.3 Quantitative data synthesis 
 
5.3.3.1 Lesion volume ± combined individual and summary data 
Due to the lack of data on individual animals that died following the start of 
treatment in summary data (where IAD were not shared), it was not 
possible to account for death in combined IAD and summary data analysis 
(18 studies, 512 animals).  
 
In an unadjusted analysis, progesterone reduced standardised lesion 
volume (SMD -0.766, 95% CI -1.173 to -0.358, P<0.001) (table 5.4, 
figure 5.3). In pre-defined subgroups of animals, significant reductions in 
lesion volume were seen with progesterone in mice, rats, male animals, 
male mice, male rats, and in both transient and permanent models of 
ischaemia. When assessed by pre-defined study design and quality 
markers, progesterone reduced lesion volume in studies that were 
randomised, had or did not have blinded surgery, had or did not have 
blinded outcome assessment, used isoflurane as the anaesthetic agent, 
and those that were of high quality (STAIR scale = 7) (table 5.4). Some 
sub-group analyses were of low statistical power because of limited data, 
e.g. sodium thiopenthal as the anaesthetic agent (1 study, 11 animals). 
Heterogeneity was present for some analyses confirming the need for the 
use of a random effects statistical model. 
 
When assessing the effect of interactions between treatment and 
subgroups, progesterone had greater effects on reducing lesion volume in 
males than young females (figure 5.3), and when the anaesthetic was 
isoflurane rather than halothane (table 5.4). 
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Table 5.4: Effect of progesterone on standardised total lesion 
volume using combined individual animal and summary data, both 
combined and in pre-defined subgroups. 
Model Studies Animals SMD 95% CI Effect P Inter-
action P 
Total 17 448 -0.766 -1.173, -0.358   
Species       
   Mice 5 108 -0.492 -0.881, -0.102 0.013 0.44 
   Rats 12 340 -0.958 -1.539, -0.376   
Sex       
   Male 10 227 -1.316 -1.902, -0.730   
   Female, adult 3 130 0.113 -0.437, 0.662 0.688  
   )HPDOHDJHGÁ 4 91 -0.333 -0.754, 0.088 0.121  
Mice       
   Male 2 44 -0.697 -1.308, -0.086 0.025  
   Female, adult       
   )HPDOHDJHGÁ       
Rats       
   Male 8 183 -1.547 -2.303, -0.792   
   Female, adult       
   )HPDOHDJHGÁ       
Model       
   Transient 14 393 -0.549 -0.928, -0.171  0.075 
   Permanent 3 55 -2.058 -3.850, -0.266   
Treatment time       
   Before MCAO       
   After MCAO       
Loading dose       
Maintenance dose *      
Total dose *      
Randomised       
   Yes 14 393 -0.674 -1.088, -0.260   
   No 3 55 -1.348 -3.046, 0.350 0.120   
Blinded surgery       
    Yes 5 132 -0.589 -0.946, -0.233 0.001  
    No 12 316 -0.934 -1.537, -0.332   
Blinded outcome       
    Yes 6 147 -0.725 -1.134, -0.316 0.001  
    No 11 301 -0.813 -1.413, -0.213   
Anaesthetic       
    Isoflurane 8 144 -1.512 -2.324, -0.701   
    Halothane 8 293 -0.323 -0.700, 0.054 0.093   
    Sodium 
Thiopental 
1 11 -0.173 -1.363, 1.016 0.775  
Quality       
2 1 11 -0.173 -1.363, 1.016 0.775  
3 3 56 -1.224 -2.843, 0.395 0.138  
4 3 53 -1.828 -3.824, 0.168 0.073  
5 7 233 -0.534 -1.120, 0.052 0.074  
7 3 95 -0.636 -1.061, 0.211 0.003  
+HWHURJHQHLW\SUHVHQWEHWZHHQVWXGLHV 
ÁRURYDULHFWRPLVHG 
 
Data are standardised mean differences (SMD), 95% confidence intervals 
(95% CI) and significance for effect and interaction. Analyses are adjusted 
for random effects. Result in bold are statistically significant. 
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Figure 5.3: Forrest plot of effect of progesterone on lesion volume 
using individual animal and summary data 
 
 
 
Studies are ordeUHG E\ DQLPDOV¶ VH[ PDOH DJHG females; or adult 
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5.3.3.2 Adjustments for analyses involving individual animal data 
Using individual animal data alone, backwards elimination of covariates 
revealed that maintenance dose alone led to a minimum in AIC for 
analyses of lesion volume. For death, AIC was minimised with the 
combination of sex, time to treatment, loading dose, total dose and 
anaesthetic agent as covariates. Subsequent adjusted analyses were made 
using these covariates. 
 
 
5.3.3.3 Lesion volume ± individual animal data, death included 
Clinical trials include patients who die following treatment in their outcome 
analyses; hence, lesion volume was imputed for animals that died following 
treatment. In 12 studies (337 animals), treatment with progesterone did 
not show any benefit on standardised lesion size, whether in an adjusted 
analysis (SMD -0.322, 95% CI -0.779 to +0.135, P=0.16) or unadjusted 
analysis (SMD -0.208, 95% CI -0.542 to 0.125, P=0.20) (table 5.5). In 
view of the neutral result, subgroup analyses were not performed. The 
unpublished studies Wong et al 2012 and Murphy et al 2002 did not 
contain lesion volumes and were not included in analysis. 
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Table 5.5: Effect of progesterone on standardised total lesion 
volume, including animals that died, using individual animal data 
overall and in pre-defined subgroups. 
 
Model SMD 95% CI Effect P Interaction 
P 
Overall, adjusted -0.322 -0.779, 0.135 0.16 N/A 
Species, mice vs. rats -0.033 -0.679, 0.613 0.91 N/A 
Age, Aged vs. young -0.071 -0.637, 0.495 0.80 N/A 
Sex, adult female vs. male 
vs. aged 
0.167 -0.508, 0.842 0.86 N/A 
Model -0.138 -0.705, 0.678 0.97 N/A 
Time to treatment (per hour) -0.001 -0.005, 0.004 0.72 N/A 
Loading dose (per mg/kg) -0.002 -0.020, 0.016 0.83 N/A 
Total dose (per mg/kg) 0.003 -0.002, 0.001 0.18 N/A 
Anaesthetic, halothane vs. 
isoflurane 
-0.034 -0.789, 0.721 0.93 
N/A 
N/A: Not appropriate; N/D: Not done - no deaths in a comparator group 
 
Animals that died were assigned a lesion volume of 100%, 1000*mm3 for 
rats or 225mm3 for mice. Data are standardised mean differences (SMD), 
95% confidence intervals (95% CI) and significance for effect and 
interaction. Analyses are adjusted for random effects and species, age, 
sex, model, time to treatment, loading dose, total dose and anaesthetic 
agent. Result in bold are statistically significant. 
 
 
5.3.3.4 Lesion volume ± individual animal data, death excluded 
Using individual animal data alone and ignoring animals that died (12 
studies, 309 animals), progesterone reduced standardised lesion volume in 
both adjusted (SMD -0.349, 95% CI -0.672 to -0.025, P=0.035) and 
unadjusted (SMD -0.451, 95% CI -0.735 to -0.166, P=0.0035) analyses 
(table 5.6). Progesterone reduced standardised lesion volume in pre-
defined subgroups: males, male rats, animals anaesthetised with 
isoflurane, and when outcome was measured blinded to outcome. The 
unpublished studies Wong et al 2012 and Murphy et al 2002 did not 
contain lesion volumes and were not included in analysis. 
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Table 5.6: Effect of progesterone on standardised total lesion 
volume, excluding animals that died, using individual animal data 
overall and in pre-defined subgroups. 
 
 
Data are standardised mean differences, 95% confidence intervals and 
significance for effect and interaction. Analyses are adjusted for random 
effects and maintenance dose of progesterone. Result in bold are 
statistically significant. 
 
 
5.3.3.5 Death 
Using individual animal data alone (14 studies, 503 animals, 58 deaths), 
progesterone was associated with an increase in death, significantly so in 
an adjusted analysis (odds ratio 2.64, 95% CI 1.17 to 5.97, P=0.020), and 
with a trend in an unadjusted analysis (OR 1.81, 95% CI 0.70 to 4.66, 
p=0.22) (table 5.7, figure 5.4). When assessed in predefined subgroups, 
the increase in death rate was most prominent in mice, older animals, 
young ovariectomised females (versus males or old 
females/ovariectomised young females), and with later administration of 
Model SMD 95% CI Effect 
P 
Interaction 
P 
Overall, adjusted -
0.585 
-0.954, -
0.215 
0.004 N/A 
Species, mice vs. rats -0.031 -0.540, 
0.478 
0.90 N/A 
Age, Aged vs. young -0.037 -0.616, 
0.541 
0.90 N/A 
Sex, adult female vs. male vs. 
Aged females 
0.130 -0.445, 
0.706 
0.87 N/A 
Model, permanent vs. transient 0.004 -0.535, 
0.543 
0.99 N/A 
Time to treatment (per hour) -0.001 -0.005, 
0.003 
0.58 N/A 
Loading dose (per mg/kg) 0.011 -0.006, 
0.028 
0.20 N/A 
Total dose (per mg/kg) -0.001 -0.005, 
0.004 
0.80 N/A 
Anaesthetic (halothane vs. 
isoflurane) 
-0.000 
-0.589, 
0.588 
1.00 
0.80 
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drug. A significant interaction was present between treatment and species 
(table 5.7).  
 
Table 5.7: Effect of progesterone on death using individual animal 
*and summary* data overall and in pre-defined subgroups. 
Model SMD 95% CI Effect 
P 
Interaction 
P 
Overall, adjusted 2.64 1.17-5.97 0.020 N/A 
 
Species, mice vs. rats 
 
10.35 
 
2.14-49.93 
 
0.004 
 
0.028 
 
Age, Aged vs. young 
 
11.70 
 
1.70-80.20 
 
0.012 
 
0.76 
 
Sex, adult female vs. male vs. 
aged females 
 
11.68 
 
1.79-76.34 
 
0.028 
 
N/D 
 
Model, transient vs. permanent 
 
- 
 
- 
 
NC 
 
N/D 
 
Time to treatment (per hour) 
 
1.01 
 
1.00-1.01 
 
0.025 
 
N/A 
 
Loading dose (per mg/kg) 
 
0.89 
 
0.69-1.15 
 
0.36 
 
N/A 
 
Total dose (load + maintenance, 
per mg/g) 
 
1.03 
 
0.99-1.06 
 
0.16 
 
N/A 
 
Anaesthetic, halothane vs. 
isoflurane 
1.11 0.25-4.97 0.89 
 
N/A 
N/A: Not appropriate; N/D: Not done - no deaths in a comparator group 
 
 
Data are odds ratios, 95% confidence intervals, and significance for effect 
and interaction. Analyses are adjusted for random effects and species, age, 
sex, model, time to treatment, loading dose, total dose and anaesthetic 
agent. Subgroup analyses of sex consisted of young ovariectomised 
females versus males, or aged females, or aged females versus males. 
Young ovariectomised females were found to have significantly more 
deaths and these results were presented. Result in bold are statistically 
significant. 
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Figure 5.4: Forrest plot of effect of progesterone on death using 
individual animal and summary data.  
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5.3.3.6 Progesterone blood concentration 
The relationship between progesterone loading dose (mg/kg) and blood 
concentration (ng/ml) was assessed in four studies on rats (Murphy et al 
2000, 2002, Parker et al 2005 and Murphy 2002 unpublished (Murphy et 
al., 2002; Murphy et al., 2000; Parker S.M, 2005)) and one in mice (Wong 
et al 2012 (Wong et al., 2012)). Some studies did not involve stroke 
models (Murphy 2002 unpublished and Wong et al 2012 (Wong et al., 
2012)). Blood progesterone concentration was measured 1 hour from the 
start of treatment. A linear concentration-dose relationship was seen 
(P=<0.0001, figure 5.5) with: 
[Progesterone] = 1.304 + 4.156 x progesterone loading dose 
 
Figure 5.5: Relationship between blood concentration and loading 
dose of progesterone.   
 
 
Progesterone blood concentration was measured at 1 hour from the start 
of treatment. Equation of best fit [Progesterone] in blood (ng/ml) = 4.156 
x progesterone loading dose (mg/kg) + 1.304.  
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5.4 DISCUSSION  
 
In our earlier systematic review and meta-analysis, based on published 
summary data, progesterone was associated, in a dose-dependent 
manner, with reduced lesion volume following experimental brain injury 
(Gibson et al., 2008b). However, meta-analysis based on summary data 
does not allow subgroup analyses to be performed, unlike a meta-analysis 
based on IAD which does. Therefore, it was not possible to assess the 
effect of treatment on death or in sub-groups of animals or experimental 
designs. In the present systematic review and meta-analysis, data for 
individual animals, including those that died, was assessed from both 
published and unpublished studies focusing on progesterone in surgically-
induced stroke. Such meta-analyses are considered to be the gold 
standard for assessment of intervention effects (Stewart and Parmar, 
1993). The main findings were that progesterone reduced lesion volume 
but increased the incidence of stroke-related death. In a pharmacokinetic 
sub-study, progesterone concentration in the blood was proportional to 
loading dose (figure 5.5). 
 
Progesterone was found to reduce lesion volume in analyses based on both 
combined IAD and summary data (which excluded animals that died post-
treatment), or using IAD alone where animals that died were excluded. 
Although analyses based on summary data or IAD varied somewhat (fewer 
significant effects in the IAD analysis compared to summary data, most 
likely due to summary data having more statistical power from having a 
greater number of animals), lesion volume was reduced regardless of 
rodent species (mice and rats) or model of occlusion (transient and 
permanent) yet only in males. However, when animals that died were 
included in the analysis of lesion volume (amounting to analysis of the 
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composite outcome of lesion volume or death), progesterone exerted no 
beneficial effect. The explanation is that progesterone increased the 
incidence of death, particularly in mice versus rats, older animals versus 
younger, young ovariectomised females versus males or older females, 
and when administered late in the protocol.  
 
Several drug-subgroup interactions bear further comment. The 
administration of exogenous progesterone appeared to be detrimental in 
young ovariectomised females as compared to males (as seen previously 
(Gibson et al., 2008b)) and older females, indicating other factors 
involved, other than endogenous levels of progesterone. This finding has 
been observed previously in individual studies; e.g. Gibson & Murphy 
(2004), who found progesterone to aid survival after ischaemia in young 
male mice (Gibson and Murphy, 2004), although others found no effect 
(Alkayed et al., 2000; Coomber and Gibson, 2010; Gibson et al., 2011). 
Other studies have either not investigated survival or the reported 
numbers of deaths are small, thereby preventing detailed analysis. 
Importantly, only death post-treatment should be included, and earlier 
culling, e.g. due to inadequate occlusion (as determined using laser 
Doppler), does not amount to attrition bias. Equally, animals that have to 
be killed humanely after treatment because they are in poor condition, e.g. 
they exhibit barrel-rolling, must be included in the numbers that died. The 
application of humane endpoints to inform decisions regarding termination 
of animals will vary between institutions and so it is important to include 
these animals in this type of analysis. A large proportion of studies had 
more deaths from progesterone treatment versus control (figure 5.4), and 
even when adjusted for sex progesterone is still associated with increased 
death (table 5.7), indicating other factors independent of sex could be 
involved.    
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The finding that progesterone appears to reduce lesion size but increase 
death is important since most pre-clinical studies only report the former. 
This may not be surprising since such studies are usually small and, 
therefore, do not have sufficient statistical power to individually assess 
death. However, the issue of low numbers of deaths also applies to clinical 
trials, and they typically report both death alone, and the combination of 
death and poor non-fatal outcome (lesion size in this study). The problem 
LVWKDWSXEOLVKHGVWXGLHVGRQ¶WUHSRUWGHDWKDQGWKDWDFWXDOO\WKLVHIIHFWRQ
death has been revealed though analysis of IAD by contacting authors. 
Several potential neuroprotectants have been reported to be protective in 
pre-clinical studies but hazardous in clinical trials, these including DCLHb, 
enlimomab, selfotel and tirilazad (2000; Davis et al., 2000; Furuya et al., 
2001; Saxena et al., 1999). It is interesting to speculate on whether these 
agents increased death in pre-clinical studies, and whether clinical trials 
would have proceeded if IAD meta-analyses had been performed 
beforehand. Pre-clinical studies and analysis should strive to reflect the 
design of clinical trials to screen out ineffective and even deleterious 
interventions before reaching human testing. Nevertheless, IAD meta-
analyses of pre-clinical studies may not successfully predict the results of 
clinical trials. In the only other IAD meta-analysis performed to date, NXY-
059 was found to reduce stroke lesion volume but it failed to be effective 
in clinical trial (Bath et al., 2009; Diener et al., 2008; Shuaib et al., 
2007a). Our results, and previous experience in experimental stroke and 
clinical trials, suggest that it is essential that pre-clinical studies are 
analysed rigorously, including performing IAD meta-analysis, before clinical 
trials are initiated. 
 
Several caveats concerning the present study need to be considered; some 
reflecting issues with the meta-analysis itself and others concerned with 
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the relative paucity of experimental data relating to progesterone. First, 
there was evidence of significant publication bias on the basis of the effects 
of progesterone on lesion volume when assessed using summary data 
DVVHVVHG ERWK YLVXDOO\ ILJXUH  DQG XVLQJ (JJHU¶V WHVW (Egger and 
Davey Smith, 1998). Missing studies may well have been neutral, or even 
negative, raising the possibility that progesterone does not, in fact, have 
neuroprotective effects in cerebral ischaemia.  
 
Second, although 18 studies (19 datasets) were identified as being 
potentially relevant, IAD were only obtained from 12 of these. Data from 6 
trials could not be obtained in spite of repeated requests to the authors. In 
the absence of any response from the authors it is difficult to gauge 
whether these studies were unusual in any respect. However, only one of 
these studies had extremely positive data for lesion volume (figure 5.2) so 
it is unlikely that the overall results for lesion volume would have changed 
significantly if IAD had been available for all studies.  
 
Third, data were only available for rodents (mice and rats), so effects in 
SULPDWHVRUDQ\RWKHU³VHFRQGVSHFLHV´FRXOGQRWEHDVVHVVHGLQFRQWUDVW
to NXY-059 for which marmosets were also studied (Bath et al., 2009). 
Differences in stroke outcomes and the effect of potential neuroprotectants 
on them, between agyric and gyric brains have been well discussed 
previously. Rodents have agyric brains and so possess a higher proportion 
of white matter compared to grey and so do not represent cortical ratios 
found in humans (Mehra et al., 2012). The STAIR recommendations 
suggests a sequential hierarchy of drug and device testing from small 
animal models to large animals stroke models prior to initiating enrolment 
for clinical trials (Stroke Therapy Academic Industry Roundtable (STAIR), 
1999).    Fourth, most data involved young male animals (n=11) and few 
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related to aged males, or females. Further experiments in older animals 
are required before the translational potential of progesterone treatment 
can be predicted. Nevertheless, the data suggest that progesterone may 
be hazardous in young females.  
 
Fifth, few animals had any co-morbidities such as hypertension or 
diabetes, as are commonly present in human stroke victims (Ankolekar et 
al., 2012). The presence of co-morbidities, such as hypertension, might 
attenuate neuroprotective effects, as seen with NXY-059 (Bath et al., 
2009).  
 
Sixth, lesion volume data were only available for total lesion size and not 
for cortical or subcortical damage. Many putative neuroprotectants appear 
to exert most of their effect on cortical stroke (Bailey et al., 2009b), which 
is a potential disadvantage, since many human strokes only involve small 
subcortical (lacunar) lesions.  
 
Seventh, studies should assess functional measures as well as lesion 
volume and few of the included studies provided such data. This contrasts 
with our previous IAD meta-analysis of NXY-059 in which data were also 
available on motor function(Bath et al., 2009). Ideally functional measures 
should include death, as does the modified Rankin Scale, the preferred 
outcome in acute stroke trials (Lees et al., 2012; in press ).  
 
Eighth, although both transient and permanent models of stroke were 
represented, all experimental protocols involved stroke induction with a 
monofilament. In general, it is better if experiments utilise a number of 
different systems for inducing ischaemia. Each different system will have 
their strengths and weaknesses e.g. cerebral vessel occlusion with a 
209 
 
monofilament is highly reproducible and is reversible but do not accurately 
replicate the hemodynamic features of thrombolytic reperfusion (Mehra et 
al., 2012). 
 
Ninth, although a wide range of time between stroke induction to initiation 
of treatment (ranging from 7-10 days before MCAO to 2 hrs afterwards), 
only post-stroke treatment is relevant to human stroke, so that many of 
the experiments do not really contribute data relevant to the decision on 
whether it is appropriate to take this treatment into man.  
 
Tenth, it has been suggested that anaesthetics without their own 
neuroprotective activity should be used to avoid confounding the effects of 
the potential neuroprotectant under examination with those of the 
anaesthetic agent. However, isoflurane, an aesthetic with well described 
neuroprotective potential (Sanders et al., 2005) was used in most 
experiments, and was associated with a lower lesion volume that in 
experiments using halothane. However, halothane use is in decline due to 
its potential hepatotoxic effects and the increased availability of other 
inhalational agents with fewer systemic side effects.(Kitano et al., 2007) 
 
Finally, the studies were of varying quality with respect to randomisation 
and blinding of surgery and outcome assessment, so that selection, 
performance and observer bias may have been present. However, where 
adjusted, analysis of lesion volume appeared to be related to high rather 
than low study quality, as found in our earlier summary-based meta-
analysis of progesterone (Gibson et al., 2008b). This contrasts with the 
common finding in meta-analyses of pre-clinical studies  of neuroprotection 
being reported in low quality studies (Crossley et al., 2008). Other quality 
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markers were missing in many of the included studies, including presence 
of a sample size calculation. 
 
In conclusion, whilst progesterone might reduce ischaemic lesion volume, 
it also appears to increase the incidence of stroke-related death.  Its 
negative effects appear to be particularly evident in young ovariectomised 
female animals, highlighting the fact that endogenous hormone 
background needs to be taken into account in experimental stroke studies. 
These findings suggest that clinical trials, for any potential 
neuroprotectant, should not be commenced until an IAD-based meta-
analysis of pre-clinical data has been performed. Publications and meta-
analysis should include death, and combined death and lesion volume as 
outcomes, since interventions may have both positive and negative effects. 
To enable such analysis, authors of pre-clinical studies should be 
encouraged to share their data with IAD pooling projects as is common 
practice in clinical medicine. 
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CHAPTER 6 
General Discussion 
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6.1 GENERAL DISCUSSION 
There are still gaps in our understanding of the neuropotective properties 
of progesterone and the purpose of this project was to clarify some of 
these issues. The aims of the studies reported herein were to investigate; 
the pharmacokinetics of progesterone, the efficacy of progesterone 
administration via osmotic mini-pump in conferring neuroprotection after 
the onset of experimental stroke and the influence of co-morbidities on the 
effectiveness of neuroprotection from progesterone.  In addition to 
investigating in vivo aspects, progesterone actions was explored in vitro by 
studying the effects of progesterone on NO production and microglia 
viability, as well as the viability of SHSY5Y neuroblastoma cells, subjected 
to simple models of OGD that are associated with ischaemia. Finally, to 
better understand the overall neruoprotective effectiveness of 
progesterone, by means of a systematic review and meta-analysis, based 
on IAD of pre-clinical studies of progesterone in experimental models of 
stroke.   
Previous studies demonstrating the neuroprotective properties of 
progesterone, following experimental stroke in animals, have used a 
dosing regimen of 8mg/kg progesterone injected intraperitoneally (Gibson 
et al., 2005b; Gibson et al., 2011; Gibson and Murphy, 2004; Ishrat et al., 
2009; Kumon et al., 2000; Sayeed et al., 2009; Sayeed et al., 2007). 
However, the progesterone pharmacokinetic profile in both plasma and 
brain, following intraperitoneal administration was not established. 
Progesterone delivered via a single i.p. injection had a very short half-life 
in both plasma and brain. Despite delivering only transient peaks of the 
steroid in the brain, this dosing method was successful in providing 
neuroprotection to young male mice (Gibson and Murphy, 2004). 
Progesterone treatment seems to be most effective 0-2hrs following 
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cerebral ischaemia (Gibson et al., 2007), although no studies in pre-clinical 
stroke have administered progesterone after this period. Therefore, an 
early, high transient peak of progesterone may be enough to initiate 
neuroprotection. Although, the ideal profile would be to maintain 
progesterone concentration at as high as possible, due to the lack of 
toxicity from the steroid (Gaver et al., 1985; Little et al., 1974) and 
continuous drug administration has the advantage of avoiding the 
associated oscillating drug concentrations, produced by intermittent bolus 
administration. Continuous progesterone administration has been shown to 
produce enhanced benefit in traumatic brain injury (TBI) as compared to 
repeated injections in a rat model (Cutler et al., 2006a). This may also be 
the case with progesterone in stroke and a continuous dosing method 
would allow tapering off progesterone to be more easily achieved. 
Infusion methods are commonly used to maintain drug concentrations 
within the therapeutic range. Delivering progesterone via osmotic mini-
pumps has not been employed prior to this study and so information about 
the release characteristics was investigated. It was hypothesise that 
osmotic mini-pump infusion could be more effective in delivering 
progesterone to the target organ of the brain, when compared to a bolus 
intraperitoneal injection. Osmotic mini-pump delivery (in conjuction with a 
bolus i.p loading dose) was found to be an effective way of delivering high, 
maintained concentrations of progesterone to the target areas of the brain 
(higher than the peak of pregnancy), which supports our hypothesis. Also, 
progesterone appears to distribute itself equally in areas of predominant 
white and gray matter, which is encouraging as the lack of white matter 
protection may be a contributing factor in the failure of experimental 
neuroprotective strategies (Cheng et al., 2004; Ho et al., 2005). However, 
caution is needed when extrapolating results from rodent models to 
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humans as the amount of white matter in rodents is far smaller in 
comparison (Green, 2003). Also, it was hypothesised that animals 
receiving progesterone, via osmotic mini-pump infusion, will have a better 
outcome compared to vehicle treatment. Osmotic mini-pump delivery (in 
conjuction with a bolus i.p loading dose) of progesterone following the 
onset of transient MCAO was found to be beneficial in terms of promoting 
functional recovery in the current investigation, supporting the hypothesis.  
7KHSKDUPDFRNLQHWLFVRISURJHVWHURQHVKRZLQJWKHVWHURLG¶VDELOLW\WRHQWHU
the brain quickly and to be maintained in high concentrations are desirable 
traits for a clinical neuroprotectant. The time immediately after the onset 
of stroke is the most crucial in terms of neuroprotectant efficacy (Ginsberg, 
2008). As well as factoring in the amount of time taken for a 
neuroprotectant to enter the brain after it has been administered, the 
timing of administration also needs to be considered. The ASSIST study 
showed that, in the UK, only around 37% of patients with suspected stroke 
reached hospital within 3hrs from the onset of symptoms and only 50% 
within 6hrs of the onset of symptoms (Harraf et al., 2002). Therefore, 
experimental studies must consider the efficacy of neuroprotectants 
beyond a few hours after stroke onset. In the meta-analysis presented in 
Chapter 5, the longest delay from the initiation of experimental stroke to 
treatment in the studies identified was 2 hrs in rats and 1hr in mice. This 
was also found for the systematic review of progesterone for the treatment 
of experimental brain injury (Gibson et al., 2008a). Further investigation is 
required to explore the effectiveness of progesterone beyond 2hrs after 
onset of experimental stroke. Also, future clinical trials may wish to 
consider treatment by paramedics in the ambulance in order to administer 
potential neuroprotectants such as progesterone more quickly.  Pilot 
clinical trials for the administration of drugs for stroke therapy by 
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paramedics are feasible and have been conducted in the past (Saver et al., 
2004; Shaw et al., 2011). Already, clinical trials investigating the 
neuroprotective properties of progesterone following TBI have shown the 
hormone to be beneficial and safe (Wright et al., 2007; Xiao et al., 2008). 
In these trials, steady-state serum concentrations of progesterone were 
achieved, following continuous intravenous infusion in patients with acute 
moderate to severe TBI injury (Wright et al., 2005). Progesterone efficacy 
in stroke therapy is feasible due to the similar pathological mechanisms 
involved in both TBI and stroke.   
There is considerable evidence to suggest that microglial activation 
precedes and predominates over macrophage infiltration into the brain 
after cerebral ischaemia (Jin et al., 2010). Active microglia, are particularly 
detrimental for the injured brain and contribute to infarct volume (Schilling 
et al., 2003; Schilling et al., 2005). The iNOS gene is transcriptionally 
activated in active microglia, resulting in the production of NO and 
substantial evidence supports the involvement of NO in ischaemic brain 
injury (Moro et al., 2004). Progesterone has been shown to suppress the 
inflammatory response and iNOS expression following cerebral ischaemia 
in vivo (Gibson et al., 2005b). Therefore, we hypothesised progesterone to 
attenuate NO production in microglia. Also, glutamate overload is a key 
neurotoxic effect that is thought to occur following brain injury, including 
acute ischaemic stroke. The molecular mechanisms of glutamate-induced 
excitotoxicity have been investigated with in vitro neuronal models, and 
progesterone has been shown to protect against excitotoxicity in 
dissociated cell cultures (Luoma et al., 2011; Mannella et al., 2009; Nilsen 
and Brinton, 2003; Ogata et al., 1993). Ischaemia models have been used 
to reduce viability in neuronal cultures and progesterone was shown to 
provide protection in a concentration-dependent manner via GABAA 
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receptor activation, thereby reducing excitotoxicity in purkinje neurons 
(Ardeshiri et al., 2006). These studies have lead to our hypothesis that 
progesterone will reduce cell death. 
Neither of the microglial cell lines, BV-2 and HAPI cells used in the present 
studies produced elevations in NO formation under ischaemic conditions. 
Production of NO from primary microglia and microglial cell lines (including 
BV-2) in hypoxic conditions without any pre-activation has been 
demonstrated in other studies (Lu et al., 2006; Son et al., 2009). Microglia 
may require activation conditions, such as exposure to LPS or cytokines 
including TNF-Į DQG ,)1Ǆ LQ RUGHU WR SURGXFH 12 &RQYHQWLRQDOO\ LW KDV
been thought that, microglia cells are activated by signals originating from 
dying neurons (Gehrmann et al., 1995; Gonzalez-Scarano and Baltuch, 
1999), and further experiments are required, in order to determine the 
effects of pre-activation with cytokines TNF-Į DQG ,)1Ǆ $73 HWF LQ
ischaemic conditions. Also, co-cultures with neurones could clarify the 
interactions involved between microglia and neurones challenged with 
ischaemia.  
The in vitro model of ischaemia, OGD, reduced viability of both microglial 
and neuronal cells and progesterone increased cell death, compared to 
non-treated cells in these conditions, which conflicts against our 
hypothesis. This was unexpected, as in vivo studies have found 
progesterone to be neuroprotective (Gibson et al., 2005b; Gibson and 
Murphy, 2004) However, Murphy et al (2000) did find daily administration 
of progesterone for a week prior to ischaemia exacerbated brain injury in 
overectomised rats. The authors speculated that the detrimental effects 
was due to modulation of the GABA system by a sharp decline of 
progesterone after the pre-stroke treatment (Murphy et al., 2000). This is 
unlikely to be the case in this investigation, as cells were continuously 
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treated throughout OGD and re-oxygenation. Necrosis from ischaemia is 
characterised by cellular metabolism failure and loss of membrane integrity 
(Padosch et al., 2001). Progesterone could possibly aggravate this further, 
as steroid hormones, particular progesterone, can readily insert into 
bilayers and perturb plasma membrane functions (Snart and Wilson, 
1967), resulting in increased cell death.  
A possibility for why neuroprotection was not observed, in the presence of 
progesterone in the present study may be due to the cell types employed. 
Coughlan et al found progesterone to protect PC12 neurons deprived of 
trophic support but not cerebellar granule neurons (Coughlan et al., 2009). 
It is possible that cells from different brain regions or different cell lines 
may require a combination of sex steroids present, in order to benefit from 
neuroprotection. Some neurones have been observed to respond in a 
sexually dimorphic manner, while other neurones in different brain regions 
do not. Other studies found cellular stress responses, leading to cell death 
to be gender-dependent, (Du et al., 2004; Lieb et al., 1995), while others 
found no such responses to ischaemic insult in other cell lines (Ardeshiri et 
al., 2006). Cellular responses to ischaemia can vary due to gender and so 
responses to therapy could be affected in a similar manner. 
3URJHVWHURQH¶V DELOLW\ WR UHGXFH 12 KDV EHHQ GHPRQVWUDWHG in vitro 
previously in microglia. Also, the present investigation identified, that PR 
GLGQRWKDYHDPDMRUUROHLQSURJHVWHURQH¶VDWWHQXDWLRQRI12SURGXFWLRQLQ
a microglial cell line. Although, the involvement of PR in the mechanism of 
neuroprotection by progesterone has been identified in an  in vivo study of 
PR knock-out mice (Liu et al., 2012). However, further investigation is 
required on primary cells and in vivo to determine the importance of 
progesterone, PR and NO formation by microglia in stroke.    
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Previous studies have utilised LPS to investigate the inflammatory 
response of microglia without the use of hypoxia (Horvath et al., 2008; 
Jiang et al., 2011). Therefore, LPS was used to stimulate NO production in 
order to investigate the effects of progesterone. Progesterone reduced NO 
production after challenging microglia with LPS and supports our 
hypothesis. However, blocking the PR receptor did not inhibit the 
attenuating effect of progesterone on NO production, indicating other 
mechanisms not involving the PR mediated pathway. In a previous  study  
Drew et al (2000), also found progesterone to attenuate LPS-stimulated 
NO production (Drew and Chavis, 2000), although, unlike in the present 
study, the authors did not investigate the use of a PR receptor antagonist 
to investigate the mechanism of the effect. Oestrogen-mediated 
attenuation of microglial NO production has also been demonstrated. A 
possible non-PR mediated mechanism for NO reduction from progesterone 
is iNOS inhibition through binding to the glucocorticoid response element in 
murine macrophages (Miller et al., 1996). However, Kohmura et al (2000) 
found progesterone mainly uses a receptor other than the glucocorticoid 
receptor (Kohmura et al., 2000), but at a high enough concentrations, it is 
possibly for progesterone to use the glucocorticoid receptor (Werb et al., 
1978).       
OGD in vitro modelling is relatively simple to perform and has the 
advantage of allowing key mechanisms to be identified and studied, 
without counter regulations that are found in complex systems being 
present. Although, neuroprotectants are, of course, required to go through 
in vivo stages of testing, due to the complexities of biological systems.  
The sustained delivery of progesterone in young C57 Bl/6 mice, initiated 
following the onset of transient MCAO, was beneficial in terms of promoting 
functional recovery. In the present study, our outcomes have focused on 
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functional measures, as clinical trials of novel stroke therapies use 
functional measures as their primary end-point. In humans, the size of the 
lesion from stroke does not always correlate well with functional 
impairment (Pineiro et al., 2000). It is important for pre-clinical studies to 
have functional measures relevant to stroke outcomes in patients, as the 
major goal for the treatment of stroke is for patients to be functionally 
independent and, therefore, pre-clinical studies need to reflect the 
importance of functional outcomes. Restoration of behavioural function 
needs to be demonstrated in the pre-clinical evaluation of any putative 
stroke therapy. However, pre-clinical studies vary in terms of species, age, 
sex and doses, all of which might be contributing factors to variations in 
SURJHVWHURQH¶VDSSDUHQWHIILFDF\DVDQHXURSURWHFWDQW 
In the present investigation, functional outcomes have also taken into 
account animals that died, by giving them a higher score than the 
maximum in analysis. However, care must be taken when considering 
death as a factor in analysis, as the value of death can be arbitrary and a 
high-death rate can significantly influence the overall outcome. Although, 
giving animals that died, a higher score in analysis can be useful in 
determining whether the benefits of neuroprotection, outweigh the 
potential increase of deaths, due to adverse effects.   
In humans, age is a predictor of worse outcome following stroke. This 
investigation has also shown this to be true in aged animals. Aged animals 
were very susceptible to MCAO, even when occlusion time was greatly 
reduced and the aged mice did not display, in the outcomes measured 
here, any benefit from progesterone treatment. Animals used in the 
present study were in the age range of 15-16 months, which is a period 
considered to be the equivalent of human middle to old age. Middle age, in 
both mice and rats, is considered to be 10-15 months and old age is 
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considered to be 18-24 months. In the upper range of 14-15 months of 
middle age, most biomarkers may not have changed to their full extent 
and some have yet to start changing (Flurkey K, 2007). A limited number 
of studies have investigated neuroprotection of progesterone in this age 
range in rodents, but mostly in animals treated prior to occlusion. Toung et 
al found female rats, 14-18 months of age, did not benefit from pre-MCAO 
treatment with progesterone (Toung et al., 2004), while Alkayed et al 
using 16 month old female rats found progesterone to be beneficial when 
administered prior to MCAO (Alkayed et al., 2000). Studies have not been 
previously performed in aged mice that are as old as the ones investigated 
in the present study. Although, Gibson et al did use 12 months old female 
mice that were pre-treated with progesterone before occlusion and this 
was found to be protective (Gibson et al., 2011). Presently only one study 
has administered progesterone, post-onset of occlusion in old animals; in 
this, Wang et al found progesterone to improve outcomes in 24 month old 
male rats (Wang et al., 2010). Overall, studies of progesterone and 
experimental stroke involving aged animals are limited, particularly for the 
treatment of animals after the start of occlusion. The present study did not 
FRQVLGHUJHQGHUDVDIDFWRULQSURJHVWHURQH¶VHIILFDF\DQGLQWKHIXWure, it 
would be useful to address this, since post-menopausal females represent 
the population at highest risk of stroke (Appelros et al., 2009).  
On the basis of the present study, NOD/ShiLtJ mice would not be 
recommended, as a model of diabetes for experimental stroke research 
because of their severe symptoms, which we found to contribute to a high 
mortality rate after surgery. The surviving animals were monitored for the 
severity of diabetic symptoms and only a few animals were found to have 
high glucose in their urine and considered to be symptomatic of diabetes. 
High ketones in blood, an indicator of type-1 diabetes at the end of 
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monitoring, helped to confirm this. Monitoring of symptomatic mice found 
reduced weight compared to non-symptomatic mice, which was not 
surprising, as NOD mice are a model of spontaneous type one diabetes and 
is known to be susceptible to weight loss at the onset, similar to patients 
that develop the condition (Kikutani and Makino, 1992). Also, symptomatic 
NOD mice had increased thirst, which is characteristic for the onset of 
symptoms (Zhao et al., 2008). Although, this strain has characteristics of 
type-1 diabetes, the development of diabetes in these animals can be 
abrupt and age-dependent, and this can vary between animals. Therefore, 
constant monitoring is required and the number of animals that can 
undergo surgery at any one time is limited. Also, the excessive thirst found 
in this investigation for symptomatic mice makes them unlikely to survive 
post-surgery due to their demand for water intake.  
Studies have used other diabetic rodent strains to investigate experimental 
stroke, including type-1 (Toung et al., 2000) and type-2 diabetic strains 
(Tureyen et al., 2011; Vannucci et al., 2001). There are no studies utilising 
type-1 diabetic mice in experimental stroke but there are studies that 
employed type-1 diabetic rats (Ning et al., 2012; Toung et al., 2000; Yan 
et al., 2012). However, these studies involving type-1 diabetic rats do not 
report survival and so it is not possible to judge mortality rates. Studies 
that investigated type-2 diabetes and stroke utilise the C57BLKS db/db 
mouse strain, which has a mutation on the leptin recepter. This strain also 
develops obesity and hyperphagia (Chen et al., 1996), which is not 
associated with the NOD/ShiLtJ strain used in this current investigation. 
Tureyen et al found mortality to be 75% at 2 hrs of occlusion and 31% at 
45 minutes of occlusion in female C57BLKS mice (Tureyen et al., 2011), 
while Vannucci et al found mortality to be at 75% in male and 40% in 
female C57BLKS mice at 30 minutes of occlusion (Vannucci et al., 2001). 
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Although these studies show diabetic strains can have high cases of 
mortality, none have mentioned increased thirst as a contributing factor to 
mortality or measured water intake.       
BPH/2 mice are a potential hypertensive model and progesterone was 
neuroprotective when compared to non-treated hypertensive animals in 
our small and limited investigation. Overall, progesterone was found to be 
beneficial and this is consistent with the findings of Kumon et al, who 
found progesterone to be neuroprotective in spontaneous hypertensive rats 
(Kumon et al., 2000). Spontaneously hypertensive rats and the related 
stroke-prone hypertensive rats are the most widely used hypertensive 
animals in stroke research, a choice that has been criticised due to the 
DQLPDOV¶ OLPLWHG UHSUHVHQWDWLRQ RI SURFHVVHV LQYROYHG LQ KXPDQ
hypertension (Pinto et al., 1998). BPH/2 mice represent another possible 
model of hypertension, one that is rennin-independent, while spontaneous 
hypertensive rats are rennin-dependent and so BPH/2 provides a model of 
a different type of human hypertension. 
We hypothesised co-morbidity can affect the efficacy of progesterone 
treatment in outcomes. Our investigation using different co-morbid models 
supports this, as there was no apparent benefit found in aged animals, but 
hypertensive animals did benefit from progesterone treatment. However, 
care must be taken when interpreting results from these co-morbid 
animals due to high mortality in aged animals and low animal numbers of 
hypertensive animals in comparison groups. The use of co-morbid models 
is difficult, considering the welfare and survival of animals when conducting 
stroke research, as shown in this investigation. However, there is a real 
need to investigate efficacy of neuroprotectants in these animals due to 
the common co-morbidities present in patients (Ankolekar et al., 2012). 
The presence of co-morbidities, such as hypertension, might attenuate 
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neuroprotective effects, as seen with the putative neuroprotectant NXY-
059 (Bath et al., 2009). There has only been one study conducted 
previously involving hypertensive rats (Kumon et al., 2000), and none in 
diabetic animals involving progesterone and stroke prior to this 
investigation and so more studies involving such animals are needed.   
Meta-analysis of individual animal data found that, whilst progesterone 
might reduce ischaemic lesion volume, it also appears to increase the 
incidence of stroke-related death, particularly in young ovariectomised 
females.  ProJHVWHURQH¶VQHJDWLYHHIIHFWV in this sub-group, highlights the 
fact that endogenous hormone background needs to be taken into account 
in experimental stroke studies. This is partly supported by the findings in 
the in vitro OGD model of ischaemia, conducted in this investigation, in 
which progesterone reduced viability and increased cell death, in both 
microglial and neuronal cells compared to non-treated cells. 
The finding that progesterone appears to reduce lesion size but increases 
death is important since most pre-clinical studies only report the former. 
This may not be surprising since such studies are usually small and, 
therefore, do not have sufficient statistical power to individually assess 
death. However, the issue of low numbers of deaths also applies to clinical 
trials, and they typically report both death alone, and the combination of 
death and poor non-fatal outcome (lesion size in this study). The problem 
is that published preclinical studies do not routinely report death rates and 
that the effect of progesterone on survival has only now been revealed 
though analysis of IAD by contacting authors. Several potential 
neuroprotectants have been reported to be protective in pre-clinical studies 
but later proved to be hazardous in clinical trials; these include DCLHb, 
enlimomab, selfotel and tirilazad (2000; Davis et al., 2000; Furuya et al., 
2001; Saxena et al., 1999). It is interesting to speculate on whether these 
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agents increased death in pre-clinical studies, and whether clinical trials 
would have proceeded if IAD meta-analyses had been performed 
beforehand. Pre-clinical studies and analysis should strive to reflect the 
design of clinical trials to screen out ineffective and even deleterious 
interventions before reaching the stage of human testing. Nevertheless, 
IAD meta-analyses of pre-clinical studies may not successfully predict the 
results of clinical trials. In the only other IAD meta-analysis performed to 
date, NXY-059 was found to reduce stroke lesion volume but it failed to be 
effective in clinical trial (Bath et al., 2009; Diener et al., 2008; Shuaib et 
al., 2007a). It is essential that pre-clinical studies are analysed rigorously, 
including performing IAD meta-analysis, before clinical trials are initiated. 
Also, the size and design of pre-clinical studies need to better reflect the 
human situation, including the use of compromised animals.  
 
The majority of data in the meta-analysis involved young male animals and 
few related to aged males, or females. Further experiments in older 
animals are required before the translational potential of progesterone 
treatment can be predicted. Nevertheless, the data suggest that 
progesterone may be hazardous to young ovariectomised females. 
Although, as mentioned, there are very few studies involving female 
animals and the majority of these have been treated prior to stroke onset 
and only post-stroke treatment is relevant to human stroke, so that many 
of the experiments do not really contribute data relevant to the decision on 
whether it is appropriate to take this treatment into patients. More 
experimental studies involving female animals, which have been dosed 
after the initiation of stroke, preferably over different clinically relevant 
time windows, are needed.    
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The findings of this meta-analysis suggest that clinical trials, for any 
potential neuroprotectant, should not be commenced until an IAD-based 
meta-analysis of pre-clinical data has been performed. Meta-analysis 
should include death, and combined death and lesion volume as outcomes, 
since interventions may have both positive and negative effects. To enable 
such analysis, authors of pre-clinical studies should be encouraged to 
share their data with IAD pooling projects as is common practice in clinical 
medicine.  
A possible alternative to progesterone as a potential neuroprotectant for 
clinical trials is its metabolite allopregnanolone. The metabolite has been 
found to have greater neuroprotective properties than progesterone 
(Sayeed et al., 2006; Sayeed et al., 2009). It has advantages of not being 
associated with female reproduction and so male patients may be more 
accepting of it in clinical trials. Although, there have only been a handful of 
studies involving allopregnanolone and neuroprotection. This metabolite 
still requires further investigation in order to determine its efficacy and 
safety as a neuroprotectant.     
This investigation has clarified some issues and expanded our 
understanding on the neuroprotective properties of progesterone. 
However, these findings indicate further investigation is still required 
before progesterone can be considered for use in clinical trials as a 
neuroprotectant in stroke. The neuroprotective mechanisms of 
progesterone are still not fully understood and needs further exploration. 
In the meta-analysis of IAD, progesterone reduced lesion size but there 
was an increase of death in young ovariectomised female animals. 
However, there is a lack of studies involving female animals, particularly 
ones that treat animals after the onset of stroke. Therefore, more studies 
involving young female animals are needed to confirm, whether or not, 
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progesterone increases mortality in this subpopulation. Also, the meta-
analysis reveals a need to utilise more co-morbid animals in studies, as 
currently they under-represent the demographic of stroke patients with co-
morbidities. Pre-clinical studies need to be designed, so they are more 
clinically relevant, including consideration in terms of most effective dose, 
delivery method and window of opportunity available in the clinical setting.      
 
7. APPENDIX 
7.1 Pharmacokinetics Method development 
The progesterone enzyme-linked immunosorbant assay (ELISA) kit from 
Alphadiagnostic was first evaluated by measuring plasma with and without 
spike concentrations of progesterone. False positives were found and 
sample purification methods, such as serum albumin/IgG removal and 
ether extraction did not produce accurate results. Samples at this stage 
only received one round of ether extraction due to the inability to measure 
progesterone accurately to determine ether extraction efficiency. It was 
not until adopting the progesterone enzyme immunoassay kit from 
Cayman Chemicals, after it was determined to be accurate in plasma 
samples before the ether extraction protocol for brain homogenate could to 
be refined.  
 
7.1.1 Progesterone ELISA kit from Alphadiagnostic 
The ELISA kit from Alphadiagnostic (San Antonio, USA) was first evaluated 
to quantify progesterone levels in mouse serum. The principle of the assay 
involves the competition of progesterone in a sample or standard against 
horseradish peroxidase enzyme linked progesterone (progesterone-HRP 
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conjugate) for a limited number of binding sites on antibodies (anti-mouse 
IgG) bound on coated plates. In this solid phase system the antibody-
bound progesterone will be retained, while unbound progesterone will be 
removed after washing. The added tetramethyl benzidine substrate is 
mixed with the antibody bound progesterone-HRP conjugate, which results 
in the development of a colour reaction (Blue in this case). After a short 
incubation (30 minutes with this assay) the enzyme reaction is stopped, by 
adding a stopping solution (blue turning to yellow) and the intensity of the 
colour (yellow) is measured with a plate reader. The intensity of colour is 
inversely proportional to the concentration of progesterone in the sample 
or control, and was read using a plate reader at 450 nm (Dynex 
Technologies MRX II).                
However, it became evident that the kit was showing false positives in 
plasma controls without added progesterone. The method was reviewed, 
and no source of procedural error was found. Manufacture guide-lines 
stated that the assay has not been tested using animals, however it led on 
to state because progesterone is identical in all species, it can be adapted 
for animal use and that cross-linking with different protein complexes is 
unlikely. Yang Q et al 2006 (Yang et al., 2006) successfully used the 
progesterone assay in mouse serum without mentioning any additional 
purification steps. Due to irregularities in plasma controls (table 7.1.1), it 
became evident that a purification step would be required in order to 
remove any interference and so ether extraction was used. At this point in 
time, ether extraction was still in development and samples only 
undergone one round of extraction (see ether extraction development). 
There was a reduction in anomalous readings in ether-extracted plasma so 
that a reading was possible (table 7.1.2). However, a false positive was 
still present in plasma. It was possible that anti-mouse IgG were not only 
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binding to the enzyme-linked progesterone in the kit but also to mouse 
proteins thereby resulting in false positive readings. Ether extraction of 
plasma samples did not significantly remove all interference. The protocol 
was checked to see if the source of interference was due to contamination 
from equipment, reagents or poor experimental protocol. However, false 
positives were still present in controls.  The addition of 1M hydrochloric 
acid (HCL) was added to the samples prior to the addition of ether in the 
ether extraction protocol with the intention that any proteins would be 
denatured to prevent IgG antibody from binding them (final concentration 
of HCL, after being added to the sample was not determined). This step did 
not prove to be effective and results were still similar (table 7.1.3).   
 
Table 7.1.1: Plasma controls with Alphadiagnostic assay 
Progesterone (ng/ml) Reading 
Control 38.83  
4 38.06  
40 35.16  
Plasma controls and spiked plasma with different concentrations of 
progesterone measured with Alphadiagnostic progesterone assay. Readings 
are means of two independent assays. 
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Table 7.1.2: Plasma controls through ether extraction with 
Alphadiagnostic assay 
Progesterone (ng/ml) Reading 
Control 16.59 
4 20.26 
40 64.63 
Plasma controls and spiked plasma with different concentrations of 
progesterone measured with Alphadiagnostic progesterone assay after 
ether extraction. Readings are means of two independent assays. 
 
Table 7.1.3: Plasma with HCL and ether extraction 
Progesterone (ng/ml) Reading 
Control 18..69  
4 29.57  
40 54.43  
Plasma controls and spiked plasma with different concentrations of 
progesterone measured with Alphadiagnostic progesterone assay after HCL 
and ether extraction. Readings are means of two independent assays. 
 
7.1.2 Serum albumin/IgG removal 
Body fluids have a high abundance of serum albumin and 
immunoglobulins. Serum albumin and immunoglobulins (IgG being the 
most abundant) can constitute approximately 60-97% of the total serum 
protein (Ahmed N, 2003). As this is a high abundance of proteins, it is 
probably the main contributing factor to our false positive results. The 
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addition of HCL may not have helped as serum albumin is a constituent in 
serum, that helps in buffering pH and, therefore, it is possible that it could 
neutralise the HCL used but could not be verified at the time. Also, HCL 
may denature proteins into fragments thereby making them more 
susceptible to binding by antibodies. A ProteoExtract albumin/IgG removal 
kit from Calbiochem (Darmstadt, Germany) was used to evaluate the 
removal of plasma/serum albumin and IgG.  The kit consists of both 
albumin and IgG removal columns, which can be used either 
independently, or connected in a row with the IgG column downstream 
from the Albumin removal column. It is claimed that more than 80% of 
both albumin and IgG can be removed using the kit. The albumin removal 
column, despite being optimised for human serum, can be used for mouse 
plasma/serum and removes 72% of albumin in mouse samples compared 
to 86% in human serum. IgG removal column contains protein A, a highly 
stable protein receptor produced by Staphyicoccus aureus. Protein A binds 
to the Fc receptor region of IgGs from a large number of species.  
Ether extraction of control samples, followed by albumin and IgG removal 
did remove more false positive values as compared to ether extraction 
alone but were slightly more than expected (table 7.1.4). The time and 
number of steps required from ether extraction to albumin/IgG removal 
was also too impractical for a large number of samples and so another 
alternative was sought to measure progesterone. 
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Table 7.1.4: Plasma albumin/IgG removal and ether extraction 
Progesterone (ng/ml) Reading 
Control 6.05  
4 8.52  
40 54.63  
Plasma controls and spiked plasma with different concentrations of 
progesterone measured with Alphadiagnostic progesterone assay after 
Albumin/IgG removal and ether extraction. Readings are means of two 
independent assays. 
 
7.1.3 Progesterone enzyme immunoassay kit from Cayman 
Chemicals 
The progesterone enzyme immunoassay (EIA) kit from Cayman chemicals 
works in a similar way to the one from Alpha diagnostic and uses mouse 
monoclonal antibodies bound on coated plates. However, these bind to 
progesterone-specific rabbit antiserum, therefore eliminating the problems 
with anti-mouse antibodies binding to mouse proteins such as 
immunoglobulins. The assay is based on competition between 
progesterone and an acetylcholinesterase (AChE) conjugate (progesterone 
tracer) for a limited number of progesterone-specific rabbit antiserum 
binding sites. Due to the concentration of the kit progesterone tracer being 
held constant and the progesterone concentration in sample varying, the 
amount of progesterone tracer that is able to bind to the rabbit antiserum 
is inversely proportional to the concentration of progesterone in the well. 
Rabbit antiserum-progesterone (free or tracer) complex binds to the 
mouse monoclonal anti-rabbit IgG attached to the well. The plate is 
ZDVKHGWRUHPRYHXQERXQGUHDJHQWVDQGWKHDGGLWLRQRI(OOPDQ¶V5HDJHQW
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(contains substrate to AChE) results in an enzymatic reaction with the 
production of a strong yellow colour which absorbs strongly at 412nm 
(405nm was the nearest available wavelength to 412nm for reading the 
plate, but the assay can be read from 405-420nm). Intensity of colour is 
inversely proportional to progesterone present. This can be represented by 
calculating % sample or standard bound/Maximum bound (%B/B0), as 
recommended for the kit.  
The progesterone EIA kit was evaluated at first with control plasma 
followed by plasma spiked with different concentrations of progesterone 
(table 7.1.5). The concentration readings for plasma were consistent and 
accurate with regard to concentration standards used to spike the samples. 
Brain control and brain progesterone-spiked samples were evaluated after 
initial ether extraction optimisation (see ether extraction development and 
ether extraction protocol) and were found also to be consistent (table 
7.1.5).  
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Table 7.1.5: Progesterone-spiked plasma and brain readings with 
progesterone EIA kit  
Progesterone (ng) Plasma (ng/ml) Brain (ng/g) 
500 500.21 ± 5.1 501.92 ± 7.3 
100 100.13 ± 0.91 101.53 ± 4.91 
50 51.03 ± 2.13 50.38 ± 2.49 
25 25.89 ± 2.11 26.41 ± 0.95 
10 10.43 ± 0.15 11.09 ± 0.73 
Control 0.89 ± 0.41 0.72 ± 0.56 
Plasma/brain controls and spiked samples with different concentrations of 
progesterone measured with progesterone EIA. Brain samples were ether 
extracted and re-suspended prior to assay. Means are expressed as means 
± SEM, n= 3 each concentration 
 
7.1.4 Ether extraction development  
Ether extraction of progesterone from brain homogenate was based on a 
protocol described by Frye et al (Frye et al., 1998). Progesterone was 
extracted by mixing ice-cold diethyl ether with brain homogenate. The 
water/debris layer was then flash frozen in acetone and dry ice bath, 
followed by the ether layer being decanted off. Ether extract was allowed 
to evaporate to dryness and reconstituted prior to progesterone assay. A 
single round of extraction (1x) yielded only 60.35% ± 22.8 extraction 
efficiency across 2 different concentrations from spike homogenate (table 
7.1.6 for different concentration efficiencies). Therefore, further ether 
extraction repeats were required.  
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Table 7.1.6: Ether extraction 1x of progesterone from brain 
homogenate (%)   
50 ng/ml Progesterone 25 ng/ml Progesterone 
76.82 43.88 
Progesterone-spiked brain homogenate (20%) ether extraction efficiency 
(%). Average extraction efficiency overall was 60.35% ± 22.8. Background 
brain progesterone has been accounted for, by measuring progesterone 
concentration in the same brain homogenate sample separately and 
subtracting this from brain homogenate plus progesterone spike. 
Concentrations are means of two independent assays. 
 
Ether extraction of brain homogenate by 3 consecutive extractions (3x) 
resulted in higher efficiency of 98.63% ± 1.86 across 2 different 
concentrations (see table 7.1.7 for different concentration efficiencies). 
This was compared to the extraction efficiency for a range of standards 
under the same protocol without homogenate (table 7.1.8 for efficiency 
extraction of standards). Extraction efficiency of these standards over all 
was 98.94% ± 0.81, a similar level of extraction. All progesterone assays 
for optimisation of extraction protocols was performed with a commercial 
kit, which proved to have worked after initial testing (Progesterone Enzyme 
Immunoassay Kit; Cayman Chemicals, Michigan, USA). These initial 
optimisation experiments were used to develop the ether extraction 
protocol for pharmacokinetics of progesterone in treated animals.      
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Table 7.1.7: Ether extraction 3x of progesterone from brain 
Homogenate (%)   
100 ng/ml Progesterone 10 ng/ml Progesterone 
97.32 99.95 
Progesterone-spiked brain homogenate (20%) ether extraction efficiency 
(%). Background brain progesterone has been accounted for, by 
measuring progesterone concentration in the same brain homogenate 
sample separately and subtracting this from brain homogenate plus 
progesterone spike. Average extraction efficiency overall was 98.63% ± 
1.86. Concentrations are means are of two independent assays. 
 
Table 7.1.8: Ether extraction 3x of progesterone standards (%) 
Progesterone (ng/ml) % Extraction 
500 99.45 
100 98.67 
50 97.90 
25 100.00 
10 98.70 
Extraction efficiency (%) of progesterone ether extracted standards. 
Background brain progesterone has been accounted for, by measuring 
progesterone concentration in the same brain homogenate sample 
separately and subtracting this from brain homogenate plus progesterone 
spike. Average extraction efficiency overall was 98.94% ± 0.81 (Mean ± 
SEM). 
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7.2. Method development for SHSY5Y viability 
7.2.1 MTT viability assay 
The MTT assay was found to indicate lower cell viability compared to the 
resazurin assay in OGD controls and progesterone-treated cells (figure 
7.2.1). However, in other experiments using MTT with increasing 
progesterone concentrations in OGD conditions, the assay appeared not to 
be detecting cell death.  This inconsistency can be attributed to the step in 
the method when aspirating cell culture media after incubation with MTT. 
The cytotoxicity of MTT formazan makes it difficult to remove cell culture 
media from culture wells. MTT formazan needles form causing cells to 
float, allowing formazen to be aspirated with culture media, resulting in 
inconsistent results (higher ischaemic controls to normal, figure 7.2.2).     
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Figure 7.2.1: Comparison of MTT and resazurin assay controls after 
2 hrs of OGD for SHSY5Y cell line 
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Cell viability is expressed as % normoxic control.  Cultures consisted of 
vehicle and progesterone (prog, 50 µM) treated cells and incubated for 
2hrs in OGD conditions. Cell viability was then measured with Neutral Red 
assay. Data are expressed as means ± SEM (n=3). Analysis with two-way 
ANOVA showed a significant trend for the MTT assay to detect lower levels 
of viability compared to the resazurin one [F(1,6)=31.00, P=0.0014].  
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Figure 7.2.2: SHSY5Y viability after 3 hrs of OGD using MTT 
assay 
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Cell viability is expressed as % of normoxic control.  Cultures were 
incubated increasing concentrations of progesterone (0-30µM) over 3hrs of 
OGD. Cell viability was measured with MTT assay. All treatment wells 
contained 0.1% DMSO. Data are expressed as means of eight repeats on 
one occasion. Analysis with one-way ANOVA found no significant effect of 
progesterone [F(1,28)= 0.91, P= 0.4504]. 
 
7.2.2 Resazurin viability assay 
The resazurin assay requires an incubation period for the dye to be 
converted to resorufin. Incubation times of 1 and 2 hrs were evaluated to 
determine the optimum incubation time under OGD conditions (figure 
7.2.3). There was no significant difference found between incubation times. 
One hour incubation was, therefore, used in further resazurin experiments 
due to the reduced time required to complete the assay.   
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Figure 7.2.3: SHSY5Y viability after 2hrs of OGD, followed by 
incubation with resazurin at 1 and 2hrs before assay 
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Cell viability is expressed as % normoxic control.  Cultures consisted of 
vehicle and progesterone (prog, 50 µM) treated cells and incubated for 2 
hrs in OGD conditions. Cell viability was then measured with resazurin 
assay after 1 hr and 2 hr incubation with resazurin. Data are expressed as 
means ± SEM (n=3). Analysis with two-way ANOVA found no significant 
differences between 1 and 2 hr incubation with resazurin [F(1,12)= 3.57, 
P= 0.0833]. 
 
7.2.3 Viability of SHSY5Y using the resazurin assay 
SHSY5Y cells were exposed to increasing OGD conditions to reduce 
viability. However, no significant reduction of viability was found over 6 hrs 
(figure 7.2.4).  
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Figure 7.2.4: SHSY5Y viability of OGD controls with increasing 
incubation time using resazurin assay 
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Cell viability is expressed as % of normoxic control. Cultures were 
subjected to increasing periods of OGD. Cell viability was then measured 
after 1hr incubation with resazurin. All treatment wells contained 0.1% 
DMSO. Data are expressed as means ± SEM (times 3 and 6 hrs n=4, 2 and 
4 hrs n=3). One-way ANOVA revealed no significant differences from 
control [F(4,12)= 0.11, P= 0.1142]. 
 
Due to the lack of cell death caused by OGD conditions, 24 hrs of re-
oxygenation after OGD was introduced to mimic reperfusion injury. Cells 
were exposed to OGD with progesterone for 4 hrs, with and without re-
oxygenation. Because no significant differences were found between OGD 
time points between 2-6 hrs, 4 hrs of OGD was chosen followed by re-
oxygenation as a compromise to complete the experiment in the time 
available and to observe any effects from progesterone. It was not known 
at the time if re-oxygenation would increase cell death. Therefore, as a 
precaution, progesterone concentrations were included, in case a reduction 
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of viability was achieved. However, the addition of re-oxygenation 
following OGD did not increase cell death compared to OGD alone, but 
unexpectedly, increasing progesterone concentrations did reduce cell 
viability (figure 7.2.5).  Also, viability of non-treated controls in figure 3.5 
(91.89 %) are greater than figure 3.3 (85.09 %) for the same time in OGD 
conditions and incubation with resazurin. A positive control for cell killing 
(e.g. hydrogen peroxide or staurosporine) may have been useful as a 
comparison to OGD, but was not available at the time.   
 
Figure 7.2.5: Viability of SHSY5Y cells exposed to increasing 
concentrations of progesterone during 4 hrs of OGD, with or 
without 24 hrs of re-oxygenation using resazurin assay 
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Cell viability is expressed as % of normoxic control. Cultures were either 
exposed to 4 hrs of OGD alone or followed by 24 hrs of re-oxygenation in 
SFM. All treatment wells contained 0.1% DMSO. Cell viability was then 
measured with resazurin assay after 1hr incubation with risazurin. Data are 
expressed as means of 8 repeats in one experiment.  
242 
 
7.2.4 Viability comparison of resazurin assay with trypan blue (cell 
counter) in SHSY5Y 
The results of the resazurin assay were then compared to those generated 
in the trypan blue assay with an automated cell counter. The assays were 
compared with OGD controls over increasing periods of OGD (figure 7.2.6). 
The trypan blue with automated cell counter assay at 6hrs was found to 
indicate a lower viability compared to the resazurin assay. Due to the 
resazurin assay showing no significant drop in viability of SHSY5Y cells due 
to OGD, the trypan blue with cell counter assay was used to measure 
viability in subsequent experiments. Trypan blue selectively colours dead 
cells blue by its negatively charged chromopore, which does not interact 
with the cell unless the membrane is damaged and the membrane 
potential collapsed. In apoptosis, the integrity of the cell membrane is 
maintained until late in the process (Bohm and Schild, 2003), and so a 
clear indicator of cell death when it reaches this threshold. Other assays 
based on the biochemical or enzyme activity of mitochondria, such as MTT 
or resazurin is dependent on metabolic activity. But if a cell is metabolically 
quiet it may not necessarily mean it is not viable.       
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Figure 7.2.6: SHSY5Y viability of OGD controls over time: 
comparison of resazurin and trypan blue assays 
Time (Hrs)
% 
Vi
ab
ili
ty
 
o
f N
or
m
o
x
ic
 
Co
n
tr
o
l
2 4 6
0
50
100
150 Resazurin
Trypan Blue (Cell Counter)
*
 
Cell viability is expressed as % of normoxic control. Cultures were either 
exposed to OGD conditions over time. Cell viability was then measured 
with either resazurin or trypan blue assay. Data are expressed as means ± 
SEM (Risazurin n= 2-4, Trypan Blue n= 3-6). Two-way ANOVA shows there 
was a significant for trypan blue assay to detect lower viability compared 
to resazurin [F(1,14)=11.55, P=0.0043].  Bonferroni post-hoc analysis 
revealed that the trypan blue assay showed significantly reduced viability 
at 6hrs of ischaemia (P=<0.01).  
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7.3.1 Invitation letter template to authors for individual animal 
meta-analysis collaboration 
Dear 
I am writing to you on behalf of my group in the hope that you will be 
willing to share your raw animal data from your work on progesterone in 
experimental stroke.  
We are performing an individual animal data meta-analysis of all the 
available data on the use of progesterone as a neuroprotectant in stroke.  
At present there has only been two clinical trials aimed at using 
progesterone as a neuroprotectant, this suggesting and improved outcome 
and good safety tolerance after traumatic brain injury. There have been no 
clinical trials however that has examined the effect of acute administration 
of progesterone after stroke so far. In order to design future clinical trials 
aimed at assessing the neuroprotective potential of progesterone, further 
experimental investigation is needed. In order to assess how we can 
improve and identify the key factors that require further investigation we 
would like to look at the individual animal data. Individual subject data 
meta- analyses are the gold standard and offer significant advantages over 
using summary data, not least since subgroup analyses may be performed.  
I should add that my group has significant experience in performing 
systemic reviews, both clinical and pre-clinical, and using individual subject 
and summary data. Recently, we have performed one of the first (if not 
first) meta-analyses using individual animal data of NXY-059 (Bath et al., 
2009). In particular, we understand the need for maintaining 
FRQILGHQWLDOLW\ ZKHQ ZRUNLQJ ZLWK RWKHU SHRSOH¶V GDWD $OVR ZH GR QRW
identify individual data from authors. Rather, we put together all the data 
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from the different studies and then try to explore why it gives the results it 
does and also whether differences in subgroups are important. 
We believe that the results may help clarify the similarities and differences 
in existing progesterone animal studies. I do hope that you will be able to 
support this potential project through sharing the raw data from your 
studies of progesterone in stroke. 
If you are willing, I will send you the kind of data we are looking for but 
broadly this will relate to characteristics (age, weight, sex), drug 
administration (dose, timing) and the effect (lesion size, behavioural 
effects) animal by animal. 
At present we have received much interest in our investigation and have 
already received individual animal data from ten published studies, as well 
as unpublished data. We are hopeful by the response so far and even now 
we are expecting to receive even more data. On behalf of our group we 
would like to encourage you to be a part of this endeavour and would be 
grateful with whatever data from your progesterone animal studies you 
can provide. We hope that inevitably we will be able to even further clarify 
our understanding of progesterone in stroke.     
Many thanks for considering this request. 
Raymond Wong, MSc 
David Ray, PhD 
Claire Gibson, PhD 
Philip Bath, FRCP 
------------------------------------------------------------------- 
Philip Bath BSc MB BS MD FRCPath FRCP FESC 
Stroke Association Professor of Stroke Medicine 
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Division of Stroke Medicine 
University of Nottingham 
Nottingham City Hospital campus 
Hucknall Road 
Nottingham NG5 1PB UK 
 
Email: philip.bath@nottingham.ac.uk 
Tel:  +44 (0) 115 823 1768 
Fax: +44 (0) 115 823 1767 
Secretary: +44 (0) 115 823 1765 
Web: www.nottingham.ac.uk/stroke-medicine/ 
ENOS trial: www.enos.ac.uk/ 
------------------------------------------------------------------- 
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7.3.2 Document outlining individual animal data meta-analysis to 
authors 
Progesterone in experimental stroke: assessment of safety and 
efficacy using data from individual animals in completed preclinical 
studies (PISA) 
Raymond Wong,1 MSc; Michael Tracy,1 MSc; David Ray,1 PhD; Claire 
Gibson,2 PhD; Philip Bath,1 FRCP 
Institute of Neuroscience,1 University of Nottingham, and School of 
Psychology,2 University of Leicester 
 
Introduction  
At present there has only been two clinical trials aimed at using 
progesterone as a neuroprotectant, suggesting improved outcome and 
good safety tolerance after traumatic brain injury (Wright et al., 2007; 
Xiao et al., 2008). However, there have been no clinical trials examining 
the effect of acute administration of progesterone after ischaemic stroke. 
Several studies assessing the safety and efficacy of progesterone in 
preclinical models of stroke have been performed, (Alkayed et al., 2000; 
Chen and Chopp, 1999; Chheng-Orn Evans et al., 2004; Gibson et al., 
2005b; Gibson and Murphy, 2004; Jiang et al., 1996; Kumon et al., 2000; 
Murphy et al., 2002; Murphy et al., 2000; Roof et al., 1996) and these 
have been integrated in a systematic review based on published summary 
µJURXS¶ GDWD (Gibson et al., 2008a). However, this systematic review 
suggests that key important questions remain to be answered, including 
efficacy by sex and age, and dose and time responses to progesterone. In 
order to assess how to improve and identify the key factors that require 
further investigation, a meta-analysis using individual animal data (IAD) is 
248 
 
required. Individual subject data meta-analyses are the gold standard and 
offer significant advantages over using summary data, not least since 
subgroup analyses may be performed. The results from the IAD meta-
analysis will be used to inform the design of future preclinical studies of 
progesterone in stroke. 
 
Methods 
Study Identification 
Experimental studies examining the effect of progesterone or progesterone 
metabolite on lesion size and functional recovery in animal models of 
stroke will be identified from electronic searches (e.g PubMed), references 
lists in known published studies, (Alkayed et al., 2000; Chen and Chopp, 
1999; Chheng-Orn Evans et al., 2004; Gibson et al., 2005b; Gibson and 
Murphy, 2004; Jiang et al., 1996; Kumon et al., 2000; Murphy et al., 
2002; Murphy et al., 2000; Roof et al., 1996) and a systematic review of 
them (Gibson et al., 2008a), reference lists in published review articles and 
personal communication with authors of all of these. 
 
Study Selection 
Studies must be controlled (whether randomised or not) and involve 
exogenous administration of progesterone or progesterone metabolite in 
experimental stroke. Stroke models may include transient or permanent 
focal cerebral ischemia. Studies, whether published or unpublished, will be 
included if they contain data on lesion volume, vital status, and/or 
functional outcome. 
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Initiation of the Collaboration 
The Chief Investigator of each identified study will be contacted as to 
whether they are willing to join the collaboration and share data on 
individual animals. 
 
Data extraction 
The following information will be sought from each Chief Investigator: 
animal species, experimental model of brain injury (permanent or 
transient), design, randomisation/pseudo-randomisation, blinding of 
surgeons to treatment, whether the outcomes were accessed blinded to 
treatment.       
 
Study Characteristics 
The individual animal data will include (accepting that not all variables will 
have been recorded for each study): 
x Sex/hormonal state 
x Species 
x Number of Animals 
x Age  
x Weight  
x Model (global/focal, permanent/transient) 
x Lesion/infarct volume (total, cortical and sub-cortical if available)  
x Neuroscore (Bederson and type) 
x Motor impairment and scale 
250 
 
x Functional outcome and scale (foot fault, Rotarod, Morris water 
maze, etc) 
x Temperature during treatment (different time points, max and min)  
x Vital Status (Death)  
x MRI (lesion values) 
x Deaths (spontaneous or early culling for poor health) 
x Physiological variables (temperatures, blood pressure) 
 
Information on treatment will also be obtained including:  
x Time to treatment in relation to onset of ischemia  
x Treatment- Number of Doses, interval or duration if continuous    
x Progesterone load mg dose 
x Progesterone maintenance dose 
x Progesterone concentration in blood 
x Time at which concentration measured   
x Form of occlusion  
x Occlusion time   
x Plasma concentration 
x Type of Anaesthetic 
x Reperfusion start relative to onset time 
 
Methodological Quality 
Methodological quality of each study will be assessed using a 9 point score 
based on the STAIR (1999) rating (STAIR rating is a 8 point score, 
however with addition of masked surgery it is now 9 points) (Stroke 
Therapy Academic Industry Roundtable (STAIR), 1999). A point is given 
for the written evidence for each of the following criteria:  
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x Presence of randomisation (0.5 given for pseudo-randomisation),  
x Monitoring of physiological parameters,  
x Assessment of dose-response relationship,  
x Optimal time window assessment,  
x Masked outcome measurement,  
x Outcome assessment of days 1-3 and 1-30,  
x Combined measurement of lesion/infarct volume,  
x Functional outcome  
x Masked surgery (addition to STAIR rating)         
Data Analysis 
IAD and summary data will be analysed together followed by IAD analysed 
separately. Analysis of both summary and IAD will involve random effect 
models to produce standardised mean differences (SMD, for continuous or 
ordinal data, www.cochrane-net.org/openlearning/html/modA1-4.htm, 
25/11/08) and 95% confidence intervals (95% CI). Random effects models 
will be used since biological heterogeneity is expected due to the expected 
varied nature of studies involving different species, model of ischaemia, 
time to treatment and doses of progesterone. The statistical heterogeneity 
will be calculated using I2 statistic and presence of publication bias will be 
assessed by funQHOSORWDQG(JJHU¶VWHVW (Egger et al., 1997). 
In the case of IAD analysis, the data will merged into an Excel spreadsheet 
with each row containing data for an individual animal. Multilevel models 
will be built to compare progesterone with control taking into account 
differences between trials. The infarct volume will be standardised (score-
mean/standard deviation) to account for any differences in between brain 
and infarct sizes in different species. Motor impairment will be similarly 
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standardised since difference scales is expected (although most be derived 
from Bederson et al) (Bederson et al., 1986). The coefficients for dose 
given will be per 100mg kg-1. Analyses of dose/concentration and 
concentration/response relationships for progesterone (if measured) will be 
identified reflecting steady state levels, typically at 24 hours. 
 
Experience 
The team are experienced at performing preclinical and clinical systematic 
reviews, including with summary data and individual subject data. 
Completed reviews include: 
x
 Preclinical ± summary data: progesterone, oestrogen, nitric 
oxide, nitric oxide synthase inhibitors (Gibson et al., 2008a; 
Gibson et al., 2005c; Willmot et al., 2005a; Willmot et al., 
2005b)  
x Preclinical ± individual animal data: NXY-059 (Bath et al., 2008)  
x Clinical - summary data: see Cochrane Library, heparin (Bath et 
al., 2002; Bath et al., 2000)  
x Clinical - individual patient data: dipyridamole, occupational 
therapy (Leonardi-Bee et al., 2005; Walker et al., 2004) 
Publication Strategy  
7KH ILQGLQJVZLOO EHSXEOLVKHGXQGHU WKHJURXSQDPHRI µ3URJHVWHURne In 
6WURNH$QLPDOV¶3,6$ 
 
The Collaboration 
The collaboration will comprise: 
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Project secretariat: 
Philip Bath: Chief Investigator (and PhD supervisor) 
Raymond Wong: Administer project (and PhD student) 
Michael Tracy: Bio-medical statistician (and PhD student) 
David Ray: Scientific advisor (and PhD supervisor) 
Claire Gibson: Scientific advisor 
 
Collaborators: 
All the Chief Investigators 
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